



創美藥業

創美·CH/MEI

CHARMACY PHARMACEUTICAL

股份代號 STOCK CODE
2289.HK

2022 中期報告

INTERIM REPORT



關於我們

創美藥業股份有限公司（「公司」、「本公司」或「我們」）（股份代號：2289.HK）主營醫藥分銷業務，主要向下游分銷商和零售終端分銷西藥、中成藥、保健品等產品，並提供醫藥產品諮詢服務。公司創立於2000年，經過22年的快速發展，已成長為華南地區領先的醫藥分銷商之一。公司堅持「深耕廣東，輻射周邊」的發展戰略，在汕頭、佛山、珠海、廣州及惠州設有物流中心並擁有專業的運輸服務團隊，對非招標市場實行「半徑10公里內一日三配、50公里內一日兩配、250公里內一日一配」的高效配送機制。公司具有現代化信息系統，涵蓋整個醫藥分銷供應鏈，包括採購、銷售、倉儲、運輸及交付等。公司同時運營自建的B2B電子商務平臺：「創美e藥」，供客戶線上下單、查詢及支付等。公司於2021年全國批發企業主營業務收入前100位排序前40。

憑藉良好的信譽和優質服務，本公司近年來分別於不同的醫藥行業權威機構或協會獲得多個榮譽，包括但不限於：「醫藥商業最具發展潛力企業」、「醫藥冷鏈物流最佳物流中心（基地）」、「醫藥冷鏈物流服務推

ABOUT US

Charmacy Pharmaceutical Co., Ltd. (the “Company” or “we”) (stock code: 2289.HK) is principally engaged in the pharmaceutical distribution business. It mainly distributes western medicine, Chinese patent medicine and healthcare products to downstream distributors and retail terminals, as well as provides consultation service on pharmaceutical products. Founded in 2000, over the past 22 years of rapid development, it has become one of the leading pharmaceutical distributors in the Southern China region. The Company adheres to the development strategy of “Intensive Engagement in Guangdong Province and Extensive Coverage across Surrounding Areas”, and has built logistics centres in Shantou, Foshan, Zhuhai, Guangzhou and Huizhou, all equipped with professional transportation teams, and has a highly efficient delivery mechanism of delivering pharmaceutical products three times per day for customers within a radius of 10 kilometers, twice per day for customers within a radius of 50 kilometers and once per day for those within a radius of 250 kilometers. In addition, the Company has a modern information system that covers the entire supply chain for pharmaceutical distribution, including procurement, sales, warehousing, transportation and delivery. Apart from that, the Company operates its own B2B e-commerce platform “Charmacy e-Medicine” (創美e藥), a platform for customers to place orders online, make inquiries and payment, etc. In 2021, the Company ranked top 40 among top 100 PRC wholesalers, in respect of revenue generated from the principal business.

With good reputation and high-quality service, the Company has won a number of honors in different authoritative institutions or associations in the pharmaceutical industry in recent years, including but not limited to: “The Most Promising Enterprise in The Pharmaceutical Business industry”, “The Best Logistics Center For Pharmaceutical Cold Chain Logistics

薦企業」、「中國物流行業金螞蟻創新獎」、「廣東省守合同重信用企業（2001-2020 連續二十年）」、「抗疫積極貢獻獎」、「中國醫藥行業醫藥商業百強企業」、「醫藥供應鏈”金質獎”——十佳商業企業」、「企業信用評價 AAA 級信用企業」、「《藥品冷鏈物流運作規範》國家標準達標企業」等。

(Base)”, “The Medical Cold Chain Logistics Services Recommended Enterprises”, “The Golden Ant Innovation Award of Chinese Logistics Industry”, “The Title of Contract Abiding and Credit Respecting Enterprise in Guangdong Province (For 20 Consecutive Years from 2001 to 2020)”, “The Anti-Epidemic Positive Contribution Award”, “The Top 100 Pharmaceutical Enterprises in China’s Pharmaceutical Industry”, “The “Gold Award” Medical Supply Chain--Procurement - Top Ten Commercial Enterprises”, “The AAA Credit Rating issued by the China Enterprise Confederation and the China Entrepreneurs Association”, “Obtained the National Standard of Pharmaceutical Cold Chain Logistics Operation Specification”.

目錄

CONTENTS

| | |
|--|----|
| 公司資料 | 5 |
| Corporate Information | |
| 財務摘要 | 7 |
| Financial Summary | |
| 管理層討論及分析 | 8 |
| Management Discussion and Analysis | |
| 其他資料 | 31 |
| Other Information | |
| 未經審核中期財務報表 | 38 |
| The Unaudited Interim Financial Statements | |
| 合併資產負債表 | 39 |
| Consolidated Balance Sheet | |
| 母公司資產負債表 | 42 |
| Balance Sheet of the Parent Company | |
| 合併利潤表 | 44 |
| Consolidated Income Statement | |
| 母公司利潤表 | 47 |
| Income Statement of the Parent Company | |
| 合併現金流量表 | 49 |
| Consolidated Statement of Cash Flow | |
| 母公司現金流量表 | 51 |
| Statement of Cash Flow of the Parent Company | |
| 合併股東權益變動表 | 53 |
| Consolidated Statement of Changes in Shareholder's Equity | |
| 母公司股東權益變動表 | 56 |
| Statement of Changes in Shareholder's Equity of the Parent Company | |
| 未經審核中期財務報表附註 | 59 |
| Notes To The Unaudited Interim Financial Statements | |

公司資料

*董事

執行董事

姚創龍 (董事會主席)

鄭玉燕

張寒孜^(註)

非執行董事

李偉生

嚴京斌

付征^(註)

獨立非執行董事

尹智偉

周濤

關鍵 (又稱關蘇哲)

*監事

張玲

鄭禧玥

林志傑

*聯席公司秘書

姚潔晞

黃慧玲

*審核委員會

尹智偉 (主席)

周濤

關鍵

*提名委員會

周濤 (主席)

姚創龍

關鍵

*薪酬委員會

周濤 (主席)

尹智偉

鄭玉燕

*風險管理委員會

姚創龍 (主席)

鄭玉燕

尹智偉

*戰略發展委員會

姚創龍 (主席)

鄭玉燕

周濤

CORPORATE INFORMATION

* DIRECTORS

Executive Directors

Yao Chuanglong (Chairman of the Board)

Zheng Yuyan

Zhang Hanzhi^(Note)

Non-executive Directors

Li Weisheng

Yan Jingbin

Fu zheng^(Note)

Independent Non-executive Directors

Wan Chi Wai Anthony

Zhou Tao

Guan Jian (also known as Guan Suzhe)

* SUPERVISORS

Zhang Ling

Zheng Xiyue

Lin Zhijie

* JOINT COMPANY SECRETARIES

Yao Jiexi

Wong Wai Ling

* AUDIT COMMITTEE

Wan Chi Wai Anthony (Chairman)

Zhou Tao

Guan Jian

* NOMINATION COMMITTEE

Zhou Tao (Chairman)

Yao Chuanglong

Guan Jian

* REMUNERATION COMMITTEE

Zhou Tao (Chairman)

Wan Chi Wai Anthony

Zheng Yuyan

* RISK MANAGEMENT COMMITTEE

Yao Chuanglong (Chairman)

Zheng Yuyan

Wan Chi Wai Anthony

* STRATEGIC DEVELOPMENT COMMITTEE

Yao Chuanglong (Chairman)

Zheng Yuyan

Zhou Tao

***授權代表**

鄭玉燕

姚潔晞

***核數師**

信永中和會計師事務所

(特殊普通合伙)

***法律顧問**

鍾氏律師事務所與德恒律師事務所聯
營(香港法律)

廣東信達律師事務所(中國法律)

***註冊辦公室及總部**

中國廣東省汕頭市龍湖區嵩山北路
235 號

***香港主要營業地點**

香港灣仔皇后大道東 248 號大新金融
中心 40 樓

***主要往來銀行**

廣發銀行股份有限公司(汕頭分行)

中國工商銀行股份有限公司(汕頭分
行)

***H 股證券登記處**

香港中央證券登記有限公司

香港灣仔皇后大道東 183 號

合和中心 17 樓 1712-1716 號舖

***公司網站**

www.chmyy.com

***股份代號**

2289.HK

註: 自二零二二年七月十三日起, 張
寒孜女士獲委任為本公司執行董事;
付征女士獲委任為本公司非執行董
事。

*** AUTHORISED REPRESENTATIVES**

Zheng Yuyan

Yao Jiexi

*** AUDITOR**

ShineWing Certified Public Accountants (Special General
Partnership)

*** LEGAL ADVISERS**

Chungs Lawyers in association with DeHeng Law Offices (as to
Hong Kong laws)

Shu Jin Law Firm (as to PRC laws)

*** REGISTERED OFFICE AND HEADQUARTERS**

No. 235, Song Shan North Road, Longhu District, Shantou City,
Guangdong Province, PRC

*** PRINCIPAL PLACE OF BUSINESS IN HONG KONG**

40th Floor, Dah Sing Financial Centre, No. 248 Queen's Road
East, Wanchai, Hong Kong

*** PRINCIPAL BANKS**

China Guangfa Bank Co., Ltd. (Shantou Branch)

Industrial and Commercial Bank of China Limited (Shantou
Branch)

*** H SHARE REGISTRAR**

Computershare Hong Kong Investor Services Limited

Shops 1712-1716, 17th Floor Hopewell Centre, 183 Queen's
Road East, Wanchai, Hong Kong

*** COMPANY WEBSITE**

www.chmyy.com

*** STOCK CODE**

2289.HK

Note: With effect from 13 July 2022, Ms. Zhang Hanzhi has been
appointed as an executive director of the Company; Ms. Fu
Zheng has been appointed as a non-executive director of the
Company.

財務摘要

FINANCIAL SUMMARY

| 項目 Items | 截至 6 月 30 日止六個月 Six months ended 30 June | | 變動 (%) Change (%) |
|--|---|---|----------------------------|
| | 2022 年 人民幣千元(未經審核) 2022(Unaudited) RMB'000 | 2021 年 人民幣千元(未經審核) 2021(Unaudited) RMB'000 | |
| 營業收入 Operating revenue | 1,887,079 | 1,993,014 | -5.32 |
| 利潤總額 Total profit | 25,848 | 34,530 | -25.14 |
| 歸屬於母公司股東的淨利潤 Net profit attributable to the Shareholders of parent company | 20,639 | 25,961 | -20.50 |
| 基本及稀釋每股收益 (以每股人民幣元列示) Basic and diluted earnings per share (expressed in RMB per share) | 0.1911 | 0.2404 | -20.50 |

| 項目 Items | 於 2022 年 6 月 30 日 人民幣千元(未經審核) As at 30 June 2022 RMB'000 (Unaudited) | 於 2021 年 12 月 31 日 人民幣千元(經審核) As a 31 December 2021 RMB'000 (Audited) | 變動 (%) Change (%) |
|--|---|--|----------------------------|
| 總資產 Total assets | 2,646,289 | 2,763,092 | -4.23 |
| 總負債 Total liabilities | 2,121,548 | 2,258,990 | -6.08 |
| 股東權益 Equity of Shareholders | 524,741 | 504,102 | 4.09 |
| 每股淨資產 (以每股人民幣元列示) Net assets per share (as stated in RMB per share) | 4.8587 | 4.6676 | 4.09 |

管理層討論及分析

行業概覽

2022 年上半年，國內多地新冠疫情出現反覆，國際形勢更爲複雜嚴峻，我國經濟頂住壓力實現正向增長。國內疫情防控進入新階段，人們對於身體健康的重視程度明顯提升，加之多項醫藥行業政策發佈並落地，中國醫藥行業轉型升級進程加快。隨著「健康中國」戰略、集採擴面、「互聯網+醫療健康」、分級診療、醫保支付基金等醫改新政加速落地，以及醫藥行業數字化轉型的賦能與帶動，藥品流通行業生態格局繼續重塑，持續向高質量方向發展。此外，在監管趨嚴及政策鼓勵並存的環境下，醫藥流通企業在產業鏈中的作用越發突顯，藥品流通行業市場集中度不斷提升，正加速從資源競爭時代轉型至能力競爭方向。

政策引領高質量發展，醫藥流通行業格局持續重塑

「十四五」時期是國家深化「健康中國」戰略的關鍵階段，國家及相關部門出台了一系列政策推動醫藥行業高

MANAGEMENT DISCUSSION AND ANALYSIS

INDUSTRY OVERVIEW

In the first half of 2022, COVID-19 outbreaks occurred repeatedly in many places in China, and the international situation became more complicated and severe. China's economy achieved positive growth despite the pressure. The process of transformation and upgrading of China's pharmaceutical industry has been accelerating with the epidemic prevention and control in China having entered a new stage, people's significantly increasing attention to health, and the promulgation and implementation of a number of pharmaceutical industry policies. The pharmaceutical distribution industry will continue to reshape its ecological structure and move towards high-quality development with the acceleration of the implementation of new medical reform policies including the "Healthy China" strategy, the increased adoption of centralised procurement, "Internet + Healthcare", the tiered diagnosis and treatment system and the introduction of medical insurance payment fund, coupled with the empowerment and promotion of the digital transformation of the pharmaceutical industry. In addition, in the context of stricter supervision and incentive policies, the role of pharmaceutical distribution enterprises in the industry chain is becoming more and more prominent, the pharmaceutical distribution industry has a constantly increasing market concentration, and is accelerating its transformation from an era of competition for resources to competition for capacities.

Policies aim at high-quality development, and the pattern of the pharmaceutical distribution industry continues to reshape

The "14th Five-Year Plan" period is the key stage for China to deepen the "Healthy China" strategy. The state and relevant authorities have issued a series of policies to drive the high-

質量發展。2021年10月，商務部發佈《關於「十四五」時期促進藥品流通行業高質量發展的指導意見》（「《指導意見》」），提出到2025年，藥品流通行業與我國新發展階段人民健康需要相適應，創新引領、科技賦能、覆蓋城鄉、佈局均衡、協同發展、安全便利的現代藥品流通體系更加完善，到2025年，藥品批發百強企業年銷售額佔藥品批發市場總額98%以上。其明確了藥品流通行業未來五年的發展方向，為全行業實現高質量發展提供了重要指引。2021年12月，國家藥監局等八部門聯合印發了《「十四五」國家藥品安全及促進高質量發展規劃》，明確到「十四五」末，藥品監管能力整體接近國際先進水平，藥品安全保障水平持續提升，人民群眾對藥品質量和安全更加滿意、更加放心。

2022年3月，李克強總理代表國務院在十三屆全國人大五次會議上作《政府工作報告》（「《工作報告》」）。《工作報告》提出，支持中醫藥振興發展，推進中醫藥綜合改革，要著眼推動分級診療和優化就醫程序，加快建設國家、省級區域醫療中心，推動優質醫療資源向市縣延伸，提升基層防病治病能力，使群眾

quality development of the pharmaceutical industry. In October 2021, the Ministry of Commerce issued the Guiding Opinions on Promoting the High-quality Development of the Pharmaceutical Distribution Industry During the “14th Five-Year Plan” period (the “**Guiding Opinions**”), proposing that by 2025, the pharmaceutical distribution industry will have met people’s health needs in China’s new development stage, and the modern pharmaceutical distribution system will function better thanks to leading innovation, technology empowerment, urban and rural coverage, balanced layout, coordinated development, safety and convenience; and by 2025, the annual sales of the top 100 pharmaceutical wholesale enterprises will account for more than 98% of the total pharmaceutical wholesale market size. The Guiding Opinions clarifies the development direction of the pharmaceutical distribution industry in the next five years, and provides an important guide for the whole industry to achieve high-quality development. According to the explicit descriptions in the 14th Five-Year Plan for National Drug Safety and Promotion of High-Quality Development promulgated in December 2021 jointly by eight authorities including the National Medical Products Administration, by the end of the “14th Five-Year Plan” period, the overall drug regulatory capability will be close to the international advanced level, and the level of drug safety assurance will be continuously improved, and people will be more satisfied with the quality and safety of drugs and felt more at ease.

In March 2022, Premier Li Keqiang delivered the Government Work Report (the “**Work Report**”) on behalf of the State Council at the Fifth Session of the 13th National People’s Congress. The Work Report proposes to support the revitalization and development of traditional Chinese medicine and push forward the comprehensive reform of traditional Chinese medicine by vigorously promoting graded diagnosis and treatment, optimizing medical treatment procedures, speeding up the construction of national and provincial regional

就近得到更好醫療服務。黨的十八大以來，中醫藥於醫藥行業中的地位越來越突出，中醫藥發展上升為國家戰略，優質醫療資源下沉將成為 2022 年基層醫療衛生領域的主旋律，為醫藥行業高質量發展增添新動能。

國家持續推進建設以國內大循環為主體、國內國際雙循環相互促進的新發展格局，加快建立全國統一的市場制度，醫藥流通市場格局也加速了格局重塑步伐。2022 年 4 月，中共中央、國務院印發《關於加快建設全國統一大市場的意見》。通過建設高效規範、公平競爭、充分開放的全國統一大市場，將推動形成供需互促、產銷並進、暢通高效的國內大循環，為經濟高質量發展奠定堅實基礎。對醫藥流通企業來說，統一大市場意味著解決區域醫藥物流政策不一致的問題，通過制定統一的藥品第三方物流准入及異地設庫標準，推動醫藥物流標準體系於國際接軌，藥品流通企業可以集約化經營，市場空間的進一步拓展以及經營成本的降低。

medical centres, driving the extension of high-quality medical resources to cities and counties, and improving the disease prevention and treatment capabilities at the grassroots level, thereby enabling people to get better medical services nearby. Since the 18th National Congress of the Communist Party of China, the position of traditional Chinese medicine in the pharmaceutical industry has become more and more prominent, and the development of traditional Chinese medicine has become a national strategy. The allocation of high-quality medical resources to lower-level medical institutions will be the main theme in the grassroots-level health care in 2022, adding a new driver to the high-quality development of the pharmaceutical industry.

The state has been promoting the formation of a new development pattern with the domestic cycle as the mainstay and the domestic and international cycles promoting each other, and accelerating the establishment of a unified national market system. The pattern of the pharmaceutical distribution market has also accelerated the pace of reshaping. In April 2022, the CPC Central Committee and the State Council issued the Opinions on Accelerating the Construction of a Unified Nationwide Market. The construction of a unified nationwide market with high efficiency, fair competition and full openness will promote the formation of a smooth and efficient domestic distribution with mutual promotion of supply and demand and production and marketing, and lay a solid foundation for high-quality economic development. For pharmaceutical distribution enterprises, a unified large market means addressing the regional inconsistency in pharmaceutical logistics policies. Through the formulation of unified standards for third-party pharmaceutical logistics access and setup of warehouses in different places and through the promotion of the alignment between pharmaceutical logistics standards system and the international standards, pharmaceutical distribution enterprises can conduct intensive operations, further expand market room and reduce operating costs.

處方外流和互聯網醫療共同推進醫藥分開

2022 年 1 月，國家發改委、商務部發布《關於深圳建設中國特色社會主義先行示範區放寬市場准入若干特別措施的意見》（「《意見》」）。

《意見》支持深圳建立電子處方中心，對接互聯網醫院、醫療機構處方系統、各類處方藥銷售平台、廣東省國家醫保信息平台等。所有處方藥將以此中心為依托，展開網絡銷售，不再另行審批。深圳是繼海南自由貿易港的處方藥網售試點後，又一個互聯網處方藥銷售試點，兩個電子處方中心實現信息互聯互通，將對區域市場的處方藥流動產生深遠影響，也給承接的零售藥店帶來更多的流量機會。

在醫改持續深化的背景之下，醫藥分開已經成為大勢所趨。藥品零加成、控制藥佔比、雙通道等因素，以及海南與深圳的電子處方中心建設試點成果均有助於加快我國處方外流的步伐，帶來可觀流量增量。根據艾昆緯數據預測，隨著醫藥分家的推進，處方藥外流規模約為人民幣 4,000-5,000 億元，其中零售市場規模約人民幣 3,000 億元。隨著醫藥分開政策深化落地，未來處方外流所帶來的市場規模將直接惠及醫保門店、院邊店及直接面向患者（DTP）藥房，並直接拉高醫藥零售行業整體增速。

Separation of prescribing and dispensing has been driven jointly by prescription outflow and online medical care

In January 2022, the National Development and Reform Commission and the Ministry of Commerce issued the Opinions on Various Special Measures to Relax Market Access in Developing Shenzhen into a Pilot Demonstration Zone of Socialism with Chinese Characteristics (the “Opinions”). The Opinions supports the establishment of an electronic prescription centre in Shenzhen and connecting with Internet hospitals, prescription systems of medical institutions, sales platforms for various prescription drugs, and the national medical insurance information platform of Guangdong Province. All prescription drugs will be sold online based on this centre without further approval. Shenzhen is another Internet prescription drug sales pilot area after the pilot of online sales of prescription drugs in Hainan Free Trade Port. The information interconnection between the two electronic prescription centres will have far-reaching influence on the flow of prescription drugs in the regional market and bring more orders to the retail pharmacies.

With the deepening of medical reform, the separation of prescribing and dispensing has become the general trend. Factors such as zero-markup drug policy, control of the proportion of drug sales in hospital revenues, and dual channels and the results of the pilot construction of electronic prescription centres in Hainan and Shenzhen help speed up the pace of prescription outflow in China and increase drug orders considerably. According to IQVIA’s data forecast, with the advancement of the separation of prescribing and dispensing, the size of outflow of prescription drugs is about RMB400-500 billion, of which the retail market is about RMB300 billion. With the further implementation of the policy for separation of prescribing and dispensing, the market size from the outflow of prescriptions in the future will directly benefit medical insurance-covered stores, hospitals and direct-to-patient (DTP) pharmacies, and directly boost the overall growth of the



2022年6月，國家衛健委和國家中醫藥局聯合發布《互聯網診療監管細則（試行）》（「《細則》」），意味著互聯網診療直接進入強監管階段。《細則》對互聯網醫療服務質量和安全提出嚴格要求，其中包括：處方應由接診醫生本人開具，嚴禁使用人工智能等生成處方，嚴禁在處方開具前向患者提供藥品等。隨著醫藥監管部門持續強化電子處方監管，加之各地逐步探索推進電子處方中心建設，互聯網診療活動將有章可依，網售處方藥將有迹可循，患者亦將能夠獲得更加安全的線上醫藥服務。

廣東省加快推動藥品零售連鎖產業規模化、集約化和規範化發展

2022年4月，廣東省藥品監督管理局印發《廣東省藥品零售連鎖經營監督管理辦法》（「《辦法》」），《辦法》於2022年5月1日起正式實施。《辦法》提出：（1）支持單體藥店加盟連鎖企業，拓寬連鎖企業配送渠道，增加連鎖企業藥品銷售市場份額，加盟藥店於連鎖企業實現優勢互補、資源共享，有利於提高廣東藥品零售連鎖率和零售藥店規範管理水平，加快推動藥品零售連鎖產業規模化、集約化和規範化發展；（2）允許連鎖總部集中儲存、包裝、發運

pharmaceutical retail industry.

In June 2022, the National Health Commission and the State Administration of Traditional Chinese Medicine jointly issued the Detailed Rules on Supervision of Internet-based Diagnosis and Treatment (Trial) (the “**Detailed Rules**”), which means that the Internet-based diagnosis and treatment have directly entered the stage of strong supervision. The Detailed Rules contain strict requirements for the quality and safety of online medical services, including: prescriptions shall be issued by the doctors who diagnose the patients; it shall be strictly forbidden to use artificial intelligence to generate prescriptions; and it shall be strictly forbidden to provide drugs for patients before the prescriptions are issued. As the medical and drug regulatory authorities continue to strengthen the supervision of electronic prescriptions and various places gradually explore and promote the construction of electronic prescription centres, there are rules for Internet-based diagnosis and treatment activities and traces of online sales of prescription drugs, so that patients will receive safer online medical services.

Guangdong Province has accelerated the expansive, intensive and standardized development of the pharmaceutical retail chain industry

In April 2022, the Medical Products Administration of Guangdong Province issued the Measures for the Supervision and Administration of Drug Retail Chain Operations in Guangdong Province (the “**Measures**”), which was officially implemented from 1 May 2022. The Measures proposed to: (1) support independent pharmacies to join chain enterprises, broaden the distribution channels of chain enterprises, increase the market shares of drug sales of chain enterprises, and realise complementary advantages and resource sharing among chain enterprises, which is conducive to improving the drug retail chain rate and standardised management level of retail pharmacies in Guangdong, and accelerating the expansive, intensive and standardized development of the drug retail chain

其直營連鎖門店網絡銷售的藥品、直營門店之間調撥藥品，有利於降低連鎖企業藥品流通的成本，方便消費者購藥；及（3）規定連鎖企業可以將其經營範圍內藥品委托不超過兩家藥品批發企業承擔藥品配送業務，也可以在自建配送中心的基礎上再委托不超過兩家批發企業配送藥品。既有利於消除區域配送障礙，提高連鎖企業區域覆蓋，增加配送品種範圍，方便企業擴大經營，亦有利於零售單店加盟後的採購選擇及提升配送時效。

2022年7月，廣東省藥監局發佈相關通知，明確廣東省將加快培育大型現代藥品流通骨幹企業，支持藥品零售連鎖企業通過兼併、重組、收購、加盟等方式創新發展，全面提升藥品零售連鎖率和規範化管理水平。

《指導意見》提出，到2025年，藥品零售百強企業年銷售額佔藥品零售市場總額65%以上，藥品零售連鎖率接近70%的總體目標。根據米內網（www.menet.com.cn）數據，2021年三大終端六大市場藥品銷售額為人民幣17,747億元，較2020年增長8%。其中，零售藥店終端銷售額受疫情影響最小，恢復較快，增速為10.3%，市場份額佔比為26.9%，較

industry; (2) allow the chain headquarters' centralised storage, packing and shipment of the drugs sold by the network of its direct chain stores, and allow the transfer of the drugs between the direct chain stores, which is conducive to reducing chain enterprises' drug distribution costs and facilitating consumers' drug purchase; and (3) allow chain enterprises to engage no more than two pharmaceutical wholesale enterprises to distribute the drugs within their business scopes, or engage no more than two wholesale enterprises to distribute drugs on the basis of their own distribution centres. This is not only conducive to eliminating regional distribution barriers, improving the regional coverage of chain enterprises, increasing the range of distribution varieties, and facilitating enterprises to expand their operations, but also conducive to purchase choices and improving distribution timeliness after independent retail stores' joining.

In July 2022, the Medical Products Administration of Guangdong Province issued a relevant notice, which made it clear that Guangdong Province would speed up the cultivation of modern large-scale backbone pharmaceutical distribution enterprises, support the innovative development of pharmaceutical retail chain enterprises by mergers, reorganizations, acquisitions, franchises and other means, and comprehensively improve the drug retail chain rate and standardized management level.

According to the Guiding Opinions, by 2025, the annual sales of the top 100 pharmaceutical retail enterprises will have accounted for more than 65% of the total pharmaceutical retail market size, and the pharmaceutical retail chain rate will approach the overall goal of 70%. According to the data on MENET (www.menet.com.cn), in 2021, the drug sales in the six major markets on the three major terminals were RMB1,774.7 billion, an annual increase of 8% compared with 2020. Among them, the sales on the retail pharmacy terminal were the least affected by the epidemic, and recovered more quickly, with a



2020 年上升 0.6 個百分點。而 2021 年度廣東全省共有《藥品經營許可證》持證企業 57,784 家。其中，零售連鎖總部 528 家，零售連鎖門店 23,092 家，單體藥店 32,696 家，按照這一數據統計，廣東省藥品零售連鎖率為 41%。若按 70% 目標發展，廣東省或將有約一半的單體藥店面臨加盟、併購或被淘汰情況。

醫藥生產商和流通商加速轉型升級， 呈現多元化和數智化發展趨勢

在「醫保控費」政策引導、公立醫療機構用藥格局改變、分級診療制度等多重因素影響下，整個醫藥行業產業鏈面臨新變革，醫藥生產商和流通商紛紛加快商業模式轉型升級。面對更為激烈的業態競爭，醫藥流通企業商業模式勢必轉型升級，並不斷探索創新服務理念與服務模式，針對客戶不同需求提供差異化增值服務；醫藥生產商則加大對於藥品零售市場的投入和推廣，零售終端基礎扎實的藥品流通企業將更多地獲得生產商的青睞，鞏固開拓市場的優勢。

隨著大數據、物聯網等前沿技術被廣泛應用，醫藥物流領域業務呈現數智化和多元化發展趨勢。《指導意見》進一步指出，要推進「互聯網+藥品流通」，推動藥品流通行業進行數字

growth rate of 10.3% and a market share of 26.9%, which was 0.6 percentage points higher than that in 2020. In 2021, there were 57,784 enterprises holding the Pharmaceutical Business Licenses in Guangdong Province. Among them, there were 528 retail chain headquarters, 23,092 retail chain stores and 32,696 independent pharmacies. According to this data, the drug retail chain rate in Guangdong was 41%. In view of the target of 70%, about half of the independent pharmacies in Guangdong Province may join franchises, be merged or acquired, or be eliminated.

Pharmaceutical manufacturers and distributors have been accelerating their transformation and upgrading, showing a trend of diversified and digital-intelligence development

Under the influence of multiple factors such as the guidance of the policy for “control of expenses covered by medical insurance”, the change in the pattern of drug use in public medical institutions, and the graded diagnosis and treatment system, the whole pharmaceutical industry chain is facing new changes, and pharmaceutical manufacturers and distributors have been accelerating the transformation and upgrading of their business models. Facing more intense business competition, pharmaceutical distribution enterprises are bound to transform and upgrade their business models, and constantly explore innovative service concepts and service models to provide differentiated value-added services according to customers’ different needs; pharmaceutical manufacturers will increase their investments and promotion in the pharmaceutical retail market, and pharmaceutical distribution enterprises with solid retail terminals will gain more favor from manufacturers and consolidate their advantages in market development.

With the wide application of cutting-edge technologies such as big data and Internet of Things, pharmaceutical logistics presents a trend of digital intelligence and diversification. The Guiding Opinions further proposed to push forward the “Internet plus Drug Distribution” and promote the digital

化改造與升級。在此環境下，許多藥品流通企業積極探索數字化轉型，加強智能化、自動化物流技術和智能裝備的升級應用，並持續增強跨區域供應鏈物流協同能力，不斷探索分倉建設和多倉運營，助力整合供應鏈上下游各環節資源，促進「物流、信息流、資金流」三流融合，建立多元協同的醫藥供應鏈體系，提升全產業鏈的運行效率和競爭力。同時，全國性和區域性醫藥流通企業越來越重視向醫藥供應鏈解決方案服務商轉型，逐步建立起從製藥企業到病患者的全鏈條配送體系，並加快第三方物流業務拓展，充分發揮自身物流網絡優勢，為製藥企業提供全國、區域內多倉聯動的第三方醫藥物流服務。

委托第三方醫藥物流企業儲運的藥品批發企業數量逐步增長。據統計，截至 2022 年上半年，廣東省共有 1,400 多家藥品批發企業，其中委托第三方醫藥物流企業儲存、配送藥品的超 280 家，共有 560 多家連鎖藥店企業，其中委托廣東省內第三方醫藥物流企業的超 40 家。廣東省藥品零售格局市場格局呈現加速變化趨勢，區域性流通巨頭將憑藉自身綜合競爭優勢持續擴大市場份額。

transformation and upgrading of the drug distribution industry. In this context, many pharmaceutical distribution enterprises actively explore digital transformation, strengthen the upgrading and application of intelligent and automated logistics technology and intelligent equipment, continuously enhance the logistics collaboration capabilities of cross-regional supply chains, and constantly explore the construction of sub-warehouses and multi-warehouse operations, which will help integrate the resources of the upstream and downstream components of the supply chain, promote the integration of “logistics, information flow and capital flow”, and establish a diversified but collaborative pharmaceutical supply chain system, so as to enhance the operational efficiency and competitiveness of the whole industry chain. Meanwhile, the national and regional pharmaceutical distribution companies are increasingly focused on transforming into pharmaceutical supply chain solution service providers, gradually setting up a full-chain delivery system from pharmaceutical manufacturers to patients, accelerating the expansion of third-party logistics business, and giving better play to the advantages of their logistics networks to provide pharmaceutical manufacturers with nationwide and regional third-party pharmaceutical logistics services with synergistic effect among multiple warehouses.

The number of pharmaceutical wholesale enterprises engaging third-party pharmaceutical logistics enterprises for storage and transportation has gradually increased. According to statistics, for the first half of 2022, there were more than 1,400 pharmaceutical wholesale enterprises in Guangdong, among which more than 280 engaged third-party pharmaceutical logistics enterprises to store and distribute drugs, there were more than 560 chain pharmacy enterprises, among which more than 40 engaged third-party pharmaceutical logistics enterprises in Guangdong. Guangdong's drug retail market pattern shows a trend of accelerating changes, and regional distribution giants will continue to expand their market shares by virtue of their comprehensive competitive advantages.



踐行全生命週期健康管理理念，持續推動「健康中國」建設

中國「十四五」規劃提出，全面推進「健康中國」建設，把保障人民健康放在優先發展的戰略位置，為人民提供全方位全週期健康服務。

全生命週期健康管理，是從健康影響因素的廣泛性、社會性、整體性出發，以人的生命週期為主綫，對人的不同階段進行連續的健康管理和服務，對影響健康的因素進行綜合治理。後疫情時代，社會對健康的重視程度越來越高，居民健康消費意識逐步提升，越來越多的醫藥企業開啓藥品全生命週期管理模式探索，充分利用互聯網醫療、大數據等新技術，推動醫療服務體系為全民提供集預防、治療、康復和健康管理為一體的整合醫療，有助於推動醫藥產業健康發展，從而促進終端市場容量的增長。

以上數據及資料來源於：國家藥品監督管理局南方醫藥經濟研究所數據；米內網；《中國藥品流通行業發展報告》(2021)；《廣東省藥品監管統計年度報告（2021年）》；《中國藥品流通》期刊。

Health management throughout the life cycle has been implemented to continuously promote the construction of “Healthy China”

China’s 14th Five-Year Plan proposes to exhaustively advance the “Healthy China” initiative, put the protection of people’s health in a strategic position for prioritised development, and provide people with a full range of whole cycle health services.

Proceeding from the whole set of overall, wide-ranging and social influential factors on health, the whole life cycle health management performs continuous health management and provides relevant services at different stages of the mankind with a focus on their life cycle for the purpose of integrated management over those factors. In the post-epidemic era, society attaches more and more importance to health, and the health spending awareness of the residents gradually increases, more and more pharmaceutical companies are exploring the whole life cycle management model of drugs. They leverage on new technologies such as Internet-based medical care and big data to promote a medical service system that provides all the people with a full package of medical solutions integrating prevention, treatment, rehabilitation and health management, which helps promote the pharmaceutical industry’s healthy development and the volume expansion of the end market.

Sources of the above information: data of the Southern Medical Economic Research Institute of the National Medical Products Administration; MENET; Annual Report on China’s Pharmaceutical Distribution Industry (2021) (《中國藥品流通行業發展報告》(2021)); Guangdong Province Drug Regulatory Statistics Annual Report (2021) (《廣東省藥品監管統計年度報告（2021年）》), Journal of China Drug Circulation (《中國藥品流通》期刊).

業務回顧

我們的主要業務是於中國分銷藥品，而絕大部分營業收入來自藥品分銷。我們從醫藥生產商及分銷供應商採購藥品，銷售予分銷商，零售藥店、醫院、診所、衛生站及其他類客戶。我們始終專注於非招標市場業務，打破了傳統的大型分銷商專注於調撥，中小型分銷商專注於配送的模式，以自有物流中心為中心，對物流中心半徑 250 公里內非招標市場實行全面覆蓋，以精細化的管理和信息化技術進行「多品種、小批量、高頻次」的配送，同時，為上下游提供諮詢、推廣服務和第三方物流服務。

我們遵循制定的經營目標，繼續深耕廣東及輻射周邊市場，積極拓展零售終端網絡。截至 2022 年 6 月 30 日，我們的分銷網絡覆蓋 11,463 名客戶，其中 601 名為分銷商，7,211 名為零售藥店，3,651 名為醫院、診所、衛生站及其他。較上年度同期，客戶數量增加 824 名，其中分銷商減少 18 名，零售藥店增加 577 名，醫院、診所、衛生站及其他增加 265 名。

為滿足客戶不同需求及增強客戶黏合度，我們與國內外知名廠商加強合作，提高一級經銷產品的品種和規模；持續優化產品結構，引進適銷、毛利率高的優質產品，豐富產品種類。截至 2022 年 6 月 30 日，我們共

BUSINESS REVIEW

Our principal business is pharmaceutical distribution in the PRC, with most of our operating revenue derived from pharmaceutical distribution. We procure pharmaceutical products from pharmaceutical manufacturers and distributor suppliers and sell the products to distributors, retail pharmacy stores, hospitals, clinics, health centres and other customers. We have always been specialising in the non-tendering market business, changing the traditional mode that large distributors focus on allocation while small and medium distributors focus on distribution. We have fully covered the non-tendering markets within the radius of 250 km from our logistics centres as center point, and achieved “multi-variety, small-batch, high-frequency” distribution with refined management and information technology. Meanwhile, we provide consulting, promotion and third-party logistics services for upstream and downstream participants.

We followed the operation target set, and continued to explore Guangdong market in depth and radiating to surrounding areas, and developing the business with retail end-customers. As at 30 June 2022, our distribution network covered 11,463 customers, among which 601 were distributors, 7,211 were retail pharmacy stores and 3,651 were hospitals, clinics, health centres and others, representing an increase of 824 in the number of customers, a decrease of 18 distributors, an increase of 577 retail pharmacy stores, and an increase of 265 hospitals, clinics, health centres and others compared to the corresponding period of last year.

In order to meet the different needs of customers and enhance customer adhesion, we strengthened cooperation with well-known domestic and overseas manufacturers, and expanded the variety and scale of first-level distribution products; and continued to optimise product structure by introducing marketable, high-quality products with high profit margin to

有供應商 1,006 名，其中醫藥生產商 590 家及分銷供應商 416 家，較上年度同期持平。截至 2022 年 6 月 30 日止，我們分銷 11,657 種產品，較上年度同期減少 184 種。

enrich product categories. As at 30 June 2022, we had a total of 1,006 suppliers, of which 590 were pharmaceutical manufacturers and 416 were distributor suppliers, with the flat over the same period last year. As at 30 June 2022, we distributed 11,657 types of products, representing a decrease of 184 types of products compared to the corresponding period of last year.

| 產品類別 Product Category | 產品數量 截至 6 月 30 日止六個月 For the six months ended 30 June | |
|---------------------------------|---|----------------------------------|
| | 2022 年(未經審核) 2022 (Unaudited) | 2021 年(未經審核) 2021 (Unaudited) |
| 西藥 Western medicines | 4,431 | 4,383 |
| 中成藥 Chinese patent medicines | 4,283 | 4,513 |
| 其他 Others | 2,943 | 2,945 |
| 總計 Total | 11,657 | 11,841 |

積極拓展第三方物流，提升盈利能力

本公司及其附屬公司（統稱「本集團」）擁有完善的物流網絡和信息系統，統一 GSP 管理標準的倉儲條件，以創美藥業（廣州）醫藥分揀配送中心作為核心倉，打造領先的區域物流中心樞紐，通過與其他四個物流中心實現多倉協同，共享庫存及配送網絡優勢，能夠全面滿足自身藥品品類及數量快速增長對倉儲的需求同時，利用剩餘倉儲空間和物流配送能力，可為上下游提供其他倉儲或運輸等增值服務，為本集團創造收入，增強本集團的盈利能力。在滿足本集團自身業務倉儲、物流需求的情況下，截至 2022 年 6 月 30 日，本集團與廠家、商業分銷及連鎖藥店等近 100 家

We have actively expanded third-party logistics to improve profitability

The Company and its subsidiaries (the “Group”) has a well-established logistics network and information system and uniform storage conditions conforming to GSP management standards. It takes Charmacy (Guangzhou) Pharmaceutical Sorting and Distribution Center as the core warehouse, and has built a leading regional logistics hub. The Company had realised multi-warehouse collaboration with the other four logistics centers and shared the advantages in inventory and distribution network. As such, the Company can not only fully meet its own warehousing need due to the rapid growth of drug categories and quantities, but also provide warehousing, transportation or other value-added services for upstream and downstream participants by using the surplus storage room and logistics distribution capacity, thereby generating revenues for the Group and improving the Group’s profitability. In addition to meeting the warehousing and logistics needs from the Group’s own

客戶達成第三方醫藥物流委托業務及其他倉儲或運輸等增值服務合作。

未來展望

我們牢記「創造健康美好生活」的使命，秉承「誠信經營，利他利眾，合作共贏」的經營理念，堅持以「深耕廣東，輻射周邊」為發展戰略，致力成為中國醫藥健康產業最具市場競爭力服務商。

當前國內新冠疫情防控進入常態化，隨著我國加快構建以國內大循環為主體、國內國際雙循環相互促進的新發展格局，藥品流通行業將迎來新的發展機遇。「三醫聯動」改革的深入推進加速「健康中國」戰略落地，以「兩票制」、「帶量採購」為關鍵詞的醫藥改革，一方面引起覆蓋招標市場的流通企業成本上升、利潤下滑、產品結構調整，另一方面則提升了市場集中度、放大了產品品種優勢，使第三方物流服務迎來機遇。

藥品批發企業努力優化網絡結構及服務功能，由過去橫向拓展轉變為縱向下沉，進一步優化城市與鄉鎮等地區

business, by 30 June 2022, the Group had cooperated with nearly 100 customers (such as manufacturers, commercial distributors and chain pharmacies) in third-party pharmaceutical logistics business and other value-added services (such as warehousing or transportation).

PROSPECTS

With the mission of “Creating a healthy, beautiful life” firmly in mind, we will uphold the business philosophy of “Operating honestly, creating benefits for others and the general public and achieving win-win outcomes through cooperation”. We follow the development strategy of focusing on “Intensive Engagement in Guangdong Province and Extensive Coverage across Surrounding Areas”, and commit ourselves to becoming the most competitive health and medical service provider in China.

The pharmaceutical distribution industry will have new development opportunities with the prevention and control of COVID-19 epidemic in China having become a regular practice, and with China accelerating the establishment of a dual circulation development pattern in which domestic and foreign markets reinforce each other with the domestic market as the mainstay. The in-depth promotion of reform of medical care, medical insurance and pharmaceutical industry has speeded up the implementation of the “Healthy China” initiative. The medical reform represented by the “Two-Invoice System” and “Centralised Procurement In Large Quantities” leads to cost increase, profit decrease, and product structure adjustment in distribution enterprises which cover the bidding market and bring up opportunities to the third-party logistics service under the advantages of higher market concentration and greater product.

Pharmaceutical wholesale enterprises have been striving to optimise their network structures and service capabilities, and transitioning from previous horizontal expansion to vertical



的配送服務網絡。以「醫藥分開」、「分級診療」為主的醫療改革，在使招標市場商業規模受到擠壓的同時，也使零售、基層診療市場迎來重大機遇。

從長期來看，中國經濟韌性及潛力兼備，穩中求進的趨勢不會改變。並且，隨著醫改的推進，國家對醫療衛生持續加大投入，人口老化程度加速，及人民健康意識的增強，國內醫療健康產業的潛力預計將會加速釋放，帶動非招標市場的市場份額將逐步擴大，將有利於我們業務的長期發展。

面對行業發展機遇，我們順應政策變化，認真學習、深入領會，並在實踐中努力貫徹實施醫藥行業相關政策，緊抓政策機遇，積極尋找市場機會，不斷推進市場網絡拓展和服務提升，加強精細化管理，促進高質量發展，確保在競爭中保持優勢。

我們將堅持實施「深耕廣東，輻射周邊」的市場戰略，建設全面覆蓋廣東省及周邊地區的醫藥零售終端網絡。我們將加強風險管理，提高經營質量，把握基層醫療市場擴容的機遇，不斷拓展和細化滲透每個區域的分銷網絡，優化網點布局，擴大零售藥店、各類基層醫療衛生服務機構等醫藥零售終端的藥品配送覆蓋面，全方位實現廣東市場及周邊地區的銷售、服務及物流網絡的密集覆蓋。

sinking so as to further optimise their delivery service networks in cities, towns and other areas. The medical reform which focuses on the separation of medical care and pharmacy and the hierarchical medical system squeezes the business scale of bidding market, but also brings up significant opportunities for the retail and primary diagnosis market.

In the long run, China's economy has both tenacity and growth potential, and the trend of steady progress will not change. Moreover, with the advancement of the medical reform, the government's increasing inputs into healthcare, the acceleration of ageing population and the enhancement of people's health awareness, the potential of China's medical and health industry is expected to be released faster, driving the market share of the non-tendering market to gradually expand, which will contribute to the long-term growth of our business.

Facing the industry development opportunities, we need to secure an edge in competition, earnestly study, deeply understand, and conscientiously implement the relevant policies for the pharmaceutical industry, positively grasp the policy opportunities and seek market opportunities to constantly push our market network development and improve our services, enhance our refined management, and achieve a high quality growth, so as to maintain a leading position in competition.

We adhere to the market strategy of “Intensive Engagement in Guangdong Province and Extensive Coverage across Surrounding Areas” and build a pharmaceutical retail terminal network with full coverage in Guangdong Province and surrounding areas. We will strengthen risk management, improve business quality, seize the opportunities arising from the expansion of the primary medical market, further construct the regional pharmaceutical distribution centres and constantly expand and develop the distribution networks in all areas by constantly expanding and refining the distribution networks that permeate every region, optimising the network layout, and

expanding the pharmaceutical delivery coverages of pharmaceutical retail terminals such as retail pharmacies and various grassroots medical and health service institutions to fully achieve a dense coverage of sales, service, and logistics network in Guangdong and its surrounding areas.

我們將積極探索「互聯網+醫藥」的可行性落地方法，通過電商平台進行服務賦能。我們將抓住基層醫療市場擴容中「互聯網+醫療」和分級診療等制度逐步落地的契機，不斷升級開發 B2B 電商平台的功能應用，積極探索新技術及新營銷手段，結合多維度全方位的營銷及運營，更高效地提升供應鏈產品流轉，以優質的服務和契合的工具讓更多的客戶獲利，進一步提升客戶黏性。我們將積極推動醫藥流通及配送服務的標準化、流程化、智慧化，不斷提升我們的服務能力，以達到低成本、高效率的經營效果。

我們將尋求與各大醫藥生產商的長期及深度的戰略合作。我們將著重加強與各大處方藥廠商的合作，爭取更多轉戰非招標市場產品的增長機會，豐富我們的產品組合，夯實品種優勢，並借助本集團的醫藥零售終端網絡資源及優勢，為上游供應商提供全方位的品牌宣傳及產品落地方案設計和支持服務保障。

We will actively develop feasible promotion measures for “Internet + Healthcare” and empower services through e-commerce platforms. We will grasp the opportunity arising from gradual implementation of regulations including “Internet + Healthcare” and the hierarchical medical system in the expansion of primary medical market, and constantly upgrade, develop the functions and applications of B2B e-commerce platform, and actively explore new technologies and new marketing methods, combining with multi-dimensional and comprehensive marketing and operation. We will speed up the product transfer in supply chain with higher efficiency and allow more clients to benefit from our excellent services and suitable tools, thus further enhancing customer stickiness. We will actively promote standardised, streamlined, and intelligent pharmaceutical delivery service and constantly improve our service ability to achieve operation result efficiently with a low cost.

We will search for long-term and deep strategic cooperation with pharmaceutical producers. We will focus on strengthening our cooperation with major prescription drug manufacturers to capture more growth opportunities in non-tendering market products, diversify our product portfolios and cement the strength of our products. Using the pharmaceutical retail terminal network resources and supremacy of the Group, we will provide upstream suppliers with across-the-board brand promotions and product landing program design and support service guarantee.

我們將繼續加強醫藥物流現代化的能力建設，積極拓展第三方物流業務。

我們將積極探索智慧物流技術應用，整合運輸資源提升配送服務能力，推進區域一體化物流的協調發展，提升整體運營能力。我們將憑藉強大的物流倉儲能力，通過整合藥品倉儲和運輸資源，實現多倉協同。我們將進一步發揮本集團精細化管理和服務的優勢，拓展終端配送網絡，使醫藥物流網絡布局更加合理。同時，我們將積極拓展第三方醫藥物流業務，利用自身物流網絡優勢，為上游供貨商及下游客戶提供專業便利的倉儲、物流及貨物運輸等更多增值服務，以增強本集團市場競爭能力和盈利能力。

我們將積極探索與國有戰略股東的合作模式，進一步優化本集團股東結構與治理結構。我們將適時為本集團引入新的業務發展資源，助力市場影響力持續提升，進一步強化本集團的軟實力和競爭力，促進本集團更好更可持續發展。

展望未來，我們將持續把握醫藥非招標市場未來增長潛力，加快複製成熟的醫藥非招標市場運營模式，致力提高醫藥供應鏈運營效率，優化醫藥產品組合及客戶服務體驗，降低醫藥流

We will continue to strengthen the capacity building for pharmaceutical logistics modernisation and actively expand the third-party logistics business. We will actively explore the application of smart logistics technology, integrate transportation resources to enhance delivery service capabilities and promote the coordinated development of regional integrated logistics, thereby enhancing the overall operational capability. Leveraging on our strong logistic and warehousing capabilities, our warehousing and sorting scale will be expanded, and multi-warehouse collaboration by integrating pharmaceutical warehousing and transportation resources will be attained. We will further unleash our advantages in customers, products, management and services and expand the terminal delivery network, so that the pharmaceutical logistics network arrangement is more reasonable. At the same time, we will actively expand the third-party pharmaceutical logistics business to enhance storage utilisation rate, increase transportation efficiency, and leverage on our own logistics network advantages to provide upstream suppliers and downstream customers with professional and convenient warehousing, logistics and cargo transportation, so as to enhance the Group's market competitiveness and profitability.

We will actively explore the mode of cooperation with strategic state-owned shareholders, and further optimise our Group's shareholder structure and governance structure. We will introduce new business development resources and market influence to our Group in good time, facilitate the continuous improvement of the market influence, further strengthen our Group's soft power and competitiveness, and promote our Group's better and more sustainable development.

Looking ahead, we will continue to ride on the future growth potential of the pharmaceutical non-tendering market, accelerate the duplication of the mature non-tendering pharmaceutical market operation model, strive to elevate the operation efficiency of our pharmaceutical supply chain, optimise the

通成本，努力成為中國醫藥健康產業最具市場競爭力服務商。

portfolio of pharmaceutical products and customer service experience, and reduce the cost of pharmaceutical distribution, endeavouring to become the most competitive service provider in the medical and healthcare industry in China.

財務回顧

FINANCIAL REVIEW

營業收入

Operating revenue

| 項目 Items | 截至 6 月 30 日止六個月 For the six months ended 30 June | |
|----------------------------|--|--|
| | 2022 年 人民幣千元(未經審核) 2022 RMB'000 (Unaudited) | 2021 年 人民幣千元(未經審核) 2021 RMB'000 (Unaudited) |
| 主營業務 Principal business | 1,868,014 | 1,978,106 |
| 其他業務 Other businesses | 19,065 | 14,908 |
| 營業收入 Operating revenue | 1,887,079 | 1,993,014 |

| 客戶類型 Customer type | 截至 6 月 30 日止六個月 For the six months ended 30 June | |
|---|--|--|
| | 2022 年 人民幣千元(未經審核) 2022 RMB'000 (Unaudited) | 2021 年 人民幣千元(未經審核) 2021 RMB'000 (Unaudited) |
| 分銷商 Distributors | 877,786 | 908,768 |
| 零售藥店 Retail pharmacy stores | 907,672 | 997,840 |
| 醫院、診所、衛生站及其他 Hospitals, clinics, health centres and others | 82,556 | 71,498 |
| 主營業務收入 Revenue from principal business | 1,868,014 | 1,978,106 |

於截至 2022 年 6 月 30 日止六個月，我們的主營業務收入來自向(i)分銷商客戶；(ii)零售藥店；及(iii)醫院、診所、衛生站及其他的產品銷售。截至 2022 年 6 月 30 日止六個月，超過 95% 的主營業務收入來自分銷商客戶

During the six months ended 30 June 2022, our revenue from principal business was derived from product sales to (i) distributor customers; (ii) retail pharmacy stores; and (iii) hospitals, clinics, health centres and others. During the six months ended 30 June 2022, over 95% of our revenue from principal business was derived from distributor customers and

和零售藥店客戶。

我們的營業收入由截至 2021 年 6 月 30 日止六個月的人民幣 1,993.01 百萬元減少 5.32%，至截至 2022 年 6 月 30 日止六個月的人民幣 1,887.08 百萬元，主要由於今年上半年廣東省新冠疫情反復，零售藥店受限流、限售等防疫管控，從而影響藥店客流及銷量，導致收入下降。

營業成本、毛利及毛利率

本集團的營業成本由截至 2021 年 6 月 30 日止六個月的人民幣 1,857.97 百萬元減少 5.13%，至截至 2022 年 6 月 30 日止六個月的人民幣 1,762.71 百萬元。營業成本降幅與營業收入降幅持平。

本集團的毛利由截至 2021 年 6 月 30 日止六個月的人民幣 135.05 百萬元減少 7.90% 至截至 2022 年 6 月 30 日止六個月的人民幣 124.37 百萬元。本集團的毛利率由 2021 年 6 月 30 日止六個月的 6.78% 下降至截至 2022 年 6 月 30 日止六個月的 6.59%。主要由於今年上半年廣東省新冠疫情反復，零售藥店受限流、限售等防疫管控，從而影響藥店客流及銷量，同時，也影響了部分高毛利產品的推廣和銷售。

銷售費用

本集團的銷售費用由截至 2021 年 6 月 30 日止六個月的人民幣 52.28 百萬元增加 2.92% 至截至 2022 年 6 月 30 日止六個月的人民幣 53.81 百萬

零售藥店客戶。

Our operating revenue decreased by 5.32% to RMB1,887.08 million for the six months ended 30 June 2022 from RMB1,993.01 million for the six months ended 30 June 2021, mainly because retail pharmacies' epidemic prevention and control measures (such as visitor flow and sales restrictions) affected the visitor flows and sales when the COVID-19 epidemic occurred repeatedly in Guangdong Province in the first half of this year.

Operating cost, gross profit and gross profit margin

The operating cost of the Group decreased by 5.13% to RMB1,762.71 million for the six months ended 30 June 2022 from RMB1,857.97 million for the six months ended 30 June 2021. The decline of operating costs was at par with that of revenue.

The gross profit of the Group decreased by 7.90% to RMB124.37 million for the six months ended 30 June 2022 from RMB135.05 million for the six months ended 30 June 2021. The gross profit margin of the Group decreased to 6.59% for the six months ended 30 June 2022 from 6.78% for the six months ended 30 June 2021. This is mainly because retail pharmacies' epidemic prevention and control measures (such as visitor flow and sales restrictions) affected the visitor flows and sales and the promotion and sales of some products with high gross profit margins when the COVID-19 epidemic occurred repeatedly in Guangdong Province in the first half of this year.

Selling expenses

The selling expenses of the Group increased by 2.92% to RMB53.81 million for the six months ended 30 June 2022 from RMB52.28 million for the six months ended 30 June 2021. Main reason is the corresponding market maintenance cost

元。主要原因為因開拓終端業務以致相應市場維護費用增加。

管理費用

本集團的管理費用由截至 2021 年 6 月 30 日止六個月的人民幣 18.99 百萬元減少 3.09% 至截至 2022 年 6 月 30 日止六個月的人民幣 18.40 百萬元。主要原因為通過提高職能部門人員的工作效率，優化人員結構配置，導致薪酬及辦公費用合計減少。

財務費用

本集團的財務費用由截至 2021 年 6 月 30 日止六個月的人民幣 21.80 百萬元減少 12.55% 至截至 2022 年 6 月 30 日止六個月的人民幣 19.06 百萬元。主要由於長期貸款減少，導致利息支出減少人民幣 0.85 百萬元，及充分調配資金，使貼現利息減少人民幣 2.11 百萬元。

營業外收入

截至 2022 年 6 月 30 日止六個月，營業外收入為人民幣 0.59 百萬元，較截至 2021 年 6 月 30 日止六個月的營業外收入人民幣 0.07 百萬元增加 748.50%。主要是由於收到 2020 年度汕頭市促進大型商貿企業發展拉動消費獎補貼收入，增加政府補助人民幣 0.55 百萬元。

所得稅費用

本集團的所得稅費用由截至 2021 年 6 月 30 日止六個月的人民幣 8.57 百萬元減少 39.22% 至截至 2022 年 6 月 30 日止六個月的人民幣 5.21 百萬

increased due to the developed terminal business.

Management expenses

The management expenses of the Group decreased by 3.09% to RMB18.40 million for the six months ended 30 June 2022 from RMB18.99 million for the six months ended 30 June 2021. The main reason is the decrease in the remunerations and office expenses thanks to the improvement of the working efficiency of functional departments and the optimisation of the allocation of personnel structures.

Finance costs

The finance costs of the Group decreased by 12.55% to RMB19.06 million for the six months ended 30 June 2022 from RMB21.80 million for the six months ended 30 June 2021. This is mainly because the interest expenses decreased by RMB0.85 million due to the decrease in long-term loans, and the discount interest decreased by RMB 2.11 million due to the full allocation of funds.

Non-operating revenue

For the six months ended 30 June 2022, non-operating revenue amounted to RMB0.59 million, representing a increase of 748.50% as compared with the non-operating revenue of RMB0.07 million for the six months ended 30 June 2021. This is mainly because Shantou Municipality's subsidy for promoting the development of large-scale commercial enterprises and stimulating consumption in 2020 increased the Group's government subsidy receipt by RMB0.55 million.

Income tax expenses

The income tax expenses of the Group decreased by 39.22% to RMB5.21 million for the six months ended 30 June 2022 from RMB8.57 million for the six months ended 30 June 2021, and the current income tax expenses were recognised and the

元，均按會計準則確認當期所得稅費用和調整遞延所得稅資產及遞延所得稅負債。

淨利潤

本集團的淨利潤由截至 2021 年 6 月 30 日止六個月的人民幣 25.96 百萬元減少 20.50% 至截至 2022 年 6 月 30 日止六個月的人民幣 20.64 百萬元。其中，歸屬母公司股東的淨利潤由 2021 年 6 月 30 日止六個月的人民幣 25.96 百萬元減少 20.50% 至截至 2022 年 6 月 30 日止六個月的人民幣 20.64 百萬元。主要由於收入及毛利率略微下降所致。

流動資金及財務資源

於 2022 年 6 月 30 日，本集團持有現金及銀行存款為人民幣 67.98 百萬元，而於 2021 年 12 月 31 日則為人民幣 144.23 百萬元。

於 2022 年 6 月 30 日及 2021 年 12 月 31 日，本集團分別錄得流動資產淨值人民幣 98.68 百萬元及人民幣 79.30 百萬元。於 2022 年 6 月 30 日，本集團的流動比率（按流動資產除以流動負債計算）為 1.05（2021 年 12 月 31 日：1.04）。

本集團於 2022 年 6 月 30 日銀行借款為人民幣 618.31 百萬元（短期借款：人民幣 515.49 百萬元，長期借款：人民幣 102.82 百萬元，其中，一年內到期的長期借款：人民幣 31.75 百萬元）。所有銀行借款均按固定利率計息。銀行借款的賬面值以

deferred income tax assets and liabilities were adjusted according to the accounting standards.

Net profit

The net profit of the Group decreased by 20.50% to RMB20.64 million for the six months ended 30 June 2022 from RMB25.96 million for the six months ended 30 June 2021. In particular, the net profit attributable to the shareholders of parent company decreased by 20.50% to RMB20.64 million for the six months ended 30 June 2022 from RMB25.96 million for the six months ended 30 June 2021. This is mainly due to the slight decrease in the revenue and the gross profit margin.

Liquidity and financial resources

As at 30 June 2022, the cash and bank deposits of the Group amounted to RMB67.98 million, while the cash and bank deposits amounted to RMB144.23 million as at 31 December 2021.

As at 30 June 2022 and 31 December 2021, the Group recorded net current assets of RMB98.68 million and RMB79.30 million, respectively. As at 30 June 2022, the current ratio (based on the calculation of current assets divided by current liabilities) of the Group was 1.05 (31 December 2021: 1.04).

The bank borrowings of the Group as at 30 June 2022 were RMB618.31 million (short-term borrowings: RMB515.49 million, long-term borrowings: RMB102.82 million, including long-term borrowings due within one year: RMB31.75 million). All the bank borrowings bear fixed interest rates. The carrying amount of the bank borrowings is presented in RMB, and is approximate to the fair value. The Group did not use any

人民幣為單位，與公平值相若。本集團並無使用任何財務工具作對沖用途，亦無任何以現有借款及／或其他對沖工具對沖的外幣淨額投資。

應收票據、應收賬款及應收款項融資

於 2022 年 6 月 30 日，本集團應收票據、應收賬款及應收款項融資金額為人民幣 761.79 百萬元，比 2021 年 12 月 31 日應收票據、應收賬款及應收款項融資增加人民幣 30.53 百萬元。主要由於今年廣東省於 6 月份開始持續高溫天氣，進入流感高發流行期，因此當月銷售收入同比增加人民幣 67.37 百萬元，導致報告期末應收款總額有所增加。

應付票據及應付賬款

於 2022 年 6 月 30 日，本集團應付票據及應付賬款金額為人民幣 1,333.28 百萬元，比 2021 年 12 月 31 日應付票據及應付賬款金額減少人民幣 9.35 百萬元。主要由於充分利用供應商給予的賬期及銀行給予的票據敞口額度，有效配置資金使用。

庫務政策

本集團在執行庫務政策上採取審慎的財務管理策略，因而於整段回顧期間內維持健全的流動資金狀況。本集團不斷評估其客戶的信貸狀況及財務狀況，務求降低信貸風險。為控制流動資金風險，本公司董事（「董事」）會（「董事會」）密切監察本集團的流動資金狀況，確保本集團的資產、負債及其他承擔的流動結構符合不時的資金需要。

financial instruments for hedging purposes or did not have any existing borrowings and/or other hedging instruments for hedging net foreign currency investments.

Bill receivables, trade receivables and account receivable financing

As at 30 June 2022, the Group's bills receivables, trade receivables and account receivable financing amounted to RMB761.79 million, representing an increase of RMB30.53 million compared to those as at 31 December 2021. This is mainly because Guangdong Province ushered in the hot weather and a period of high incidence of influenza in June, so that the sales revenue in that month increased by RMB 67.37 million year-on-year, resulting in an increase in the total receivables at the end of the Reporting Period.

Bills payables and trade payables

As at 30 June 2022, the Group's bill payables and trade payables amounted to RMB1,333.28 million, representing a decrease of RMB9.35 million compared to those as at 31 December 2021. This is mainly because the funds were effectively allocated through the full use of the credit periods allowed by the suppliers and the bill exposure limits granted by the banks.

Treasury policy

The Group adopts a prudent financial management strategy in executing its treasury policy. Thus, a sound liquidity position was able to be maintained throughout the period under review. The Group continues to assess its customers' credit and financial positions so as to minimise credit risks. In order to control liquidity risks, the board (the "Board") of directors of the Company (the "Directors") would closely monitor the liquidity position of the Group to ensure that its assets, liabilities and other flow structure committed by the Group would satisfy the funding needs from time to time.

外匯風險

本集團的交易以人民幣計值。大多數資產以及全部負債均以人民幣計值，本集團須承擔的外匯風險極低。截至2022年6月30日止六個月，本集團並無利用任何財務工具對沖外幣風險。

利率風險

截至2022年6月30日止六個月，本集團並無以浮動利率計息的銀行借款。

資本管理

於2022年6月30日及2021年12月31日，本集團的資本負債比率列示如下：

| | 2022年6月30日 30 June 2022 | 2021年12月31日 31 December 2021 |
|-------------------------|----------------------------|---------------------------------|
| 資本負債比率 Gearing ratio | 51.19% | 56.03% |

註：資本負債比率等於期末債務淨額除以總資本。債務淨額等於總借款減現金及現金等價物；總資本等於債務淨額與總權益總和。

資本承擔

於2022年6月30日，本集團無資本承擔（2021年12月31日：無）。

僱員資料

於2022年6月30日，本集團共有820名僱員，包括執行董事，較於2021年6月30日減少22名。總員工成本（包括董事、監事酬金）為人民幣36.87百萬元，而截至2021年6

Foreign currency exchange risk

The transactions of the Group are denominated in RMB, and most of the assets and all liabilities are denominated in RMB. The foreign exchange risk that the Group has to bear is extremely low. For the six months ended 30 June 2022, the Group did not use any financial instruments for hedging the foreign currency risk.

Interest rate risk

For the six months ended 30 June 2022, the Group had no bank borrowings which bear interest at floating rate.

Capital management

Set out below is the Group's gearing ratios as at 30 June 2022 and 31 December 2021, respectively:

Note: Gearing ratio is equal to net liabilities divided by aggregate capital as at the end of the period. Net liabilities represent total borrowings deducted by cash and cash equivalents; and aggregate capital is the sum of net liabilities and total equity.

Capital commitment

As at 30 June 2022, the Group's capital commitment amounted to nil. (31 December 2021: Nil).

Employees' information

As at 30 June 2022, the Group had a total of 820 employees (including executive Directors), representing a decrease of 22 employees compared with the number of employees as at 30 June 2021. The total staff cost (including emoluments of directors and supervisors) was RMB36.87 million, as compared

月 30 日止六個月則為人民幣 37.67 百萬元。酬金乃參考市場常規及個別僱員的表現、資歷及經驗釐定。

除基本薪金外，亦可視乎本集團的業績及個人表現獲發花紅。其他員工福利包括中國《勞動法》、《勞動合同法》、《社會保險法》規則及規例以及中國現行相關監管規定獲本集團聘用的僱員而設的其他相關保險。

本集團僱員的薪金及福利均處於具競爭力的水準，僱員的待遇均在本集團就薪酬及花紅設定的整體框架內按表現釐定，而該框架每年進行檢討。

本集團注重僱員的職業發展，為僱員定期舉行內部培訓以及提供外部培訓機會，支持與鼓勵僱員不斷進修，提升僱員自身綜合素質及業務能力。

所持重大投資、收購及出售

於截至 2022 年 6 月 30 日止六個月內，本集團並無任何重大投資、收購及出售。

有關重大投資及資本資產的未來計劃

截至本報告日期，本集團並無有關重大投資及資本資產的未來計劃。

有關附屬公司、聯營公司及合營企業的重大收購及出售

於截至 2022 年 6 月 30 日止六個月

to RMB37.67 million for the six months ended 30 June 2021. The emoluments were determined with reference to market practice and the performance, qualification and experience of individual employees.

The employees are entitled to bonus based on the results of the Group and individual performance other than basic salaries. Other staff benefits include other related insurances set up for the employees employed by the Group in accordance with the rules and regulations under Labor Law, Employment Contract Law, Social Insurance Law of the PRC and the current regulatory requirements of the PRC.

The salaries and benefits of the employees of the Group are kept at a competitive level. The employees are rewarded on a performance-related basis within the general framework of the Group's salary and bonus system, which is reviewed annually.

The Group focuses on the career development of its employees. We provide the employees with internal training and the opportunity of external training on a regular basis to support and encourage them to continuously study and to improve their own integrated qualities and business capability.

Significant investments held, acquisitions and disposals held

The Group had no significant investment, acquisition or disposal during the six months ended 30 June 2022.

Future plans related to significant investments and capital assets

As at the date of this report, the Group has no future plans related to significant investments and capital assets.

Material acquisitions and disposals related to subsidiaries, associates and joint ventures

During the six months ended 30 June 2022, the Group had no

內，本集團並無任何有關附屬公司、聯營公司及合營企業的重大收購及出售。

資產抵押

於 2022 年 6 月 30 日，各銀行給予本集團的授信額度為人民幣 1,444.80 百萬元，本集團已動用之銀行信貸總額為人民幣 1,069.96 百萬元，由於(i)本集團於 2022 年 6 月 30 日所持賬面值為人民幣 263.27 百萬元的物業、廠房及設備；(ii)本集團於 2022 年 6 月 30 日所持賬面值為人民幣 128.99 百萬元的土地使用權；及(iii)本集團於 2022 年 6 月 30 日的賬面值為人民幣 350 百萬元的存貨作抵押。

所有權或使用權受到限制的資產

於 2022 年 6 月 30 日，本集團受限制的貨幣資金為人民幣 375.63 百萬元，作為銀行承兌匯票保證金、借款保證金；本集團受到限制的應收票據及應收款項融資為人民幣 1.40 百萬元，受限原因為質押予銀行及票據貼現；本集團亦已抵押若干其他資產合計人民幣 742.26 百萬元，作為本集團借款之擔保。所有權或使用權受到限制的資產合計人民幣 1,119.28 百萬元。

或然負債

於 2022 年 6 月 30 日，本集團並無任何重大或然負債（2021 年：無）。

報告期後重大事項

截至本報告日期，於報告期後本集團概無須予披露的重大事項。

material acquisitions and disposals related to subsidiaries, associates and joint ventures.

Pledge of assets

As at 30 June 2022, the Group was granted a credit limit of RMB1,444.80 million by various banks, while the Group's utilised banking facilities totalled RMB1,069.96 million, which were secured by (i) property, plant and equipment held by the Group with a carrying amount of RMB263.27 million as at 30 June 2022; (ii) land use rights held by the Group with a carrying amount of RMB128.99 million as at 30 June 2022; and (iii) the Group's inventories with a carrying amount of RMB350 million as at 30 June 2022.

Assets subject to restrictions on ownership or use

As at 30 June 2022, the Group's restricted monetary funds amounted to RMB375.63 million, which served as deposit for bank acceptance bills and borrowings; the Group's restricted bills receivable and account receivable financing amounted to RMB1.40 million, which were restricted for being pledged to banks and for bill discounting; the Group also pledged certain other assets totalling RMB742.26 million as guarantee for the Group's borrowings. Assets subject to restrictions on ownership or use totalled RMB1,119.28 million.

Contingent liabilities

As at 30 June 2022, the Group had no material contingent liabilities (2021: Nil).

Significant event after the reporting period

As at the date of this report, the Group had no significant events after the Reporting Period.

中期股息

董事會不建議就截至 2022 年 6 月 30 日止六個月派付中期股息（2021 年中期股息：無）。

其他資料

企業管治常規

截至 2022 年 6 月 30 日止六個月內，本公司一直遵守香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）附錄十四第二部分所載之企業管治守則的守則條文（「守則條文」），惟下文所述偏離情況除外：

根據守則條文第 C.2.1 條，主席及首席執行官的職責應獨立分開，不應由同一人履行。姚創龍先生為本集團的首席執行官，因彼擁有豐富的醫藥分銷行業經驗，因此亦擔任董事會主席。董事會認為由同一人擔任董事會主席及首席執行官利於保證本集團領導一致，使本集團整體戰略策劃更有效及高效。本公司認為現時安排下的權力與權限之間的平衡將不會受到損害，且該架構將令本公司快捷有效地作出及執行決策。本公司將繼續檢討，並於適當與合適時基於本集團的整體情況考慮區分董事會主席及首席執行官的職責。

INTERIM DIVIDEND

The Board does not recommend the payment of an interim dividend for the six months ended 30 June 2022 (interim dividend of 2021: Nil).

OTHER INFORMATION

CORPORATE GOVERNANCE PRACTICES

The Company had been complying with the code provisions (the “Code Provision(s)”) set out in the Corporate Governance Code contained in Part 2 of Appendix 14 to the Rules (the “Listing Rules”) Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “Stock Exchange”) for the six months ended 30 June 2022, save for the deviation as stated below:

Pursuant to Code Provision C.2.1, the responsibilities between the chairman and chief executive officer should be separated and should not be performed by the same individual. Mr. Yao Chuanglong is our chief executive officer, and he also performs as the chairman of our Board as he has considerable experience in the pharmaceutical distribution industry. Our Board believes that vesting the roles of both the chairman of our Board and the chief executive officer in the same person has the benefit of ensuring consistent leadership within our Group and enables more effective and efficient overall strategic planning of our Group. The Company considers that the balance of power and authority under the present arrangement will not be impaired and this structure will enable the Company to make and implement decisions promptly and effectively. The Company will continue to review and consider splitting the roles of chairman of the Board and chief executive officer when it is appropriate and suitable by taking into account the circumstances of the Group as a whole.

本公司將繼續檢討其企業管治常規，以提升其企業管治標準，遵守日益嚴格的監管規定，並滿足本公司股東及投資者日益增長的期望。

董事及監事進行證券交易之標準守則

本公司已採納上市規則附錄十所載上市發行人董事進行證券交易的標準守則（「標準守則」）為董事及本公司監事（「監事」）進行本公司證券交易之行為守則。本公司確認經向所有董事及監事查詢，截至 2022 年 6 月 30 日止六個月內所有董事及監事均遵守了標準守則所載之規定標準。

根據香港上市規則第 13.51B 條將予披露之資料

自二零二二年七月十三日起，張寒孜女士獲委任為執行董事；付征女士獲委任為非執行董事。

經本公司作出特定查詢及經董事及監事確認後，除上文所披露者外，於 2021 年年報日期後，概無根據上市規則第 13.51(2)條第(a)至(e)段及第(g)段須予披露的任何董事及監事資料之其他變動須根據上市規則第 13.51B(1)條予以披露。

The Company will continue to review its corporate governance practices in order to enhance its corporate governance standard, to comply with the increasingly tightened regulatory requirements and to meet the rising expectations of the shareholders and investors.

MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS AND SUPERVISORS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the “**Model Code**”) set out in Appendix 10 to the Listing Rules as the code of conduct in dealings with the Company’s securities for the Directors and supervisors of the Company (“**Supervisor(s)**”). Having made enquiries with all Directors and Supervisors of the Company, the Company confirmed that all Directors and Supervisors had complied with the required standard as set out in the Model Code for the six months ended 30 June 2022.

INFORMATION TO BE DISCLOSED PURSUANT TO RULE 13.51B OF THE LISTING RULES

With effect from 13 July 2022, Ms. Zhang Hanzi has been appointed as an executive Director and Ms. Fu Zheng has been appointed as a non-executive Director.

After making specific enquiries by the Company and confirmed by the Directors and the Supervisors, save as disclosed as above, no other changes in the information of any Directors and Supervisors after the date of the Annual Report 2021 that are required to be disclosed pursuant to paragraphs (a) to (e) and paragraph (g) of Rule 13.51(2) of the Listing Rules have to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

購買、出售或贖回本公司上市證券

截至 2022 年 6 月 30 日止六個月內，本公司及其附屬公司概無購買、出售或贖回本公司任何上市證券。

董事、監事及最高行政人員於股份、相關股份及債權證之權益或淡倉

於 2022 年 6 月 30 日，本公司董事、監事及最高行政人員於本公司、其集團成員及/或相聯法團（定義見證券及期貨條例（「證券及期貨條例」）第 XV 部）的本公司股份（「股份」）、相關股份及債權證中，擁有已記入根據證券及期貨條例第 352 條規定存置的登記冊之權益，或根據標準守則已知會本公司及聯交所的權益如下：

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES OF THE COMPANY

For the six months ended 30 June 2022, the Company and its subsidiaries did not purchase, sell or redeem any of the listed securities of the Company.

INTERESTS OR SHORT POSITIONS OF THE DIRECTORS, SUPERVISORS AND CHIEF EXECUTIVES IN THE SHARES, UNDERLYING SHARES, AND DEBENTURES

As at 30 June 2022, the interests of the Directors, Supervisors and chief executives of the Company in the shares of the Company (the "Share(s)"), underlying Shares and debentures of the Company, its members of the Group and/ or any of its associated corporations (as defined in Part XV of the Securities and Futures Ordinance (the "SFO")) as recorded in the register required to be kept under Section 352 of the SFO or as notified to the Company and the Stock Exchange pursuant to the Model Code were as follows:

| 董事姓名 Name of Director | 身份／權益性質 Capacity/Nature of interest | 股份類別及數目 Class and number of Shares | 佔已發行股本總額的概約持股百分比 ⁽¹⁾ Approximate shareholding percentage of the total issued share capital ⁽¹⁾ |
|-----------------------------|--|--|---|
| 姚創龍先生 Mr. Yao Chuanglong | 實益擁有人 Beneficial owner | 44,250,000 股 H 股 (L) 44,250,000 H Shares (L) | 40.97% |

「L」代表該名人士於股份的好倉（定義見證券及期貨條例第 XV 部）。

附註：

(1) 該計算乃基於本公司於 2022 年 6 月 30 日已發行股份總數 108,000,000 股而得出。

除上文披露者外，於 2022 年 6 月 30 日，董事、監事及本公司最高行政人員概無於本公司、其任何集團成員公司或其相聯法團（定義見證券及期貨條例第 XV 部）任何股份、相關股份或債權證中，擁有根據證券及期貨條例第 XV 部第 7 及第 8 分部須知會本公司及聯交所的任何其他權益或淡倉（包括彼等根據證券及期貨條例有關條文被認為或視作擁有的權益或淡倉），或根據證券及期貨條例第 352 條須記錄在該條文所述登記冊內或根據標準守則規定的任何其他權益或淡倉。

董事及監事購買股份或債券的權利

除「董事、監事及主要行政人員於股份、相關股份及債權證之權益或淡倉」一節所披露者外，於 2022 年 6 月 30 日止六個月內的任何時間，本公司或其任何附屬公司或同系附屬公司概無訂立任何可使董事及監事通過購買本公司或任何其他法人團體的股份或債券而獲得利益的安排，且概無董事及監事或任何彼等的配偶或未滿

The letter “L” denotes a person’s long position (as defined under Part XV of the SFO) in the Shares.

Note:

(1) The calculation is based on the total number of 108,000,000 Shares in issue of the Company as at 30 June 2022.

Save as disclosed above, as at 30 June 2022, none of the Directors, Supervisors and chief executives of the Company has any other interests or short positions in the Shares, underlying Shares or debentures of the Company, its members of the Group or any of its associated corporations (as defined in Part XV of the SFO) which have to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which he/she is taken or deemed to have under such provisions of the SFO) or which are required to be entered in the register referred to therein pursuant to section 352 of the SFO or which are required pursuant to the Model Code.

DIRECTORS’ AND SUPERVISORS’ RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Save as disclosed in the section headed “Interests or Short Positions of the Directors, Supervisors and Chief Executives in the Shares, Underlying Shares, and Debentures”, at no time during the six months ended 30 June 2022, the Company, any of its subsidiaries or fellow subsidiaries was a party to any arrangement to enable the Directors and Supervisors to acquire benefits by means of acquisition of shares in, or debentures of, the Company or any other body corporate, or any Directors, Supervisors or their spouses or children under 18 years of age

18 歲的子女獲授予任何權利以認購本公司或任何其他法人團體的股本或債務證券的權利，亦無行使任何該等權利。

was granted any right to subscribe for Shares or debentures of the Company or any other body corporate or exercised any such right.

主要股東於本公司股份及相關股份中之權益及／或淡倉

INTERESTS AND/OR SHORT POSITIONS OF THE SUBSTANTIAL SHAREHOLDERS IN THE SHARES AND UNDERLYING SHARES OF THE COMPANY

於 2022 年 6 月 30 日，就董事所知，以下人士／實體（本公司董事、監事及行政人員除外）於本公司股份或相關股份中，擁有或被視為擁有根據根證券及期貨條例第 XV 部第 2 及第 3 分部條文須向本公司披露的權益或淡倉，或已記入根據證券及期貨條例第 336 條本公司須存置的登記冊內的權益或淡倉：

As at 30 June 2022, so far as the Directors are aware, the following persons/entities (other than any Directors, Supervisors or chief executives of the Company) had or deemed to have an interest or short position in the Shares or underlying Shares of the Company which fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO or which had entered in the register required to be kept by the Company pursuant to section 336 of the SFO:

| 股東名稱／姓名 Name of shareholder | 權益性質及身份 Nature and capacity of interest | 證券數目及類別 Number and class of securities | 佔已發行股本股份的概約持股百分比 ⁽¹⁾ Approximate shareholding percentage of the total issued share capital ⁽¹⁾ |
|--|---|--|---|
| 游澤燕女士 Ms. You Zeyan | 配偶權益 ⁽²⁾ Interest of spouse ⁽²⁾ | 44,250,000 股 H 股 (L) 44,250,000 H Shares (L) | 40.97% |
| 江西江中醫藥商業運營有限責任公司 Jiangxi Jiangzhong Pharmaceutical Commercial Operation Co., Ltd. | 實益擁有人 Beneficial owner | 29,050,000 股 H 股 (L) 29,050,000 H Shares (L) | 26.90% |
| | 持有股份的保證權益的人 Person having a security interest in shares | 3,000,000 股 H 股 (L) 3,000,000 H Shares (L) | 2.78% |
| 廣藥白雲山香港有限公司 Guangzhou Pharmaceutical Baiyunshan Hong Kong Company Limited | 實益擁有人 Beneficial owner | 7,906,000 股 H 股(L) ⁽³⁾ 7,906,000 H Shares (L) ⁽³⁾ | 7.32% |



| 股東名稱／姓名 Name of shareholder | 權益性質及身份 Nature and capacity of interest | 證券數目及類別 Number and class of securities | 佔已發行股本股份的 概約持股百分比 ⁽¹⁾ Approximate shareholding percentage of the total issued share capital ⁽¹⁾ |
|---|--|---|---|
| 廣州白雲山醫藥集團股份有限公司 Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited | 受控法團權益 Interest in controlled corporation | 7,906,000 股 H 股(L) ⁽³⁾ 7,906,000 H Shares (L) ⁽³⁾ | 7.32% |
| 廣州醫藥集團有限公司 Guangzhou Pharmaceutical Holdings Limited | 受控法團權益 Interest in controlled corporation | 7,906,000 股 H 股(L) ⁽³⁾ 7,906,000 H Shares (L) ⁽³⁾ | 7.32% |

「L」代表該名人士於股份的好倉（定義見證券及期貨條例第 XV 部）。

The letter “L” refers to a person’s long position (as defined under Part XV of the SFO) in the Shares.

附註：

Notes:

(1) 該計算乃基於本公司於 2022 年 6 月 30 日已發行股份總數 108,000,000 股而得出。

(1) The calculation is based on the total number of 108,000,000 Shares in issue of the Company as at 30 June 2022.

(2) 游澤燕女士為本公司主席兼執行董事姚創龍先生的配偶，根據證券及期貨條例被視為擁有公司該等股份的權益。

(2) Ms. You Zeyan is the spouse of Mr. Yao Chuanglong, the Chairman and executive Director of the Company, and is deemed to be interested in these Shares under the SFO.

(3) 該等股份由廣藥白雲山香港有限公司持有。由於廣藥白雲山香港有限公司為廣州白雲山醫藥集團股份有限公司的全資附屬公司，而廣州白雲山醫藥集團股份有限公司則由廣州醫藥集團有限公司持有 45.04% 權益，故廣州白雲山醫藥集團股份有限公司及廣州醫藥集團有限公司被視為於廣藥白雲山香港有限公司持有的本公司股份中擁有權益。

(3) These shares are held by Guangzhou Pharmaceutical Baiyunshan Hong Kong Company Limited. As Guangzhou Pharmaceutical Baiyunshan Hong Kong Company Limited is a wholly-owned subsidiary of Guangzhou Pharmaceutical Holdings Company Limited, which in turn is held by Guangzhou Pharmaceutical Holdings Limited as to 45.04%. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited and Guangzhou Pharmaceutical Holdings Limited are deemed to be interested in the shares of the Company held by Guangzhou Pharmaceutical Baiyunshan Hong Kong Company Limited.

除上文披露者外，於 2022 年 6 月 30 日，董事並不知悉任何其他人士／實體（本公司董事、監事及本公司主要行政人員除外）於本公司、其集團成

Save as disclosed above, as at 30 June 2022, none of the Directors was aware that any other persons/entities (other than any Directors, Supervisors or chief executives of the Company) had an interest or short position in the Shares or underlying

員公司或相聯法團中，擁有根據證券及期貨條例第 XV 部第 2 及 3 分部之條文須向本公司披露之股份或相關股份之權益或淡倉，或已記入根據證券及期貨條例第 336 條本公司須存置的登記冊內的權益或淡倉。

審核委員會及審閱中期業績

本公司的審核委員會（「審核委員會」）由三名成員組成，包括三名獨立非執行董事，分別為尹智偉先生（主席）、周濤先生及關鍵先生。審核委員會向董事會報告，並定期召開會議以檢討並提出推薦建議以改進本集團的財務報告程序及內部監控。除此之外，審核委員會的主要職責是就對外聘核數師的委任、重新委任和解聘向董事會提供推薦建議，審閱財務報表及本公司財務報告和海外內部監控的重大意見。

審核委員會已審閱截至 2022 年 6 月 30 日止六個月的未經審核中期簡明合併財務報表，並認為截至 2022 年 6 月 30 日止六個月的中期報告乃根據適用會計準則、規則及規例編制，並已作出適當披露。

承董事會命
創美藥業股份有限公司
姚創龍

主席兼執行董事

中國，汕頭，2022 年 8 月 31 日

Shares of the Company, its members of the Group or associated corporations which fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO or which had entered in the register required to be kept by the Company pursuant to section 336 of the SFO.

AUDIT COMMITTEE AND REVIEW ON THE INTERIM RESULTS

The audit committee of the Company (the "Audit Committee") consists of three members and three of them are independent non-executive Directors, namely Mr. Wan Chi Wai Anthony (Chairman), Mr. Zhou Tao and Mr. Guan Jian. The Audit Committee reports to the Board and has held regular meetings to review and make recommendations to improve the Group's financial reporting process and internal controls. Other than that, the primary duties of the Audit Committee are to make recommendations to the Board on the appointment, reappointment and removal of the external auditor, review the financial statements and material advice in respect of financial reporting and overseas internal control of the Company.

The Audit Committee has reviewed the unaudited interim condensed consolidated financial statements for the six months ended 30 June 2022 and is of the view that the interim report for the six months ended 30 June 2022 has been prepared in accordance with the applicable accounting standards, rules and regulations, and appropriate disclosures have been duly made.

By order of the Board
Charmacy Pharmaceutical Co., Ltd.
Yao Chuanglong

Chairman and Executive Director

Shantou, PRC, 31 August 2022

未經審核中期財務報表

本公司董事會欣然公佈本公司及其附屬公司截至 2022 年 6 月 30 日止六個月未經審核合併中期業績，連同 2021 年同期之比較數字。

註：「本期」指 2022 年 1 月 1 日至 2022 年 6 月 30 日（未經審核），「上期」指 2021 年 1 月 1 日至 2021 年 6 月 30 日（未經審核）；「期末」指 2022 年 6 月 30 日（未經審核），「上年年末」指 2021 年 12 月 31 日（經審核），下同。

THE UNAUDITED INTERIM FINANCIAL STATEMENTS

The board of directors of the Company is pleased to announce the unaudited consolidated interim results of the Company and its subsidiaries for the six months ended 30 June 2022, together with the comparative figures for the corresponding period in 2021.

Note: "Current Period" means 1 January 2022 to 30 June 2022 (unaudited) and "Prior Period" means 1 January 2021 to 30 June 2021 (unaudited); "End of the Period" means 30 June 2022 (unaudited) and "End of Prior Year" means 31 December 2021 (Audited).

合併資產負債表

CONSOLIDATED BALANCE SHEET

於 2022 年 6 月 30 日

As at 30 June 2022

(除特別註明外，金額單位均為人民幣元)

(Unless otherwise stated, amount shall be expressed in RMB.)

| 項目 | Item | 附註 六 Note VI | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|----------------|--|-----------------------|-------------------------|---|
| 流動資產： | Current assets: | | | |
| 貨幣資金 | Monetary funds | 1 | 443,608,192.02 | 630,168,026.51 |
| 交易性金融資產 | Trading financial assets | | - | - |
| 衍生金融資產 | Derivative financial assets | | - | - |
| 應收票據 | Bills receivables | 2 | 896,670.00 | 14,947,500.00 |
| 應收賬款 | Trade receivables | 3 | 746,677,884.75 | 716,312,947.43 |
| 應收款項融資 | Account receivable financing | 4 | 14,216,386.49 | - |
| 預付款項 | Prepayments | 5 | 332,242,140.79 | 312,160,694.19 |
| 其他應收款 | Other receivables | 6 | 11,989,545.20 | 32,249,707.83 |
| 其中：應收利息 | Incl: Interest receivable | | - | - |
| 應收股利 | Dividends receivable | | - | - |
| 買入返售金融資產 | Buying back the sale of financial assets | | - | - |
| 存貨 | Inventories | 7 | 558,042,719.82 | 509,156,426.37 |
| 合同資產 | Contract assets | | - | - |
| 持有待售資產 | Assets held for sale | | - | - |
| 一年內到期的非流動資產 | Non-current assets due within one year | | - | - |
| 其他流動資產 | Other current assets | 8 | 30,101,256.73 | 23,226,980.50 |
| 流動資產合計 | Total current assets | | 2,137,774,795.80 | 2,238,222,282.83 |
| 非流動資產： | Non-current assets: | | | |
| 債權投資 | Debt investment | | - | - |
| 其他債權投資 | Other debt investment | | - | - |
| 長期應收款 | Long-term accounts receivable | | - | - |
| 長期股權投資 | Long-term equity investments | | - | - |
| 其他權益工具投資 | Other equity instrument investments | | - | - |
| 其他非流動金融資產 | Other non-current financial assets | | - | - |
| 投資性房地產 | Investment properties | | - | - |
| 固定資產 | Fixed assets | 9 | 324,213,328.70 | 334,925,145.94 |
| 在建工程 | Construction in progress | | - | - |
| 使用權資產 | Right-of-use assets | 10 | 12,040,954.91 | 13,511,183.61 |
| 無形資產 | Intangible assets | 11 | 139,818,367.10 | 143,033,824.90 |
| 開發支出 | Development expenditure | | - | - |
| 商譽 | Goodwill | 12 | 6,024,104.16 | 6,024,104.16 |
| 長期待攤費用 | Long-term expenses to be amortized | 13 | 17,771,658.62 | 19,214,660.88 |
| 遞延所得稅資產 | Deferred income tax assets | 14 | 8,645,886.45 | 8,160,319.54 |
| 其他非流動資產 | Other non-current assets | | - | - |
| 非流動資產合計 | Total non-current assets | | 508,514,299.94 | 524,869,239.03 |
| 資產總計 | Total assets | | 2,646,289,095.74 | 2,763,091,521.86 |

| 項目 | Item | 附註 六 Note VI | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|----------------|---|-----------------------|-------------------------|---|
| 流動負債： | Current liabilities: | | | |
| 短期借款 | Short-term borrowings | 15 | 515,486,716.70 | 668,039,276.07 |
| 交易性金融負債 | Trading financial liabilities | | - | - |
| 衍生金融負債 | Derivative financial liabilities | | - | - |
| 應付票據 | Bills payables | 16 | 818,410,573.01 | 809,768,308.81 |
| 應付帳款 | Trade payables | 17 | 514,868,844.10 | 532,860,284.07 |
| 預收款項 | Advance receipts | | - | - |
| 合同負債 | Contract liabilities | 18 | 67,641,555.74 | 46,664,141.17 |
| 應付職工薪酬 | Salaries payable to employees | 19 | 4,670,152.37 | 5,180,138.03 |
| 應交稅費 | Tax payables | 20 | 61,719,721.19 | 44,557,999.46 |
| 其他應付款 | Other payables | 21 | 12,875,096.44 | 11,030,236.31 |
| 其中：應付利息 | Incl: Interest payable | | - | - |
| 應付股利 | Dividends payable | | - | - |
| 持有待售負債 | Liabilities held for sale | | - | - |
| 一年內到期的非流動負債 | Non-current liabilities due within one year | 22 | 34,628,688.18 | 34,758,053.67 |
| 其他流動負債 | Other current liabilities | 23 | 8,793,402.24 | 6,066,338.36 |
| 流動負債合計 | Total current liabilities | | 2,039,094,749.98 | 2,158,924,775.95 |
| 非流動負債： | Non-current liabilities: | | | |
| 長期借款 | Long-term borrowings | 24 | 71,073,337.34 | 86,867,415.04 |
| 應付債券 | Bonds payable | | - | - |
| 租賃負債 | Lease liabilities | 25 | 11,290,634.74 | 12,489,734.63 |
| 長期應付款 | Long-term payables | | - | - |
| 長期應付職工薪酬 | Long-term payroll payable | | - | - |
| 預計負債 | Estimated liabilities | | - | - |
| 遞延收益 | Deferred income | 26 | 76,176.74 | 304,706.99 |
| 遞延所得稅負債 | Deferred income tax liabilities | 14 | 12,890.18 | 402,909.62 |
| 其他非流動負債 | Other non-current liabilities | | - | - |
| 非流動負債合計 | Total non-current liabilities | | 82,453,039.00 | 100,064,766.28 |
| 負債合計 | Total liabilities | | 2,121,547,788.98 | 2,258,989,542.23 |

| 項目 | Item | 附註 六 Note VI | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|---------------------|--|-----------------------|-------------------------|---|
| 股東權益： | Shareholders' equity: | | | |
| 股本 | Share capital | 27 | 108,000,000.00 | 108,000,000.00 |
| 其他權益工具 | Other equity instruments | | - | - |
| 資本公積 | Capital reserve | 28 | 278,990,829.04 | 278,990,829.04 |
| 減：庫存股 | Less: Treasury stock | | - | - |
| 其他綜合收益 | Other comprehensive income | | - | - |
| 專項儲備 | Special reserve | | - | - |
| 盈餘公積 | Surplus reserve | 29 | 21,080,432.34 | 21,080,432.34 |
| 一般風險準備 | General Risk Preparation | | - | - |
| 未分配利潤 | Unallocated profits | 30 | 116,670,045.38 | 96,030,718.25 |
| 歸屬於母公司股東權益合計 | Total equity attributable to the shareholders of parent company | | 524,741,306.76 | 504,101,979.63 |
| 少數股東權益 | Minority interests | | - | - |
| 股東權益合計 | Total shareholders' interests | | 524,741,306.76 | 504,101,979.63 |
| 負債和股東權益總計 | Total liabilities and shareholders' interests | | 2,646,289,095.74 | 2,763,091,521.86 |

母公司資產負債表

BALANCE SHEET OF THE PARENT

COMPANY

於 2022 年 6 月 30 日

As at 30 June 2022

(除特別註明外，金額單位均為人民幣元)

(Unless otherwise stated, amount shall be expressed in RMB.)

| 項目 | Item | 附註 十四 Note XIV | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|---------------|--|-------------------------|-------------------------|---|
| 流動資產： | Current assets: | | | |
| 貨幣資金 | Monetary funds | | 168,450,631.69 | 199,227,417.10 |
| 交易性金融資產 | Trading financial assets | | - | - |
| 衍生金融資產 | Derivative financial assets | | - | - |
| 應收票據 | Bills receivables | | 896,670.00 | 14,947,500.00 |
| 應收賬款 | Trade receivables | 1 | 294,346,138.23 | 298,709,722.89 |
| 應收款項融資 | Account receivable financing | | 4,979,888.81 | |
| 預付款項 | Prepayments | | 178,259,600.74 | 146,363,638.37 |
| 其他應收款 | Other receivables | 2 | 158,543,577.09 | 163,479,388.56 |
| 其中：應收利息 | Incl: Interest receivable | | - | - |
| 應收股利 | Dividends receivable | | - | - |
| 存貨 | Inventories | | 148,443,114.19 | 133,994,946.77 |
| 合同資產 | Contract assets | | - | - |
| 持有待售資產 | Assets held for sale | | - | - |
| 一年內到期的非流動資產 | Non-current assets due within one year | | - | - |
| 其他流動資產 | Other current assets | | 7,297,092.27 | 7,790,592.20 |
| 流動資產合計 | Total current assets | | 961,216,713.02 | 964,513,205.89 |
| 非流動資產： | Non-current assets: | | | |
| 債權投資 | Debt investment | | - | - |
| 其他債權投資 | Other debt investment | | - | - |
| 長期應收款 | Long-term accounts receivable | | - | - |
| 長期股權投資 | Long-term equity investments | 3 | 219,978,852.24 | 219,978,852.24 |
| 其他權益工具投資 | Other equity instrument investments | | - | - |
| 其他非流動金融資產 | Other non-current financial assets | | - | - |
| 投資性房地產 | Investment properties | | 39,649,022.99 | 40,366,284.58 |
| 固定資產 | Fixed assets | | 285,359,043.05 | 293,196,906.89 |
| 在建工程 | Construction in progress | | - | - |
| 使用權資產 | Right-of-use assets | | 11,333,080.83 | 12,683,101.59 |
| 無形資產 | Intangible assets | | 117,812,130.37 | 120,534,679.84 |
| 開發支出 | Development expenditure | | - | - |
| 商譽 | Goodwill | | - | - |
| 長期待攤費用 | Long-term expenses to be amortized | | 17,145,797.29 | 18,496,028.24 |
| 遞延所得稅資產 | Deferred income tax assets | | 1,617,387.02 | 1,579,871.20 |
| 其他非流動資產 | Other non-current assets | | - | - |
| 非流動資產： | Non-current assets: | | 692,895,313.79 | 706,835,724.58 |
| 資產合計 | Total assets | | 1,654,112,026.81 | 1,671,348,930.47 |

| 項目 | Item | 附註 十四 Note XIV | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|------------------|--|-------------------------|-------------------------|---|
| 流動負債： | Current liabilities: | | | |
| 短期借款 | Short-term borrowings | | 288,896,695.04 | 358,786,271.06 |
| 交易性金融負債 | Trading financial liabilities | | - | - |
| 衍生金融負債 | Derivative financial liabilities | | - | - |
| 應付票據 | Bills payables | | 357,833,656.68 | 303,267,964.22 |
| 應付帳款 | Trade payables | | 124,136,365.08 | 144,029,763.59 |
| 預收款項 | Advance receipts | | - | - |
| 合同負債 | Contract liabilities | | 287,210.47 | 1,133,949.67 |
| 應付職工薪酬 | Salaries payable to employees | | 2,661,737.77 | 3,077,400.16 |
| 應交稅費 | Tax payables | | 13,228,329.79 | 6,031,470.79 |
| 其他應付款 | Other payables | | 314,299,808.58 | 292,152,010.59 |
| 持有待售負債 | Liabilities held for sale | | - | - |
| 一年內到期的非流動負債 | Non-current liabilities due within one year | | 34,556,396.65 | 34,514,203.65 |
| 其他流動負債 | Other current liabilities | | 37,337.36 | 147,413.46 |
| 流動負債合計 | Total current liabilities | | 1,135,937,537.42 | 1,143,140,447.19 |
| 非流動負債： | Non-current liabilities: | | | |
| 長期借款 | Long-term borrowings | | 71,073,337.34 | 86,867,415.04 |
| 應付債券 | Bonds payable | | - | - |
| 租賃負債 | Lease liabilities | | 10,500,272.76 | 11,855,407.89 |
| 長期應付款 | Long-term payables | | - | - |
| 預計負債 | Estimated liabilities | | - | - |
| 遞延收益 | Deferred income | | - | - |
| 遞延所得稅負債 | Deferred income tax liabilities | | - | - |
| 其他非流動負債 | Other non-current liabilities | | - | - |
| 非流動負債合計 | Total non-current liabilities | | 81,573,610.10 | 98,722,822.93 |
| 負債合計 | Total liabilities | | 1,217,511,147.52 | 1,241,863,270.12 |
| 股東權益： | Shareholders' equity: | | | |
| 股本 | Share capital | | 108,000,000.00 | 108,000,000.00 |
| 其他權益工具 | Other equity instruments | | - | - |
| 資本公積 | Capital reserve | | 282,204,487.50 | 282,204,487.50 |
| 減：庫存股 | Less: Treasury stock | | - | - |
| 其他綜合收益 | Other comprehensive income | | - | - |
| 專項儲備 | Special reserve | | - | - |
| 盈餘公積 | Surplus reserve | | 21,080,432.34 | 21,080,432.34 |
| 未分配利潤 | Unallocated profits | | 25,315,959.45 | 18,200,740.51 |
| 股東權益合計 | Total shareholders' interests | | 436,600,879.29 | 429,485,660.35 |
| 負債和股東權益總計 | Total liabilities and shareholders' interests | | 1,654,112,026.81 | 1,671,348,930.47 |

合併利潤表

截至 2022 年 6 月 30 日止六個月

(除特別註明外，金額單位均為人民幣元)

CONSOLIDATED INCOME STATEMENT

For the six months ended 30 June 2022

(Unless otherwise stated, amount shall be expressed in RMB.)

| 項目 | Item | 附註 六 Note VI | 本期金額 Current period | 上期金額 Prior period |
|----------------------------|---|-----------------------|-------------------------|-------------------------|
| 一、營業總收入 | I. Total operating revenue | | 1,887,079,386.22 | 1,993,014,120.59 |
| 其中：營業收入 | Incl: Operating Revenue | 31 | 1,887,079,386.22 | 1,993,014,120.59 |
| 二、營業總成本 | II. Total operating cost | | 1,858,822,295.81 | 1,955,424,579.88 |
| 其中：營業成本 | Incl: Operating cost | 31 | 1,762,707,467.23 | 1,857,967,782.94 |
| 稅金及附加 | Taxes and surcharges | 32 | 4,843,557.57 | 4,386,843.07 |
| 銷售費用 | Selling expenses | 33 | 53,809,120.23 | 52,284,908.17 |
| 管理費用 | Management expenses | 34 | 18,401,674.42 | 18,988,949.29 |
| 研發費用 | Research & development expenses | | - | - |
| 財務費用 | Finance costs | 35 | 19,060,476.36 | 21,796,096.41 |
| 其中：利息費用 | Incl: Interest expenses | | 17,152,560.51 | 20,300,388.76 |
| 利息收入 | Interest income | | 2,641,344.75 | 1,921,670.20 |
| 加：其他收益 | Add: Other income | 36 | 295,562.20 | 295,184.84 |
| 投資收益（損失以「-」號填列） | Investment income (“-” for loss) | | - | - |
| 其中：對聯營企業和合營企業的投資收益 | Incl: Investment income from associates and joint ventures | | - | - |
| 以攤余成本計量的金融資產終止確認收益 | Financial assets measured at amortized cost are derecognized earnings | | - | - |
| 匯兌收益（損失以「-」號填列） | Exchange gains (“-” for loss) | | - | - |
| 淨敞口套期收益（損失以「-」號填列） | Frequent exposure to hedge gains (“-” for loss) | | - | - |
| 公允價值變動收益（損失以「-」號填列） | Gain on change in fair value (“-” for loss) | | - | - |
| 信用減值損失（損失以「-」號填列） | Impairment loss of credit (“-” for loss) | 37 | -229,086.87 | -247,245.69 |
| 資產減值損失（損失以「-」號填列） | Impairment loss of assets (“-” for loss) | 38 | -2,845,084.18 | -3,136,215.98 |
| 資產處置收益（損失以「-」號填列） | Gains on disposal of assets (“-” for loss) | 39 | 20,894.19 | -11,149.73 |
| 三、營業利潤（虧損以「-」號填列） | III. Operating profit (“-” for loss) | | 25,499,375.75 | 34,490,114.15 |
| 加：營業外收入 | Add: Non-operating revenue | 40 | 588,793.44 | 69,392.04 |
| 減：營業外支出 | Less: Non-operating expenses | 41 | 240,293.80 | 29,037.34 |
| 四、利潤總額（虧損總額以「-」號填列） | IV. Total profit (“-” for total loss) | | 25,847,875.39 | 34,530,468.85 |
| 減：所得稅費用 | Less: Income tax expense | 42 | 5,208,548.26 | 8,569,088.80 |

| 項目 | Item | 附註 六 Note VI | 本期金額 Current period | 上期金額 Prior period |
|------------------------------|--|-----------------------|------------------------|----------------------|
| 五、淨利潤（淨虧損以「-」號填列） | V. Net profit (“-” for net loss) | | 20,639,327.13 | 25,961,380.05 |
| （一）按經營持續性分類 | (I) By continuity of operations | | 20,639,327.13 | 25,961,380.05 |
| 1. 持續經營淨利潤（淨虧損以「-」號填列） | 1. Net profit from continuing operation (“-” for net loss) | | 20,639,327.13 | 25,961,380.05 |
| 2. 終止經營淨利潤（淨虧損以「-」號填列） | 2. Net profit from discontinued operation (“-” for net loss) | | - | - |
| （二）按所有權歸屬分類 | (II) By ownership | | 20,639,327.13 | 25,961,380.05 |
| 1. 歸屬於母公司所有者的淨利潤（淨虧損以「-」號填列） | 1. Net profit attributable to the owners of parent company (“-” for net loss) | | 20,639,327.13 | 25,961,380.05 |
| 2. 少數股東損益（淨虧損以「-」號填列） | 2. Profit or loss of minority shareholders (“-” for net loss) | | - | - |
| 六、其他綜合收益的稅後淨額 | VI. Net of tax of other comprehensive income | | - | - |
| 歸屬母公司所有者的其他綜合收益的稅後淨額 | Net of tax of other comprehensive income attributable to the owners of parent company | | - | - |
| （一）不能重分類進損益的其他綜合收益 | (I) Other comprehensive income not subject to reclassification to profit or loss in future | | - | - |
| 1. 重新計量設定受益計劃變動額 | 1. Remeasure the change in the set benefit plan | | - | - |
| 2. 權益法下不能轉損益的其他綜合收益 | 2. Other comprehensive income under the equity method that cannot be converted into profit or loss | | - | - |
| 3. 其他權益工具投資公允價值變動 | 3. Change in fair value of other equity instrument investments | | - | - |
| 4. 企業自身信用風險公允價值變動 | 4. Changes in the fair value of the enterprise's own credit risk | | - | - |
| 5. 其他 | 5. Others | | - | - |
| （二）將重分類進損益的其他綜合收益 | (II) Other comprehensive income to be reclassified into profit or loss in future | | - | - |
| 1. 權益法下可轉損益的其他綜合收益 | 1. Other comprehensive income of convertible profit or loss under the equity method | | - | - |
| 2. 其他債權投資公允價值變動 | 2. Changes in the fair value of other debt investments | | - | - |
| 3. 金融資產重分類計入其他綜合收益的金額 | 3. The amount of financial assets reclassified into other comprehensive income | | - | - |
| 4. 其他債權投資信用減值準備 | 4. Other debt investment credit impairment provisions | | - | - |
| 5. 現金流量套期儲備（現金流量套期損益的有效部分） | 5. Cash flow hedging reserve (effective part of cash flow hedging profit or loss) | | - | - |
| 6. 外幣財務報表折算差額 | 6. Conversion difference of foreign currency statement | | - | - |
| 7. 其他 | 7. Others | | - | - |
| 歸屬於少數股東的其他綜合收益的稅後淨額 | Net other comprehensive income after-tax which belongs to minority shareholders | | - | - |

| 項目 | Item | 附註 六 Note VI | 本期金額 Current period | 上期金額 Prior period |
|------------------|---|-----------------------|------------------------|----------------------|
| 七、綜合收益總額 | VII. Total comprehensive income | | 20,639,327.13 | 25,961,380.05 |
| 歸屬於母公司股東的綜合收益總額 | Total comprehensive income attributable to the shareholders of parent company | | 20,639,327.13 | 25,961,380.05 |
| 歸屬於少數股東的綜合收益總額 | Total comprehensive income attributable to minority shareholders | | - | - |
| 八、每股收益： | VIII. Earnings per share: | | | |
| (一) 基本每股收益 (元/股) | (I) Basic earnings per share | 43 | 0.1911 | 0.2404 |
| (二) 稀釋每股收益 (元/股) | (II) Diluted earnings per share | 43 | 0.1911 | 0.2404 |

母公司利潤表

INCOME STATEMENT OF THE PARENT
COMPANY

截至 2022 年 6 月 30 日止六個月

For the six months ended 30 June 2022

(除特別註明外，金額單位均為人民幣元)

(Unless otherwise stated, amount shall be expressed in RMB.)

| 項目 | Item | 附註 十四 Note XVI | 本期金額 Current period | 上期金額 Prior period |
|------------------------|--|-------------------------|---------------------------|----------------------|
| 一、營業收入 | I. Operating revenue | 4 | 754,594,011.93 | 811,224,851.45 |
| 減：營業成本 | Less: Operating cost | 4 | 685,594,303.89 | 741,466,441.16 |
| 税金及附加 | Taxes and surcharges | | 2,971,852.34 | 2,919,638.35 |
| 銷售費用 | Selling expenses | | 32,480,437.80 | 31,946,549.42 |
| 管理費用 | Management expenses | | 9,256,004.27 | 9,161,741.20 |
| 研發費用 | Research & development expenses | | - | - |
| 財務費用 | Finance costs | | 14,755,927.18 | 16,844,938.04 |
| 其中：利息費用 | Incl: Interest expenses | | 10,461,661.48 | 11,609,475.98 |
| 利息收入 | Interest income | | 641,158.09 | 591,714.97 |
| 加：其他收益 | Add: Other income | | 61,926.36 | 61,571.41 |
| 投資收益（損失以「-」號填列） | Investment income (“-” for loss) | 5 | - | 18,000,000.00 |
| 信用減值損失（損失以「-」號填列） | Impairment loss of credit (“-” for loss) | | -151,138.76 | 876,855.61 |
| 資產減值損失（損失以「-」號填列） | Impairment loss of assets (“-” for loss) | | -661,895.33 | -1,135,025.02 |
| 資產處置收益（損失以「-」號填列） | Gains on disposal of assets (“-” for loss) | | 25,164.88 | -17,344.42 |
| 二、營業利潤（虧損以「-」號填列） | II. Operating profit (“-” for loss) | | 8,809,543.60 | 26,671,600.86 |
| 加：營業外收入 | Add: Non-operating revenue | | 469,517.75 | 3,511.06 |
| 減：營業外支出 | Less: Non-operating expenses | | 116,118.32 | 28,920.01 |
| 三、利潤總額（虧損總額以「-」號填列） | III. Total profit (“-” for total loss) | | 9,162,943.03 | 26,646,191.91 |
| 減：所得稅費用 | Less: Income tax expense | | 2,047,724.09 | 2,189,126.97 |
| 四、淨利潤（淨虧損以「-」號填列） | IV. Net profit (“-” for net loss) | | 7,115,218.94 | 24,457,064.94 |
| （一）持續經營淨利潤（淨虧損以「-」號填列） | (I).Net profit from continuing operation (“-” for net loss) | | 7,115,218.94 | 24,457,064.94 |
| （二）終止經營淨利潤（淨虧損以「-」號填列） | (II).Net profit from discontinued operation (“-” for net loss) | | - | - |

| 項目 | Item | 附註 十四 Note XVI | 本期金額 Current period | 上期金額 Prior period |
|----------------------------|--|-------------------------|---------------------------|----------------------|
| 五、其他綜合收益的稅後淨額 | V. Net of tax of other comprehensive income | | - | - |
| (一) 不能重分類進損益的其他綜合收益 | (I) Other comprehensive income not subject to reclassification to profit or loss in future | | - | - |
| 1. 重新計量設定受益計劃變動額 | 1. Remeasure the change in the set benefit plan | | - | - |
| 2. 權益法下不能轉損益的其他綜合收益 | 2. Other comprehensive income under the equity method that cannot be converted into profit or loss | | - | - |
| 3. 其他權益工具投資公允價值變動 | 3. Change in fair value of other equity instrument investments | | - | - |
| 4. 企業自身信用風險公允價值變動 | 4. Changes in the fair value of the enterprise's own credit risk | | - | - |
| 5. 其他 | 5. Others | | - | - |
| (二) 將重分類進損益的其他綜合收益 | (II) Other comprehensive income to be reclassified into profit or loss in future | | - | - |
| 1. 權益法下可轉損益的其他綜合收益 | 1. Other comprehensive income of convertible profit or loss under the equity method | | - | - |
| 2. 其他債權投資公允價值變動 | 2. Changes in the fair value of other debt investments | | - | - |
| 3. 金融資產重分類計入其他綜合收益的金額 | 3. The amount of financial assets reclassified into other comprehensive income | | - | - |
| 4. 其他債權投資信用減值準備 | 4. Other debt investment credit impairment provisions | | - | - |
| 5. 現金流量套期儲備（現金流量套期損益的有效部分） | 5. Cash flow hedging reserve (effective part of cash flow hedging profit or loss) | | - | - |
| 6. 外幣財務報表折算差額 | 6. Conversion difference of foreign currency statement | | - | - |
| 7. 其他 | 7. Others | | - | - |
| 六、綜合收益總額 | VI. Total comprehensive income | | 7,115,218.94 | 24,457,064.94 |
| 七、 每股收益： | VII. Earnings per share: | | | |
| (一) 基本每股收益 | (I) Basic earnings per share | | - | - |
| (二) 稀釋每股收益 | (II) Diluted earnings per share | | - | - |

合併現金流量表

CONSOLIDATED STATEMENT OF CASH FLOW

截至 2022 年 6 月 30 日止六個月
(除特別註明外，金額單位均為人民幣元)

For the six months ended 30 June 2022
(Unless otherwise stated, amount shall be expressed in RMB.)

| 項目 | Item | 附注 六 Note VI | 本期金額 Current period | 上期金額 Prior period |
|---------------------------|--|-----------------------|-------------------------|-------------------------|
| 一、經營活動產生的現金流量： | I. Cash flow from operating activities: | | | |
| 銷售商品、提供勞務收到的現金 | Cash received from sales of goods and rendering of services | | 1,611,377,660.65 | 1,640,091,908.42 |
| 收到的稅費返還 | Tax refund received | | - | - |
| 收到其他與經營活動有關的現金 | Other cash received relating to operating activities | | 28,973,688.83 | 1,274,164.97 |
| 經營活動現金流入小計 | Sub-total of cash inflow from operating activities | | 1,640,351,349.48 | 1,641,366,073.39 |
| 購買商品、接受勞務支付的現金 | Cash paid for purchases of goods and receiving services | | 1,569,152,104.06 | 1,662,819,639.69 |
| 支付給職工以及為職工支付的現金 | Cash paid to employees and on behalf of employees | | 36,880,726.09 | 38,337,469.00 |
| 支付的各項稅費 | Cash paid for various taxes | | 17,137,116.39 | 23,907,722.11 |
| 支付其他與經營活動有關的現金 | Other cash paid relating to operating activities | | 48,622,127.58 | 26,103,516.23 |
| 經營活動現金流出小計 | Sub-total of cash outflow from operating activities | | 1,671,792,074.12 | 1,751,168,347.03 |
| 經營活動產生的現金流量淨額 | Net cash flow from operating activities | 44 | -31,440,724.64 | -109,802,273.64 |
| 二、投資活動產生的現金流量： | II. Cash flow from investing activities: | | | |
| 收回投資收到的現金 | Cash received from sale of investments | | - | - |
| 取得投資收益收到的現金 | Cash received from investment gains | | - | - |
| 處置固定資產、無形資產和其他長期資產收回的現金淨額 | Net cash received from disposal of fixed assets, intangible assets and other long-term assets | | 297,500.00 | 7,000.00 |
| 處置子公司及其他營業單位收到的現金淨額 | Net cash received from disposal of subsidiaries and other business units | | - | - |
| 收到其他與投資活動有關的現金 | Other cash received relating to investing activities | | - | - |
| 投資活動現金流入小計 | Sub-total of cash inflow from investing activities | | 297,500.00 | 7,000.00 |
| 購建固定資產、無形資產和其他長期資產支付的現金 | Cash paid for acquisition and construction of fixed assets, intangible assets and other long-term assets | | 2,460,493.89 | 21,685,367.72 |
| 投資支付的現金 | Cash paid for acquisition of investments | | - | - |
| 取得子公司及其他營業單位支付的現金淨額 | Net cash paid for acquisition of subsidiaries and other business units | | - | - |
| 支付其他與投資活動有關的現金 | Other cash paid relating to investing activities | | - | - |
| 投資活動現金流出小計 | Sub-total of cash outflow from investing activities | | 2,460,493.89 | 21,685,367.72 |
| 投資活動產生的現金流量淨額 | Net cash flow from investing activities | | -2,162,993.89 | -21,678,367.72 |

| 項目 | Item | 附注 六 Note VI | 本期金額 Current period | 上期金額 Prior period |
|---------------------------|---|-----------------------|-------------------------|-------------------------|
| 三、籌資活動產生的現金流量： | III. Cash flow from financing activities: | | | |
| 吸收投資收到的現金 | Cash received from capital contributions | | - | - |
| 其中：子公司吸收少數股東投資收到的現金 | Incl: Cash received by subsidiaries from capital contributions of minority shareholders | | | |
| 取得借款收到的現金 | Cash received from borrowings | | 398,294,207.75 | 458,146,701.21 |
| 收到其他與籌資活動有關的現金 | Other cash received relating to financing activities | | 1,052,823,816.20 | 943,602,611.17 |
| 籌資活動現金流入小計 | Sub-total of cash inflow from financing activities | | 1,451,118,023.95 | 1,401,749,312.38 |
| 償還債務支付的現金 | Cash paid for repayment of debts | | 537,552,071.86 | 455,930,381.65 |
| 分配股利、利潤或償付利息支付的現金 | Cash payment for distribution of dividends and profits or interest payment | | 14,686,680.34 | 24,973,874.03 |
| 其中：子公司支付給少數股東的股利、利潤 | Incl: Cash paid to minority shareholders for distribution of dividends or profits by subsidiaries | | | |
| 支付其他與籌資活動有關的現金 | Other cash paid relating to financing activities | | 941,536,133.98 | 867,965,488.14 |
| 籌資活動現金流出小計 | Sub-total of cash outflow from financing activities | | 1,493,774,886.18 | 1,348,869,743.82 |
| 籌資活動產生的現金流量淨額 | Net cash flow from financing activities | | -42,656,862.23 | 52,879,568.56 |
| 四、匯率變動對現金及現金等價物的影響 | IV. Effect of change in exchange rates on cash and cash equivalents | | 16,611.61 | 240,579.13 |
| 五、現金及現金等價物淨增加額 | V. Net increase in cash and cash equivalents | | -76,243,969.15 | -78,360,493.67 |
| 加：期初現金及現金等價物餘額 | Add: Opening balance of cash and cash equivalents for the period | 44 | 149,096,068.30 | 113,771,300.25 |
| 六、期末現金及現金等價物餘額 | VI. Closing balance of cash and cash equivalents for the period | 44 | 72,852,099.15 | 35,410,806.58 |

母公司現金流量表

STATEMENT OF CASH FLOW OF THE
PARENT COMPANY

截至 2022 年 6 月 30 日止六個月
(除特別註明外, 金額單位均為人民
幣元)

For the six months ended 30 June 2022

(Unless otherwise stated, amount shall be expressed in RMB.)

| 項目 | Item | 附註 Note | 本期金額 Current period | 上期金額 Prior period |
|---------------------------|--|------------|-------------------------|-------------------------|
| 一、經營活動產生的現金流量: | I. Cash flow from operating activities: | | | |
| 銷售商品、提供勞務收到的現金 | Cash received from sales of goods and rendering of services | | 703,378,212.47 | 857,109,972.48 |
| 收到的稅費返還 | Tax refund received | | - | - |
| 收到其他與經營活動有關的現金 | Other cash received relating to operating activities | | 725,172,483.70 | 534,505,431.38 |
| 經營活動現金流入小計 | Sub-total of cash inflow from operating activities | | 1,428,550,696.17 | 1,391,615,403.86 |
| 購買商品、接受勞務支付的現金 | Cash paid for purchases of goods and receiving services | | 667,081,364.87 | 915,268,209.09 |
| 支付給職工以及為職工支付的現金 | Cash paid to employees and on behalf of employees | | 20,708,027.82 | 21,750,071.80 |
| 支付的各项稅費 | Cash paid for various taxes | | 5,707,975.31 | 6,780,683.41 |
| 支付其他與經營活動有關的現金 | Other cash paid relating to operating activities | | 694,568,724.05 | 465,018,963.90 |
| 經營活動現金流出小計 | Sub-total of cash outflow from operating activities | | 1,388,066,092.05 | 1,408,817,928.20 |
| 經營活動產生的現金流量淨額 | Net cash flow from operating activities | | 40,484,604.12 | -17,202,524.34 |
| 二、投資活動產生的現金流量: | II. Cash flow from investing activities: | | - | - |
| 收回投資收到的現金 | Cash received from sale of investments | | - | - |
| 取得投資收益收到的現金 | Cash received from investment gains | | - | - |
| 處置固定資產、無形資產和其他長期資產收回的現金淨額 | Net cash received from disposal of fixed assets, intangible assets and other long-term assets | | 36,000.00 | - |
| 處置子公司及其他營業單位收到的現金淨額 | Net cash received from disposal of subsidiaries and other business units | | - | - |
| 收到其他與投資活動有關的現金 | Other cash received relating to investing activities | | - | - |
| 投資活動現金流入小計 | Sub-total of cash inflow from investing activities | | 36,000.00 | - |
| 購建固定資產、無形資產和其他長期資產支付的現金 | Cash paid for acquisition and construction of fixed assets, intangible assets and other long-term assets | | 1,998,561.06 | 20,409,007.78 |
| 投資支付的現金 | Cash paid for acquisition of investments | | - | - |
| 取得子公司及其他營業單位支付的現金淨額 | Net cash paid for acquisition of subsidiaries and other business units | | - | - |
| 支付其他與投資活動有關的現金 | Other cash paid relating to investing activities | | - | - |
| 投資活動現金流出小計 | Sub-total of cash outflow from investing activities | | 1,998,561.06 | 20,409,007.78 |
| 投資活動產生的現金流量淨額 | Net cash flow from investing activities | | -1,962,561.06 | -20,409,007.78 |

| 項目 | Item | 附註 Note | 本期金額 Current period | 上期金額 Prior period |
|---------------------------|---|------------|------------------------|-----------------------|
| 三、籌資活動產生的現金流量： | III. Cash flow from financing activities: | | - | - |
| 吸收投資收到的現金 | Cash received from capital contributions | | - | - |
| 其中：子公司吸收少數股東投資收到的現金 | Incl: Cash received by subsidiaries from capital contributions of minority shareholders | | | |
| 取得借款收到的現金 | Cash received from borrowings | | 220,300,000.00 | 265,672,104.00 |
| 收到其他與籌資活動有關的現金 | Other cash received relating to financing activities | | 286,552,976.42 | 262,571,630.23 |
| 籌資活動現金流入小計 | Sub-total of cash inflow from financing activities | | 506,852,976.42 | 528,243,734.23 |
| 償還債務支付的現金 | Cash paid for repayment of debts | | 277,748,917.70 | 293,816,005.70 |
| 分配股利、利潤或償付利息支付的現金 | Cash payment for distribution of dividends and profits or interest payment | | 10,911,773.27 | 21,066,403.87 |
| 其中：子公司支付給少數股東的股利、利潤 | Incl: Cash paid to minority shareholders for distribution of dividends or profits by subsidiaries | | | |
| 支付其他與籌資活動有關的現金 | Other cash paid relating to financing activities | | 274,897,305.82 | 265,489,956.72 |
| 籌資活動現金流出小計 | Sub-total of cash outflow from financing activities | | 563,557,996.79 | 580,372,366.29 |
| 籌資活動產生的現金流量淨額 | Net cash flow from financing activities | | -56,705,020.37 | -52,128,632.06 |
| 四、匯率變動對現金及現金等價物的影響 | IV. Effect of change in exchange rates on cash and cash equivalents | | 16,611.61 | 240,579.13 |
| 五、現金及現金等價物淨增加額 | V. Net increase in cash and cash equivalents | | -18,166,365.70 | -89,499,585.05 |
| 加：期初現金及現金等價物餘額 | Add: Opening balance of cash and cash equivalents for the period | | 68,777,958.20 | 109,260,306.20 |
| 六、期末現金及現金等價物餘額 | VI. Closing balance of cash and cash equivalents for the period | | 50,611,592.50 | 19,760,721.15 |

合併股東權益變動表

CONSOLIDATED STATEMENT OF CHANGES IN
SHAREHOLDERS' EQUITY

截至 2022 年 6 月 30 日止六個月

For the six months ended 30 June 2022

(除特別註明外，金額單位均為人民幣元)

(Unless otherwise stated, amount shall be expressed in RMB.)

| 項目 | Item | 本期金額 current period | | | | | | | | | | | | | 少數股東權益 Minority interests | 股東 權益合計 Total shareholders' interests |
|---------------------------|--|---|------------------------------------|---|---|-------------------------|---|--|----------------------------|----------------------------|---------------------------------------|-----------------------------------|----------------|----------------|------------------------------|--|
| | | 歸屬於母公司股東權益 equity attributable to the shareholders of parent company | | | | | | | | | | | 小計 Subtotal | | | |
| | | 股本 Capital stock | 其他權益工具 other equity instruments | | | 資本公積 Capital surplus | 減：庫存 股 Less: Treasury stock | 其他綜合收益 Other comprehensive income | 專項儲備 Special reserve | 盈餘公積 Surplus reserve | 一般風險 準備 General risk reserve | 未分配利潤 Undistributed profits | | 其他 Others | | |
| 優先股 Preferred stock | 永續債 Perpetual bond | 其他 Others | | | | | | | | | | | | | | |
| 一、上年年末餘額 | I. Closing balance for last year | 108,000,000.00 | - | - | - | 278,990,829.04 | - | - | - | 21,080,432.34 | - | 96,030,718.25 | - | 504,101,979.63 | - | 504,101,979.63 |
| 加：會計政策變更 | Add: Changes in accounting policies | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 前期差錯更正 | Correction of previous errors | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 同一控制下企業合併 | Business combinations under common control | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 其他 | Others | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 二、本年初餘額 | II. Opening balance for the year | 108,000,000.00 | - | - | - | 278,990,829.04 | - | - | - | 21,080,432.34 | - | 96,030,718.25 | - | 504,101,979.63 | - | 504,101,979.63 |
| 三、本期增減變動金額 | III. Movements in current period | - | - | - | - | - | - | - | - | - | - | 20,639,327.13 | - | 20,639,327.13 | - | 20,639,327.13 |
| (一) 綜合收益總額 | (I) Total comprehensive income | - | - | - | - | - | - | - | - | - | - | 20,639,327.13 | - | 20,639,327.13 | - | 20,639,327.13 |
| (二) 股東投入和減少資本 | (II) Injection and reduction | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 1. 股東投入的普通股 | 1. Shareholders' contribution to ordinary shares | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2. 其他權益工具持有者投入資本 | 2. Capital contribution by holders of other equity instruments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 3. 股份支付計入股東權益的金額 | 3. Share-based payment credited to shareholders' equity | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 4. 其他 | 4. Others | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |



| 項目 | Item | 本期金額 current period | | | | | | | | | | | | | | 少數股東權益 Minority interests | 股東權益合計 Total shareholders' interests | |
|------------------------|--|---|------------------------------------|---|---|-------------------------|-------------------------------|--------------------------------------|-------------------------|-------------------------|--------------------------------|--------------------------------|--------------|-----------------------|---|------------------------------|---|---|
| | | 歸屬於母公司股東權益 equity attributable to the shareholders of parent company | | | | | | | | | | | | 小計 Subtotal | | | | |
| | | 股本 Capital stock | 其他權益工具 other equity instruments | | | 資本公積 Capital surplus | 減：庫存股 Less: Treasury stock | 其他綜合收益 Other comprehensive income | 專項儲備 Special reserve | 盈餘公積 Surplus reserve | 一般風險準備 General risk reserve | 未分配利潤 Undistributed profits | 其他 Others | | | | | |
| 優先股 Preferred stock | 永續債 Perpetual bond | 其他 Others | | | | | | | | | | | | | | | | |
| (三) 利潤分配 | (III) Profit appropriation | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 1. 提取盈餘公積 | 1. Appropriation of surplus reserve | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2. 提取一般風險準備 | 2. Appropriation of general risk provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 3. 對股東的分配 | 3. Allocation to shareholders | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 4. 其他 | 4. Others | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| (四) 股東權益內部結轉 | (IV) Internal carryover in shareholders' equities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 1. 資本公積轉增股本 | 1. Transfer of capital reserve to share capital | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2. 盈餘公積轉增股本 | 2. Transfer of surplus reserve to share capital | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 3. 盈餘公積彌補虧損 | 3. Surplus reserve for making up losses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 4. 設定受益計劃變動額結轉留存收益 | 4. Change in defined benefit plan carried forward to retained earnings | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 5. 其他綜合收益結轉留存收益 | 5. Other comprehensive income carried forward to retained earnings | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 6. 其他 | 6. Others | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| (五) 專項儲備 | (V) Special reserve | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 1. 本期提取 | 1. Appropriation for the period | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2. 本期使用 | 2. Use in the period | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| (六) 其他 | (VI) Others | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 四、本期期末餘額 | IV. Closing balance for the current period | 108,000,000.00 | - | - | - | 278,990,829.04 | - | - | - | 21,080,432.34 | - | 116,670,045.38 | - | 524,741,306.76 | - | 524,741,306.76 | | |

| 項目 | Item | 上期金額 Prior period | | | | | | | | | | | | 少數股東權益 Minority interests | 股東 權益合計 Total shareholders' interests | |
|------------------------|--|---|------------------------------------|---|---|-------------------------|----------------------------------|--------------------------------------|-------------------------|-------------------------|--------------------------------|--------------------------------|--------------|------------------------------|--|----------------|
| | | 歸屬於母公司股東權益 equity attributable to the shareholders of parent company | | | | | | | | | | | | | | |
| | | 股本 Capital stock | 其他權益工具 other equity instruments | | | 資本公積 Capital surplus | 減：庫存股 Less: Treasury stock | 其他綜合收益 Other comprehensive income | 專項儲備 Special reserve | 盈餘公積 Surplus reserve | 一般風險準備 General risk reserve | 未分配利潤 Undistributed profits | 其他 Others | | | 小計 Subtotal |
| 優先股 Preferred stock | 永續債 Perpetual bond | | 其他 Others | | | | | | | | | | | | | |
| 一、上年年末餘額 | I. Closing balance for last year | 108,000,000.00 | - | - | - | 278,990,829.04 | - | - | - | 18,439,830.70 | - | 97,118,259.82 | - | 502,548,919.56 | - | 502,548,919.56 |
| 加：會計政策變更 | Add: Changes in accounting policies | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 前期差錯更正 | Correction of previous errors | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 同一控制下企業合併 | Business combinations under common control | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 其他 | Others | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 二、本年年初餘額 | II. Opening balance for the year | 108,000,000.00 | - | - | - | 278,990,829.04 | - | - | - | 18,439,830.70 | - | 97,118,259.82 | - | 502,548,919.56 | - | 502,548,919.56 |
| 三、本期增減變動金額 | III. Movements in current period | - | - | - | - | - | - | - | - | - | - | 4,361,380.05 | - | 4,361,380.05 | - | 4,361,380.05 |
| (一) 綜合收益總額 | (I) Total comprehensive income | - | - | - | - | - | - | - | - | - | - | 25,961,380.05 | - | 25,961,380.05 | - | 25,961,380.05 |
| (二) 股東投入和減少資本 | (II) Injection and reduction | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 1. 股東投入的普通股 | 1. Shareholders' contribution to ordinary shares | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2. 其他權益工具持有者投入資本 | 2. Capital contribution by holders of other equity instruments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 3. 股份支付計入股東權益的金額 | 3. Share-based payment credited to shareholders' equity | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 4. 其他 | 4. Others | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| (三) 利潤分配 | (III) Profit appropriation | - | - | - | - | - | - | - | - | - | - | -21,600,000.00 | - | -21,600,000.00 | - | -21,600,000.00 |
| 1. 提取盈餘公積 | 1. Appropriation of surplus reserve | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2. 提取一般風險準備 | 2. Appropriation of general risk provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 3. 對股東的分配 | 3. Allocation to shareholders | - | - | - | - | - | - | - | - | - | - | -21,600,000.00 | - | -21,600,000.00 | - | -21,600,000.00 |
| 4. 其他 | 4. Others | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| (四) 股東權益內部結轉 | (IV) Internal carryover in shareholders' equities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 1. 資本公積轉增股本 | 1. Transfer of capital reserve to share capital | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2. 盈餘公積轉增股本 | 2. Transfer of surplus reserve to share capital | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 3. 盈餘公積彌補虧損 | 3. Surplus reserve for making up losses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 4. 設定受益計劃變動額結轉留存收益 | 4. Change in defined benefit plan carried forward to retained earnings | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 5. 其他綜合收益結轉留存收益 | 5. Other comprehensive income carried forward to retained earnings | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 6. 其他 | 6. Others | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| (五) 專項儲備 | (V) Special reserve | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 1. 本期提取 | 1. Appropriation for the period | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2. 本期使用 | 2. Use in the period | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| (六) 其他 | (VI) Others | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 四、本期期末餘額 | IV. Closing balance for the current period | 108,000,000.00 | - | - | - | 278,990,829.04 | - | - | - | 18,439,830.70 | - | 101,479,639.87 | - | 506,910,299.61 | - | 506,910,299.61 |

母公司股東權益變動表

截至 2022 年 6 月 30 日止六個月

(除特別註明外，金額單位均為人民幣元)

STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY OF THE PARENT COMPANY

For the six months ended 30 June 2022

(Unless otherwise stated, amount shall be expressed in RMB.)

| 項目 | Item | 本期金額 current period | | | | | | | | | | | | | | |
|------------------|--|------------------------|------------------------------------|-----------------------|--------------|-------------------------|----------------------------------|--------------------------------------|-------------------------|-------------------------|--------------------------------|--------------------------------|--------------|----------------|---|---|
| | | 股本 Capital stock | 其他權益工具 other equity instruments | | | 資本公積 Capital surplus | 減：庫存股 Less: Treasury stock | 其他綜合收益 Other comprehensive income | 專項儲備 Special reserve | 盈餘公積 Surplus reserve | 一般風險準備 General risk reserve | 未分配利潤 Undistributed profits | 其他 Others | 小計 Subtotal | 少數股東權益 Minority shareholders' equity | 股東權益合計 Total of shareholders' equity |
| | | | 優先股 Preferred stock | 永續債 Perpetual bond | 其他 Others | | | | | | | | | | | |
| 一、上年年末餘額 | I. Closing balance for last year | 108,000,000.00 | - | - | - | 282,204,487.50 | - | - | - | 21,080,432.34 | - | 18,200,740.51 | - | 429,485,660.35 | - | 429,485,660.35 |
| 加：會計政策變更 | Add: Changes in accounting policies | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 前期差錯更正 | Correction of previous errors | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 同一控制下企業合併 | Business combinations under common control | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 其他 | Others | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 二、本年初餘額 | II. Opening balance for the year | 108,000,000.00 | - | - | - | 282,204,487.50 | - | - | - | 21,080,432.34 | - | 18,200,740.51 | - | 429,485,660.35 | - | 429,485,660.35 |
| 三、本期增減變動金額 | III. Movements in current period | - | - | - | - | - | - | - | - | - | - | 7,115,218.94 | - | 7,115,218.94 | - | 7,115,218.94 |
| (一) 綜合收益總額 | (I) Total comprehensive income | - | - | - | - | - | - | - | - | - | - | 7,115,218.94 | - | 7,115,218.94 | - | 7,115,218.94 |
| (二) 股東投入和減少資本 | (II) Injection and reduction | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 1. 股東投入的普通股 | 1. Shareholders' contribution to ordinary shares | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2. 其他權益工具持有者投入資本 | 2. Capital contribution by holders of other equity instruments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 3. 股份支付計入股東權益的金額 | 3. Share-based payment credited to shareholders' equity | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 4. 其他 | 4. Others | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| (三) 利潤分配 | (III) Profit appropriation | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 1. 提取盈餘公積 | 1. Appropriation of surplus reserve | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2. 提取一般風險準備 | 2. Appropriation of general risk provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 3. 對股東的分配 | 3. Allocation to shareholders | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 4. 其他 | 4. Others | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |

| 項目 | Item | 本期金額 current period | | | | | | | | | | | | | | |
|--------------------|--|------------------------|------------------------------------|-----------------------|--------------|-------------------------|----------------------------------|--------------------------------------|-------------------------|-------------------------|--------------------------------|--------------------------------|--------------|-----------------------|---|---|
| | | 股本 Capital stock | 其他權益工具 other equity instruments | | | 資本公積 Capital surplus | 減：庫存股 Less: Treasury stock | 其他綜合收益 Other comprehensive income | 專項儲備 Special reserve | 盈餘公積 Surplus reserve | 一般風險準備 General risk reserve | 未分配利潤 Undistributed profits | 其他 Others | 小計 Subtotal | 少數股東權益 Minority shareholders' equity | 股東權益合計 Total of shareholders' equity |
| | | | 優先股 Preferred stock | 永續債 Perpetual bond | 其他 Others | | | | | | | | | | | |
| (四) 股東權益內部結轉 | (IV) Internal carryover in shareholders' equities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
| 1. 資本公積轉增股本 | 1. Transfer of capital reserve to share capital | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
| 2. 盈餘公積轉增股本 | 2. Transfer of surplus reserve to share capital | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
| 3. 盈餘公積彌補虧損 | 3. Surplus reserve for making up losses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
| 4. 設定受益計劃變動額結轉留存收益 | 4. Change in defined benefit plan carried forward to retained earnings | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
| 5. 其他綜合收益結轉留存收益 | 5. Other comprehensive income carried forward to retained earnings | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
| 6. 其他 | 6. Others | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
| (五) 專項儲備 | (V) Special reserve | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
| 1. 本期提取 | 1. Appropriation for the period | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
| 2. 本期使用 | 2. Use in the period | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
| (六) 其他 | (VI) Others | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
| 四、本期末餘額 | IV. Closing balance for the current period | 108,000,000.00 | - | - | - | 282,204,487.50 | - | - | - | 21,080,432.34 | - | 25,315,959.45 | - | 436,600,879.29 | 436,600,879.29 | |



| 項目 | Item | 上期金額 Prior period | | | | | | | | | | | | | | |
|--------------------|--|----------------------|------------------------------------|-----------------------|--------------|-------------------------|-------------------------------|--------------------------------------|-------------------------|-------------------------|--------------------------------|--------------------------------|--------------|----------------|------------------------------|---|
| | | 股本 Capital stock | 其他權益工具 other equity instruments | | | 資本公積 Capital surplus | 減：庫存股 Less: Treasury stock | 其他綜合收益 Other comprehensive income | 專項儲備 Special reserve | 盈餘公積 Surplus reserve | 一般風險準備 General risk reserve | 未分配利潤 Undistributed profits | 其他 Others | 小計 Subtotal | 少數股東權益 Minority interests | 股東權益合計 Total shareholders' interests |
| | | | 優先股 Preferred stock | 永續債 Perpetual bond | 其他 Others | | | | | | | | | | | |
| 一、上年年末餘額 | I. Closing balance for last year | 108,000,000.00 | - | - | - | 282,204,487.50 | - | - | - | 18,439,830.70 | - | 16,035,325.75 | - | 424,679,643.95 | - | 424,679,643.95 |
| 加：會計政策變更 | Add: Changes in accounting policies | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 前期差錯更正 | Correction of previous errors | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 同一控制下企業合併 | Business combinations under common control | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 其他 | Others | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 二、本年初餘額 | II. Opening balance for the year | 108,000,000.00 | - | - | - | 282,204,487.50 | - | - | - | 18,439,830.70 | - | 16,035,325.75 | - | 424,679,643.95 | - | 424,679,643.95 |
| 三、本期增減變動金額 | III. Movements in current period | - | - | - | - | - | - | - | - | - | - | 24,457,064.94 | - | 24,457,064.94 | - | 24,457,064.94 |
| (一) 綜合收益總額 | (I) Total comprehensive income | - | - | - | - | - | - | - | - | - | - | 24,457,064.94 | - | 24,457,064.94 | - | 24,457,064.94 |
| (二) 股東投入和減少資本 | (II) Injection and reduction | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 1. 股東投入的普通股 | 1. Shareholders' contribution to ordinary shares | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2. 其他權益工具持有者投入資本 | 2. Capital contribution by holders of other equity instruments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 3. 股份支付計入股東權益的金額 | 3. Share-based payment credited to shareholders' equity | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 4. 其他 | 4. Others | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| (三) 利潤分配 | (III) Profit appropriation | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 1. 提取盈餘公積 | 1. Appropriation of surplus reserve | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2. 提取一般風險準備 | 2. Appropriation of general risk provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 3. 對股東的分配 | 3. Allocation to shareholders | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 4. 其他 | 4. Others | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| (四) 股東權益內部結轉 | (IV) Internal carryover in shareholders' equities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 1. 資本公積轉增股本 | 1. Transfer of capital reserve to share capital | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2. 盈餘公積轉增股本 | 2. Transfer of surplus reserve to share capital | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 3. 盈餘公積彌補虧損 | 3. Surplus reserve for making up losses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 4. 設定受益計劃變動額結轉留存收益 | 4. Change in defined benefit plan carried forward to retained earnings | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 5. 其他綜合收益結轉留存收益 | 5. Other comprehensive income carried forward to retained earnings | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 6. 其他 | 6. Others | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| (五) 專項儲備 | (V) Special reserve | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 1. 本期提取 | 1. Appropriation for the period | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2. 本期使用 | 2. Use in the period | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| (六) 其他 | (VI) Others | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 四、本期末餘額 | IV. Closing balance for the current period | 108,000,000.00 | - | - | - | 282,204,487.50 | - | - | - | 18,439,830.70 | - | 40,492,390.69 | - | 449,136,708.89 | - | 449,136,708.89 |

未經審核中期財務 報表附註

NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS

一、公司的基本情況

1. 基本情況

創美藥業股份有限公司（以下簡稱“本公司”或“創美藥業公司”，在包含子公司時簡稱“本集團”）於 2000 年經汕頭市經濟體制改革委員會、汕頭市經濟委員會、汕頭市財政局、汕頭市國有資產管理辦公室以汕改委[2000]6 號文批准，由汕頭醫藥（集團）公司、汕頭市創美貿易有限公司及汕頭市創美廣告有限公司共同出資將“汕頭市醫藥貿易發展公司”改組設立的有限責任公司。公司於 2000 年 3 月 6 日取得汕頭市工商行政管理局頒發的《企業法人營業執照》。2015 年 5 月 28 日，公司變更名稱為創美藥業股份有限公司。公司的註冊地為汕頭市龍湖區嵩山北路 235 號，統一社會信用代碼：91440500722414635C。

本公司屬於醫藥流通行業，主要從事醫藥產品分銷。公司的經營範圍為：許可項目：藥品批發；第三類醫療器械經營；食品銷售；道路貨物運輸

I. GENERAL INFORMATION ABOUT THE COMPANY

1. General Information

As approved by Shantou Commission for Restructuring the Economic Systems, Shantou Economic Committee, Shantou Finance Bureau and Shantou State-owned Property Management Office with Circular [2000] No.6 of Shantou Reform Commission, Charmacy Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company” or “Charmacy Pharmaceutical Company”, together with its subsidiaries referred to as the “Group”) was restructured from “Shantou Pharmaceutical Trading Development Company (汕頭市醫藥貿易發展有限公司)” and established as a limited liability company by Shantou Medicine (Group) Limited (汕頭醫藥 (集團)公司), Shantou Chuangmei Trading Limited (汕頭市創美貿易有限公司) and Shantou Chuangmei Advertising Limited (汕頭市創美廣告有限公司) with joint investments in 2000. The Company obtained the BUSINESS LICENSE OF THE ENTERPRISE LEGAL PERSON issued by Shantou Administration for Industry and Commerce on 6 March 2000. On 28 May 2015, the Company changed its name to Charmacy Pharmaceutical Co., Ltd. The registered address of the Company is No. 235 Song Shan North Road, Longhu District, Shantou City with a uniform social credit number of 91440500722414635C.

The Company operates in the pharmaceutical distribution industry and is mainly engaged in the distribution of pharmaceutical products. The business scope of the Company: Licensed items: drug wholesale, distribution of Class III medical



(不含危險貨物)，城市配送運輸服務(不含危險貨物)，消毒器械銷售，藥品互聯網信息服務，醫療器械互聯網信息服務。一般項目：第一類醫療器械銷售，第二類醫療器械銷售，保健食品(預包裝)銷售，食品銷售(僅銷售預包裝食品)，國內貨物運輸代理，信息諮詢服務(不含許可類信息諮詢服務)，健康諮詢服務(不含診療服務)，企業管理諮詢，普通貨物倉儲服務(不含危險化學品等許可審批的項目)，低溫倉儲(不含危險化學品等需許可審批的項目)，信息技術諮詢服務，廣告設計、代理，非居住房地產租賃，倉儲設備租賃服務，辦公設備租賃服務，消毒劑銷售(不含危險化學品)，衛生用殺蟲劑銷售，化妝品批發，化妝品零售，衛生用品和一次性使用醫療用品銷售，個人衛生用品銷售，食品用洗滌劑銷售，日用雜品銷售，日用品批發，化工產品銷售(不含許可類化工產品)，勞動保護用品銷售，特種勞動防護用品銷售，初級農產品收購，農副產品銷售，食用農產品初加工，嬰幼兒配方乳粉及其他嬰幼兒配方食品銷售，特殊醫學用途配方食品銷售，裝卸搬運，運輸貨物打包服務，包裝服務，諮詢策劃服務，互聯網銷售(除銷售需要許可的商品)，食品互聯網銷售(僅銷售預包裝食品)，醫用口罩零售，醫用口罩批發，日用口罩(非醫用)銷售，國內貿易代理，租賃服務(不含許可類租賃服務)。公司的經營範圍以經公司

devices, food sale, road transportation of goods (excluding dangerous goods), urban distribution and transportation services (excluding dangerous goods), sale of disinfection equipment, online drug information services, and online medical device information services. General items: sale of Class I medical devices, sale of Class II medical devices, sale of health foods (prepackaged), sale of foods (only prepackaged foods), domestic cargo transportation agency, information consulting services (excluding information consulting services subject to licensing), health consulting services (excluding medical services), enterprise management consulting, general cargo warehousing services (excluding hazardous chemicals and other items subject to licensing and approval), low-temperature warehousing (excluding hazardous chemicals and other items subject to licensing and approval), information technology consulting services, advertisement design and agency, non-residential real estate leasing, warehousing equipment leasing services, office equipment leasing services, sale of disinfectants (excluding hazardous chemicals), sale of sanitary pesticides, cosmetics wholesale and retail, sale of sanitary products and disposable medical products, sale of personal hygiene products, sale of food detergents, sale of daily groceries, wholesale of daily necessities, sale of chemical products (excluding chemical products subject to licensing), sale of labor protection products, sale of special labor protection products, purchase of primary agricultural products, sale of agricultural by-products, primary processing of edible agricultural products, sale of infant formula milk powder and other infant formula foods, sale of formula foods for special medical purposes, loading and unloading, cargo transportation and packing services, packaging services, consulting and planning services, online sale (except for sale of commodities subject to licensing), online sale of foods (only prepackaged foods), retail and wholesale of medical masks, sale of daily masks (non-medical), domestic trade agency, and leasing services (excluding leasing services subject to

登記機關核准的項目為準。

本公司設有股東大會、董事會、監事會、總經理。本公司下設營銷中心、運維支持中心、物流中心、財務部等職能部門。

二、合併財務報表範圍

本集團合併財務報表範圍包括廣東創美藥業有限公司（以下簡稱“廣東創美公司”）、深圳創美藥業有限公司（以下簡稱“深圳創美公司”）、珠海創美藥業有限公司（以下簡稱“珠海創美公司”）、廣州創美藥業有限公司（以下簡稱“廣州創美公司”）及惠州創美藥業有限公司（以下簡稱“惠州創美公司”）5家全資子公司。

本集團報告期內合併報表範圍未有變化，詳見本附註“七、合併範圍的變化”及本附註“八、在子公司中的權益”相關內容。

三、財務報表的編制基礎

1. 編制基礎

本集團財務報表以持續經營為基礎，

licensing). The business scope of the Company is subject to the same being approved by the authority in which the Company registered.

The Company has the General Meeting, the Board of Directors, the Board of Supervisors and the General Manager. The Company has functional departments such as marketing centre, operation and maintenance support centre, logistics centre and finance department.

II. SCOPE OF CONSOLIDATED FINANCIAL STATEMENTS

The scope of consolidated financial statements of the Group covers five wholly-owned subsidiaries, Guangdong Charmacy Pharmaceutical Co., Ltd. (廣東創美藥業有限公司) (hereafter referred to as “Guangdong Charmacy Company”), Shenzhen Charmacy Pharmaceutical Limited (深圳創美藥業有限公司) (hereafter referred to as “Shenzhen Charmacy Company”), Zhuhai Charmacy Pharmaceutical Limited (珠海創美藥業有限公司) (hereinafter referred to as “Zhuhai Charmacy Company”) and Guangzhou Charmacy Pharmaceutical Limited (廣州創美藥業有限公司) (hereafter referred to as “Guangzhou Charmacy Company”) and Huizhou Charmacy Pharmaceutical Co., Ltd. (惠州創美藥業有限公司) (hereafter referred to as “Huizhou Charmacy Company”).

For details was no change in the scope of consolidated financial statements of the Group during the reporting period. For details, please refer to the relevant content as set out in “VII. CHANGES IN SCOPE OF CONSOLIDATION” and “VIII. INTERESTS IN SUBSIDIARIES” of these notes.

III. BASIS FOR THE PREPARATION OF FINANCIAL STATEMENTS

1. Preparation basis

The Group prepared its financial statements on the going

根據實際發生的交易和事項，按照財政部頒佈的《企業會計準則》及相關規定，以及香港《公司條例》和香港聯合交易所《上市規則》所要求之相關披露，並基於本附註“四、重要會計政策及會計估計”所述會計政策和會計估計編制。

2.持續經營

本集團對自 2022 年 6 月 30 日起 12 個月的持續經營能力進行了評價，未發現對持續經營能力產生重大懷疑的事項和情況。因此，本財務報表系在持續經營假設的基礎上編制。

四、重要會計政策及會計估計

本集團根據實際生產經營特點制定的具體會計政策和會計估計包括營業週期、應收款項壞賬準備的確認和計量、發出存貨計量、固定資產分類及折舊方法、無形資產攤銷、收入確認和計量等。

1.遵循企業會計準則的聲明

本公司編制的財務報表符合企業會計準則的要求，真實、完整地反映了本公司及本集團的財務狀況、經營成果和現金流量等有關信息。

concern basis, according to actual transactions and events as well as such disclosure requirements under the Accounting Standards for Enterprises (《企業會計準則》) issued by the Ministry of Finance and relevant provisions, the Companies Ordinance of Hong Kong and the Rules Governing the Listing of Securities on the Stock Exchange, and based on the accounting policies and accounting estimates set out in “IV. SIGNIFICANT ACCOUNTING POLICIES AND ACCOUNTING ESTIMATES” of these notes.

2.Going concern

The Group, having evaluated its ability to continue as a going concern for the 12 months since 30 June 2022, did not find any event or condition which may cast significant doubt on the going concern ability. Hence, the preparation of these financial statements was based on the assumption of going concern.

IV. SIGNIFICANT ACCOUNTING POLICIES AND ACCOUNTING ESTIMATES

Tips for specific accounting policies and accounting estimates: The specific accounting policies and accounting estimates formulated by the Group according to the actual production and operation characteristics include business cycle, recognition and measurement of bad debt reserves for receivables, measurement of issued inventory, classification and depreciation methods of fixed assets, amortization of intangible assets, and recognition and measurement of income.

1.Declaration on compliance with Accounting Standards for Enterprises

The Company complied with the requirements of Accounting Standards for Enterprises in preparing its financial statements, which give a true and full view of the relevant information such as the financial position, operating results and cash flows of the Company and the Group.

2.會計期間

本集團的會計期間為西曆 1 月 1 日至 12 月 31 日。

3.營業週期

本集團營業週期為 12 個月，並以其作為資產和負債的流動性劃分標準。

4.記賬本位幣

本集團以人民幣為記賬本位幣。

5.同一控制下和非同一控制下企業合併的會計處理方法

本集團作為合併方，在同一控制下企業合併中取得的資產和負債，在合併日按被合併方在最終控制方合併報表中的賬面價值計量。取得的淨資產賬面價值與支付的合併對價賬面價值的差額，調整資本公積；資本公積不足沖減的，調整留存收益。

在非同一控制下企業合併中取得的被購買方可辨認資產、負債及或有負債在收購日以公允價值計量。合併成本為本集團在購買日為取得對被購買方的控制權而支付的現金或非現金資產、發行或承擔的負債、發行的權益性證券等的公允價值以及在企業合併中發生的各項直接相關費用之和（通過多次交易分步實現的企業合併，其合併成本為每一單項交易的成本之和）。合併成本大於合併中取得的被

2.Accounting period

The Group's accounting period begins on 1 January and ends on 31 December of the calendar year.

3.Business cycle

The Group treats 12 months as a business cycle and the criteria for classifying the liquidity of assets and liabilities.

4.Functional currency

The Group adopts Renminbi as its functional currency.

5.Accounting methods for business combinations under common control and business combinations not under common control

The assets and liabilities obtained by the Group as the merging party in a business combination are measured at the combination-date carrying amount of the merged party in the consolidated statement of ultimate controller. The difference between the carrying amount of net assets obtained and the carrying amount of the combination consideration paid shall adjust additional paid-in capital; if the additional paid-in capital is not sufficient for offsetting, the retained earnings shall be adjusted.

The acquiree's identifiable assets, liabilities and contingent liabilities obtained in a business combination not under common control shall be measured at fair value at the acquisition date. The cost of combination is the sum of the fair value of cash and non-cash assets paid, liabilities incurred or assumed and equity securities issued by the Group for obtaining control of the acquiree at the acquisition date and all expenses incurred directly in the business combination (for the business combination is achieved in stages through multiple transactions, its cost of combination is the sum of costs of each single transaction). Where the cost of combination exceeds the

購買方可辨認淨資產公允價值份額的差額，確認為商譽；合併成本小於合併中取得的被購買方可辨認淨資產公允價值份額的，首先對合併中取得的各項可辨認資產、負債及或有負債的公允價值、以及合併對價的非現金資產或發行的權益性證券等的公允價值進行覆核，經覆核後，合併成本仍小於合併中取得的被購買方可辨認淨資產公允價值份額的，將其差額計入合併當期營業外收入。

6. 合併財務報表的編制方法

本集團將所有控制的子公司納入合併財務報表範圍。

在編制合併財務報表時，子公司與本公司採用的會計政策或會計期間不一致的，按照本公司的會計政策或會計期間對子公司財務報表進行必要的調整。

合併範圍內的所有重大內部交易、往來餘額及未實現利潤在合併報表編制時予以抵銷。子公司的所有者權益中不屬於母公司的份額以及當期淨損益、其他綜合收益及綜合收益總額中屬於少數股東權益的份額，分別在合併財務報表“少數股東權益、少數股東損益、歸屬於少數股東的其他綜合收益及歸屬於少數股東的綜合收益總額”項目列示。

acquirer's share of the fair value of the acquiree's identifiable net assets, the difference is recognized as goodwill; where the cost of combination is less than the acquirer's share of the fair value of the acquiree's identifiable net assets, the measurement of the fair values of all the identifiable assets, liabilities and contingent liabilities obtained in the business combination and the fair values of non-cash assets or equity securities issued as the consideration for combination are firstly reviewed. If, after that review, the cost of combination is still less than the acquirer's share of the fair value of the acquiree's identifiable net assets in the business combination, the difference shall be included in the consolidated non-operating revenue for the period.

6. Preparation methods of consolidated financial statements

The Group includes all subsidiaries controlled by it into the scope of consolidated financial statements

When preparing consolidated financial statements, if there is inconsistency on the accounting policies or accounting periods between the subsidiaries and the Company, necessary adjustments will be made to the financial statements of the subsidiaries based on the accounting policies or accounting periods of the Company.

All significant intra-group transactions, current balances and unrealized profits within the scope of consolidation shall be offset in preparing the consolidated statements. The shares of owners' equity in subsidiaries not attributable to the parent company and the shares of net loss or profit for the period, other comprehensive income and total comprehensive income attributable to minority interests shall be presented in the consolidated financial statements under the items of "minority interests, profit or loss of minority shareholders, other comprehensive income attributable to minority interests and

對於同一控制下企業合併取得的子公司，其經營成果和現金流量自合併當期期初納入合併財務報表。編制比較合併財務報表時，對上年財務報表的相關項目進行調整，視同合併後形成的報告主體自最終控制方開始控制時點起一直存在。

通過多次交易分步取得同一控制下被投資單位的股權，最終形成企業合併的，應在取得控制權的報告期，補充披露在合併財務報表中的處理方法。例如：通過多次交易分步取得同一控制下被投資單位的股權，最終形成企業合併，編制合併報表時，視同在最終控制方開始控制時即以目前的狀態存在進行調整，在編制比較報表時，以不早於本集團和被合併方同處於最終控制方的控制之下的時點為限，將被合併方的有關資產、負債併入本集團合併財務報表的比較報表中，並將合併而增加的淨資產在比較報表中調整所有者權益項下的相關項目。為避免對被合併方淨資產的價值進行重複計算，本集團在達到合併之前持有的長期股權投資，在取得原股權之日與本集團和被合併方處於同一方最終控制之日孰晚日起至合併日之間已確認有關損益、其他綜合收益和其他淨資產變動，應分別沖減比較報表期間的

total comprehensive income attributable to minority interests”, respectively.

The operating results and cash flows of a subsidiary acquired from business combination under common control shall be included in the consolidated financial statements from the beginning of the period of the combination. When preparing the comparative consolidated financial statements, relevant items in the financial statements of the previous year will be adjusted as if the reporting entity formed after the combination had been in existence since the time when the ultimate controlling party gains control.

For equity of an investee under common control acquired in stages through multiple transactions, which results in business combination, supplementary disclosure to treatment methods in consolidated financial statements shall be made in the reporting period of acquiring the control. For instance, for equity of an investee under common control acquired in stages through multiple transactions, which results in business combination, it shall be adjusted in the preparation of consolidated financial statements as if it had been in existence as the current status since the time when the ultimate controlling party obtains the control. When preparing the comparative statements, relevant assets and liabilities of the combined party are included in the comparative statements of consolidated financial statements of the Group no earlier than the time when the Group and the combined party are under the common control of the ultimate controlling party, with the increase in net assets arising from the combination being adjusted against the relevant items under owners' equity in the comparative statements. In order to avoid repeated calculation of the value of the net assets of the combined party, the long-term equity investment held by the Group before the completion of the combination, as well as the relevant recognized profit or loss, other comprehensive income

期初留存收益和當期損益。

對於非同一控制下企業合併取得子公司，經營成果和現金流量自本集團取得控制權之日起納入合併財務報表。在編制合併財務報表時，以購買日確定的各項可辨認資產、負債及或有負債的公允價值為基礎對子公司的財務報表進行調整。

通過多次交易分步取得非同一控制下被投資單位的股權，最終形成企業合併的，應在取得控制權的報告期，補充披露在合併財務報表中的處理方法。例如：通過多次交易分步取得非同一控制下被投資單位的股權，最終形成企業合併，編制合併報表時，對於購買日之前持有的被購買方的股權，按照該股權在購買日的公允價值進行重新計量，公允價值與其賬面價值的差額計入當期投資收益；與其相關的購買日之前持有的被購買方的股權涉及權益法核算下的其他綜合收益以及除淨損益、其他綜合收益和利潤分配外的其他所有者權益變動，在購買日所屬當期轉為投資損益，由於被投資方重新計量設定受益計劃淨負債或淨資產變動而產生的其他綜合收益除外。

and other changes in net assets from the later of the day of acquiring the original equity or the day when the Group and the combined party are under the same ultimate control to the combination day shall be offset against the retained earnings at the beginning of the period and the profit or loss for the period in the comparative statements, respectively.

The operating results and cash flows of a subsidiary acquired from business combination not under common control shall be included in the consolidated financial statements since the date when the Group gains control. When preparing the consolidated financial statements, the financial statements of the subsidiary shall be adjusted based on the fair values of the identifiable assets, liabilities and contingent liabilities determined on the acquisition date.

For equity of an investee not under common control acquired in stages through multiple transactions, which results in business combination, supplementary disclosure to the treatment methods in consolidated financial statements shall be made in the reporting period of acquiring the control. For instance, for equity of an investee not under common control acquired in stages through multiple transactions, which results in business combination, the equity of the acquiree held before the acquisition date shall be remeasured at the fair value of the equity on the acquisition date when preparing the consolidated financial statements, with the balance between the fair value and its book value being included in the investment gains for the period. Except for other comprehensive income arising from changes as a result of remeasurement of net liabilities or net assets of the defined benefit plan of the investee, other comprehensive income under the equity method involving the equity of the investee held before the acquisition date and other changes in owners' equity excluding net profit or loss, other comprehensive income and profit distribution shall be converted

into investment profit or loss for the period in which the acquisition date falls.

本集團在不喪失控制權的情況下部分處置對子公司的長期股權投資，在合併財務報表中，處置價款與處置長期股權投資相對應享有子公司自購買日或合併日開始持續計算的淨資產份額之間的差額，調整資本溢價或股本溢價，資本公積不足沖減的，調整留存收益。

For the partial disposal of the Group's long-term equity investments in a subsidiary without losing control, the balance between the disposal price and the share of net assets (being calculated from the acquisition date or combination date) of the subsidiary enjoyed correspondingly in the disposal of the long-term equity investment shall be used to adjust the capital premium or share premium, or the retained earnings if the capital reserves are not sufficient for offsetting, in the consolidated financial statements.

本集團因處置部分股權投資等原因喪失了對被投資方的控制權的，在編制合併財務報表時，對於剩餘股權，按照其在喪失控制權日的公允價值進行重新計量。處置股權取得的對價與剩餘股權公允價值之和，減去按原持股比例計算應享有原有子公司自購買日或合併日開始持續計算的淨資產的份額之間的差額，計入喪失控制權當期的投資損益，同時沖減商譽。與原有子公司股權投資相關的其他綜合收益等，在喪失控制權時轉為當期投資損益。

Where the Group loses its control over the investee due to the partial disposal of equity investment or other reasons, the residual equity will be remeasured at the fair value thereof on the date when the control is lost in the preparation of the consolidated financial statements. The excess of the sum of the consideration obtained from the equity disposal and the fair value of the residual equity over the share of the net assets of the original subsidiaries (being calculated in proportion to the original shareholding percentage from the acquisition date or combination date) shall be included in the investment profit or loss for the period in which the control is lost, with goodwill being offset simultaneously. Other comprehensive income relating to the equity investment of the original subsidiaries shall be transferred to investment profit or loss for the period when the control is lost.

本集團通過多次交易分步處置對子公司股權投資直至喪失控制權的，如果處置對子公司股權投資直至喪失控制權的各項交易屬於一攬子交易的，應當將各項交易作為一項處置子公司並喪失控制權的交易進行會計處理；但

When the Group disposes of its equity investment in the subsidiaries in stages through multiple transactions till losing control, if various transactions for disposing of equity investment of subsidiaries till losing control belong to a package deal, each transaction shall be accounted for as a transaction that disposes of subsidiary with loss of control; nonetheless, before

是，在喪失控制權之前每一次處置價款與處置投資對應的享有該子公司淨資產份額的差額，在合併財務報表中確認為其他綜合收益，在喪失控制權時一併轉入喪失控制權當期的投資損益。

7.現金及現金等價物

本集團現金流量表之現金指庫存現金以及可以隨時用於支付的存款。現金流量表之現金等價物指持有期限不超過 3 個月、流動性強、易於轉換為已知金額現金且價值變動風險很小的投資。

8.外幣業務和外幣財務報表折算

(1) 外幣交易

本集團外幣交易按交易發生日的即期匯率將外幣金額折算為人民幣金額。於資產負債表日，外幣貨幣性項目採用資產負債表日的即期匯率折算為人民幣，所產生的折算差額除了為購建或生產符合資本化條件的資產而借入的外幣專門借款產生的匯兌差額按資本化的原則處理外，直接計入當期損益。

9.商譽

因企業合併形成的商譽在合併財務報表中單獨列報，並按照成本扣除累計減值準備後的金額計量。商譽至少在每年年度終了進行減值測試。

the loss of control, the balance between each disposal price and the share of net assets of such subsidiary enjoyed correspondingly in investment disposal is recognized as other comprehensive income in the consolidated financial statements and transferred to investment profit or loss for the period when the control is lost.

7.Cash and cash equivalents

Cash in the cash flow statements of the Group refers to cash on hand and the deposits ready for payment at any time. Cash equivalents in the cash flow statements represent the investment with a term less than 3 months, which are highly liquidated, easy to be converted into known amounts of cash and subject to an insignificant risk of change in value.

8.Foreign currency business and translation of financial statements denominated in foreign currency

(1) Foreign currency transactions

For the Group's foreign currency-denominated transactions, the foreign currency amount is converted into RMB amount at the spot exchange rate on the day when such transactions occur. Foreign currency monetary items are converted into RMB at the spot exchange rate on the balance sheet date, and the conversion differences resulted therefrom, except that those arising from special foreign currency loans related to the acquisition and construction or production of assets eligible for capitalisation should be treated on the capitalisation principle, are all included in the current profit or loss.

9.Goodwill

The goodwill arising on a business combination shall be presented separately in the consolidated financial statements and measured at costs less accumulated provision for impairment. The goodwill is tested for impairment at least at the end of each year.

對商譽進行減值測試時，結合與其相關的資產組或者資產組組合進行。即，自購買日起將商譽的賬面價值按照合理的方法分攤到能夠從企業合併的協同效應中受益的資產組或資產組組合，如包含分攤的商譽的資產組或資產組組合的可收回金額低於其賬面價值的，確認相應的減值損失。減值損失金額首先抵減分攤到該資產組或資產組組合的商譽的賬面價值，再根據資產組或資產組組合中除商譽以外的其他各項資產的賬面價值所佔比重，按比例抵減其他各項資產的賬面價值。

可收回金額為資產的公允價值減去處置費用後的淨額與資產預計未來現金流量的現值兩者之中的較高者。資產的公允價值根據公平交易中銷售協定價格確定；不存在銷售協議但存在資產活躍市場的，公允價值按照該資產的買方出價確定；不存在銷售協議和資產活躍市場的，則以可獲取的最佳信息為基礎估計資產的公允價值。處置費用包括與資產處置有關的法律費用、相關稅費、搬運費以及為使資產達到可銷售狀態所發生的直接費用。資產預計未來現金流量的現值，按照資產在持續使用過程中和最終處置時所產生的預計未來現金流量，選擇恰當的折現率對其進行折現後的金額加以確定。

When conducting the impairment test for goodwill, the goodwill is tested together with the related asset group or portfolio of asset group. That is, the carrying amount of goodwill is reasonably allocated to the related asset group or portfolio of asset group which benefits from the synergies of the business combination since the acquisition date. Relevant impairment loss is recognized if the recoverable amount of asset group or portfolio of asset group which contains the allocated goodwill is less than its carrying amount. The amount of impairment loss is firstly used to offset against the carrying amount of goodwill allocated to that asset group or portfolio of asset group, and then will be offset against the carrying amount of other assets on a pro rata basis according to the proportion of carrying amount of all other assets (other than goodwill) within asset group or portfolio of asset group.

The recoverable amount is the higher of the fair value of an asset less costs of disposal and the present value of the future cash flows expected to be derived from the asset. The fair value of asset shall be determined according to the prices stipulated in a sales agreement in an arm's length transaction. If there is no sales agreement but active market for assets, fair value shall be determined according to the bid price of the asset. If there is no sales agreement or active market for assets, the fair value of assets shall be estimated based on the best available information. Disposal expenses include the legal costs, related taxes, carriage expenses related to asset disposal and the direct costs caused by the efforts to prepare the asset for its intended sales. The present value of expected future cash flows of an asset shall be determined by discounting the estimated future cash flows generated from the continuous use and ultimate disposal of assets at an appropriate discount rate.

商譽減值損失在發生時計入當期損益，且在以後會計期間不予轉回。

10.金融資產和金融負債

本集團成為金融工具合同的一方時確認一項金融資產或金融負債。

(1) 金融資產

1) 金融資產分類、確認依據和計量方法

本集團根據管理金融資產的業務模式和金融資產的合同現金流特徵，將金融資產分類為以攤余成本計量的金融資產、以公允價值計量且其變動計入其他綜合收益的金融資產、以公允價值計量且其變動計入當期損益的金融資產。不屬於任何套期關係的一部分的該類金融資產，按照實際利率法攤銷、減值、匯兌損益以及終止確認時產生的利得或損失，計入當期損益。本集團分類為該類的金融資產具體包括：應收賬款、應收票據、其他應收款、應付票據、合同負債、其他應付款。

本集團將同時符合下列條件的金融資產分類為以公允價值計量且其變動計入其他綜合收益的金融資產：①管理該金融資產的業務模式既以收取合同現金流量為目標又以出售該金融資產為目標。②該金融資產的合同條款規定，在特定日期產生的現金流，僅為對本金和以未償付本金金額為基礎的利息的支付。此類金融資產按照公允

The impairment loss of goodwill is charged to the profit or loss for the period when it incurred and will not be reversed in any subsequent periods.

10.Financial assets and financial liabilities

When the Group becomes a party to the financial instrument contract, a financial asset or financial liability will be recognized.

(1)Financial assets

1)Classification, recognition and measurement of financial assets

The Group classifies financial assets into financial assets at amortized cost, financial assets at fair value through other comprehensive income and financial assets at fair value through profit or loss based on its business model for managing the financial assets and the contractual cash flow characteristics of the financial assets.All gains or losses arising from the amortization, impairment, exchange loss and derecognition of such financial assets which are not part of any hedging relationships with the effective interest method are recorded into current profit or loss. The financial assets that the Group classifies into this category are: accounts receivable, notes receivable, other receivable, notes payable, contractual liabilities, and other payables.

The Group will classify financial assets that meet the following conditions into financial assets at fair value through other comprehensive income: ① the financial assets are managed within a business model whose objective is achieved both by collecting contractual cash flows and selling financial assets; and ② the contractual terms of the financial assets give rise on specific dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. Such financial assets are initially measured at fair value with related transaction

價值進行初始計量，相關交易費用計入初始確認金額。不屬於任何套期關係的一部分的該類金融資產所產生的所有利得或損失，除信用減值損失或利得、匯兌損益和按照實際利率法計算的該金融資產利息之外，所產生的其他利得或損失，均計入其他綜合收益；金融資產終止確認時，之前計入其他綜合收益的累計利得或損失應當從其他綜合收益中轉出，計入當期損益。本集團分類為該類的金融資產具體包括：應收款項融資。

本集團按照實際利率法確認利息收入。利息收入根據金融資產賬面餘額乘以實際利率計算確定，但下列情況除外：①對於購入或源生的已發生信用減值的金融資產，自初始確認起，按照該金融資產的攤余成本和經信用調整的實際利率計算確定其利息收入。②對於購入或源生的未發生信用減值、但在後續期間成為已發生信用減值的金融資產，在後續期間，按照該金融資產的攤余成本和實際利率計算確定其利息收入。

本集團將非交易性權益工具投資指定為以公允價值計量且其變動計入其他綜合收益的金融資產，該指定一經作出，不得撤銷。本集團指定的以公允價值計量且其變動計入其他綜合收益的非交易性權益工具投資，按照公允價值進行初始計量，相關交易費用計入初始確認金額；除了獲得股利（屬於投資成本收回部分的除外）計入當

costs to be included in the initial recognition amount. All gains or losses arising from the financial assets which are not part of any hedging relationships, other than credit impairment losses or gains, exchange gains or losses and interest on such financial assets calculated using the effective interest method, are recognized in other comprehensive income. Upon derecognition of the financial assets, the cumulative gains or losses previously included in other comprehensive income shall be transferred out and be included in the profit or loss for the period. The financial assets that the Group classifies into this category are: account receivables financing.

The Group recognizes interest income using the effective interest method. Interest income is calculated and determined by applying the effective interest rate to the carrying balance of the financial asset, except: ① for the purchased or internally generated credit-impaired financial assets, their interest income is calculated and determined based on amortized cost and credit-adjusted effective interest rate of such financial assets since the initial recognition; ② for the purchased or internally generated financial assets without credit-impairment but subsequently becoming credit-impaired, their interest income is calculated and determined based on amortized costs and effective interest rate of such financial assets in subsequent periods.

The Group designates the investments in equity instruments not held for trading as financial assets at fair value through other comprehensive income. Such designation cannot be revoked once made. The investments in equity instruments not held for trading designated as at fair value through other comprehensive income by the Group are initially measured at fair value with related transaction costs to be included in the initial recognition amount. Except for any received dividends (excluding those belonging to the recovery of the investment costs) which are

期損益外，其他相關的利得和損失（包括匯兌損益）均計入其他綜合收益，且後續不得轉入當期損益。當其終止確認時，之前計入其他綜合收益的累計利得或損失從其他綜合收益中轉出，計入留存收益。

除上述分類為以攤余成本計量的金融資產和分類為以公允價值計量且其變動計入其他綜合收益的金融資產之外的金融資產。本集團將其分類為以公允價值計量且其變動計入當期損益的金融資產。此類金融資產按照公允價值進行初始計量，相關交易費用直接計入當期損益。此類金融資產的利得或損失，計入當期損益。

本集團在非同一控制下的企業合併中確認的或有對價構成金融資產的，該金融資產分類為以公允價值計量且其變動計入當期損益的金融資產。

本集團在改變管理金融資產的業務模式時，對所有受影響的相關金融資產進行重分類。

2) 金融資產轉移的確認依據和計量方法

本集團將滿足下列條件之一的金融資產予以終止確認：①收取該金融資產現金流量的合同權利終止；②金融資產發生轉移，本集團轉移了金融資產所有權上幾乎所有風險和報酬；③金融資產發生轉移，本集團既沒有轉移

included in the profit or loss for the period, other related gains or losses (including exchange gains and losses) are included in other comprehensive income and may not be transferred to the profit or loss for the period subsequently. Upon derecognition, the cumulative gains or losses previously included in other comprehensive income shall be transferred out and be included in retained earnings.

Other than the above financial assets classified as financial assets measured at amortized cost and financial assets at fair value through other comprehensive income, the Group classifies its financial assets as financial assets at fair value through profit or loss. Such financial assets are initially measured at fair value with related transaction costs to be directly included in profit or loss for the period. Gains or losses on such financial assets are included in profit or loss for the period.

Financial assets arising from contingent consideration recognized by the Group during the business combination not under common control, are classified as financial assets at fair value through profit or loss.

The Group reclassifies all impacted financial assets at the time of changing the business model of managing a financial asset.

2) Recognition and measurement of transfer of financial assets

The Group derecognizes financial assets if one of the following conditions is satisfied: ① the contractual rights to collect the cash flows from the financial asset expire; ② the financial asset has been transferred, and the Group has transferred substantially all the risks and rewards of ownership of the financial asset; and ③ the financial asset has been transferred,

也沒有保留金融資產所有權上幾乎所有風險和報酬，且未保留對該金融資產控制的。

金融資產整體轉移滿足終止確認條件的，將所轉移金融資產的賬面價值，與因轉移而收到的對價及原直接計入其他綜合收益的公允價值變動累計額中對應終止確認部分的金額（涉及轉移的金融資產的合同條款規定，在特定日期產生的現金流量，僅為對本金和以未償付本金金額為基礎的利息的支付）之和的差額計入當期損益。

金融資產整體轉移滿足終止確認條件的，將所轉移金融資產在終止確認日的賬面價值，與因轉移而收到的對價及原直接計入其他綜合收益的公允價值變動累計額中對應終止確認部分的金額（涉及轉移的金融資產的同時符合下列條件：集團管理該金融資產的業務模式是以收取合同現金流量為目標；該金融資產的合同條款規定，在特定日期產生的現金流，僅為對本金金額為基礎的利息的支付）之和的差額計入當期損益。

金融資產部分轉移滿足終止確認條件的，將所轉移金融資產整體的賬面價值，在終止確認部分和未終止確認部分之間，按照各自的相對公允價值進行分攤，並將因轉移而收到的對價及應分攤至終止確認部分的原計入其他

and the Group neither transfers nor retains substantially all the risks and rewards of ownership of the financial asset, and it has not retained control over such financial asset.

If the transfer of an entire financial asset satisfies the conditions for derecognition, the difference between the carrying amount of the transferred financial assets and the sum of the consideration received from the transfer and the accumulative amount of the changes of the fair value originally included in other comprehensive income which shall be apportioned to the derecognized portion (where the contractual terms of the financial assets transferred give rise on specific dates to cash flows that are solely payments of principal and interest on the principal amount outstanding), are included into current profit or loss.

If the whole transfer of the financial asset meets the conditions for derecognition, the difference between the carrying amount of the transferred financial asset at the date of derecognition and the sum of the consideration received for the transfer and the accumulative amount of fair value changes originally recorded into other comprehensive income which is relevant to the portion of derecognition (the transferred financial asset shall meet all of the following conditions: the Group's business model for managing the financial asset is to collect contractual cash flows; and the contractual terms of the financial asset require that the cash flow generated on a specific date is only for the payment of interest based on the principal).

If the transfer of financial asset partially satisfies the conditions of derecognition, the entire carrying amount of the transferred financial asset is, between the portion which is derecognized and the portion which is not, apportioned according to their respective relative fair value, and the difference between the sum of the consideration received from the transfer and the

綜合收益的公允價值變動累計額中對應終止確認部分的金額（涉及轉移的金融資產同時符合下列條件：集團管理該金融資產的業務模式是以收取合同現金流量為目標；該金融資產的合同條款規定，在特定日期產生的現金流量僅為對本金金額為基礎的利息的支付）之和，與分攤的前述金融資產整體賬面價值的差額計入當期損益。

（2）金融負債

1）金融負債分類、確認依據和計量方法

除下列各項外，本集團將金融負債分類為以攤餘成本計量的金融負債，採用實際利率法，按照攤餘成本進行後續計量：

①以公允價值計量且其變動計入當期損益的金融負債（含屬於金融負債的衍生工具），包括交易性金融負債和初始確認時指定為以公允價值計量且其變動計入當期損益的金融負債，此類金融負債按照公允價值進行後續計量，公允價值變動形成的利得或損失以及與該金融負債相關的股利和利息支出計入當期損益。

②不符合終止確認條件的金融資產轉移或繼續涉入被轉移金融資產所形成的金融負債。此類金融負債，本集團按照金融資產轉移相關準則規定進行計量。

accumulative amount of the changes of the fair value originally included in other comprehensive income which shall be apportioned to the derecognized portion (the transferred financial asset shall meet all of the following conditions: the Group's business model for managing the financial asset is to collect contractual cash flows; and the contractual terms of the financial asset require that the cash flow generated on a specific date is only for the payment of interest based on the principal), and the apportioned entire carrying amount of the said financial assets are included into current profit or loss.

(2) Financial liabilities

1) Classification, recognition and measurement of financial liabilities

The Group classifies financial liabilities except the following items as being measured at amortized cost. Such financial liabilities are recognized with the effective interest method and subsequently measured at amortized cost

① Financial liabilities (includes derivative instruments that are financial liabilities) at fair value through profit or loss include held-for-trading financial liabilities and financial liabilities designated as measured at fair value through profit or loss at initial recognition. Such financial liabilities subsequently measured at fair value. Gains or losses arising from changes in fair value, as well as dividends and interest expenditure related to such financial liabilities are recorded in profit or loss for the period.

② financial liabilities arising from financial assets of which the transfer does not meet the conditions for derecognition or continuing involvements in the transferred financial assets. The Group measures such financial liabilities according to the relevant rules on financial assets transfer.

③不屬於以上①或②情形的財務擔保合同，以及不屬於以上①情形的以低於市場利率貸款的貸款承諾。本集團作為此類金融負債的發行方的，在初始確認後按照依據金融工具減值相關準則規定確定的損失準備金額以及初始確認金額扣除依據收入準則相關規定所確定的累計攤銷後的餘額孰高進行計量。

本集團將在非同一控制下的企業合併中作為購買方確認的或有對價形成金融負債的，按照以公允價值計量且其變動計入當期損益進行會計處理。

2) 金融負債終止確認條件

當金融負債的現時義務全部或部分已經解除時，終止確認該金融負債或義務已解除的部分。本集團與債權人之間簽訂協定，以承擔新金融負債方式替換現存金融負債，且新金融負債與現存金融負債的合同條款實質上不同的，終止確認現存金融負債，並同時確認新金融負債。本集團對現存金融負債全部或部分的合同條款作出實質性修改的，終止確認現存金融負債或其一部分，同時將修改條款後的金融負債確認為一項新金融負債。終止確認部分的賬面價值與支付的對價之間的差額，計入當期損益。

(3) 金融資產和金融負債的公允價值確定方法

本集團以主要市場的價格計量金融資

③financial guarantee contracts that do not fall within the range of ① or ②, and loan commitments that do not fall within the range of above ① and are at a rate less than the market interest rate. When the Group is the issuer of such financial liabilities, their value is measured at whichever is higher of the loss reserve amount determined in accordance with the financial instrument impairment rules and the balance after subtracting the accumulated amortization amount determined in accordance with the income rules from the initially recognized amount, after initial recognition.

Financial liabilities arising from contingent consideration recognized by the Group as the purchaser during the business combination not under common control, are accounted for at fair value through profit or loss.

2)Derecognition conditions of financial liabilities

When the present obligation of such financial liability was wholly or partially discharged, that financial liability or the discharged obligation shall be derecognised. If the Group and a creditor enter into an agreement to replace the existing financial liability with a new financial liability on substantially different terms, the existing financial liability shall be derecognized, whereas the new financial liability shall be recognized. Where the Group made substantial modifications to the terms of the existing financial liabilities in whole or in part, it derecognizes the existing financial liability in whole or in part and recognizes the financial liability with the revised terms as a new financial liability. The difference between the book value of the derecognized part of financial liability and the consideration paid is included in profit or loss for the period.

(3)Recognition methods of fair value of financial assets and financial liabilities

The Group measures the fair value of financial assets and

產和金融負債的公允價值，不存在主要市場的，以最有利市場的價格計量金融資產和金融負債的公允價值，並且採用當時適用並且有足夠可利用數據和其他信息支持的估值技術。公允價值計量所使用的輸入值分為三個層次，即第一層次輸入值是計量日能夠取得的相同資產或負債在活躍市場上未經調整的報價；第二層次輸入值是除第一層次輸入值外相關資產或負債直接或間接可觀察的輸入值；第三層次輸入值是相關資產或負債的不可觀察輸入值。本集團優先使用第一層次輸入值，最後再使用第三層次輸入值。公允價值計量結果所屬的層次，由對公允價值計量整體而言具有重大意義的輸入值所屬的最低層次決定。

本集團對權益工具的投資以公允價值計量。但在有限情況下，如果用以確定公允價值的近期信息不足，或者公允價值的可能估計金額分佈範圍很廣，而成本代表了該範圍內對公允價值的最佳估計的，該成本可代表其在該分佈範圍內對公允價值的恰當估計。

(4) 金融資產和金融負債的抵銷

本集團的金融資產和金融負債在資產負債表內分別列示，不相互抵銷。但同時滿足下列條件時，以相互抵銷後的淨額在資產負債表內列示：（1）本集團具有抵銷已確認金額的法定權利，且該種法定權利是當前可執行的；（2）本集團計劃以淨額結算，

financial liabilities at the price in the principal market, and does so using the price in the most advantageous market if there is not a principal market and adopts valuation techniques that are applicable then and are supported by sufficient available data and other information. The inputs for fair value measurements are divided into three levels: Level 1-quoted and unadjusted prices in active markets obtained for identical assets or liabilities at the measurement date; Level 2-directly or indirectly observable inputs of the relevant assets or liabilities except the Level 1 inputs; Level 3-unobservable inputs of the related assets or liabilities. The Group gives top priority to using Level 1 inputs and last priority to using Level 3 inputs. The level to which the fair value measurement result belongs is subject to the lowest level of the input that is of great significance to the overall measurement of fair value.

The Group's investments in equity instruments are measured at fair value. However, in limited circumstances where there is insufficient recent information available to determine fair value, or where the distribution range of possible estimates of fair value is so wide while cost represents the best estimate of fair value within that range, such cost may appropriately represent such estimate.

(4) Offsetting of financial assets and financial liabilities

The Group's financial assets and financial liabilities are presented separately in the balance sheet and are not offset against each other. However, they are presented in the balance sheet in net amounts after offsetting each other if both of the following conditions are met: (1) the Group has the legal right to offset the recognised amounts and such legal right is currently enforceable; and (2) the Group plans to settle on a net basis, or

或同時變現該金融資產和清償該金融負債。

(5) 金融負債與權益工具的區分及相關處理方法

本集團按照以下原則區分金融負債與權益工具：(1) 如果本集團不能無條件地避免以交付現金或其他金融資產來履行一項合同義務，則該合同義務符合金融負債的定義。有些金融工具雖然沒有明確地包含交付現金或其他金融資產義務的條款和條件，但有可能通過其他條款和條件間接地形成合同義務。(2) 如果一項金融工具須用或可用本集團自身權益工具進行結算，需要考慮用於結算該工具的本集團自身權益工具，是作為現金或其他金融資產的替代品，還是為了使該工具持有方享有在發行方扣除所有負債後的資產中的剩餘權益。如果是前者，該工具是發行方的金融負債；如果是後者，該工具是發行方的權益工具。在某些情況下，一項金融工具合同規定本集團須用或可用自身權益工具結算該金融工具，其中合同權利或合同義務的金額等於可獲取或需交付的自身權益工具的數量乘以其結算時的公允價值，則無論該合同權利或義務的金額是固定的，還是完全或部分地基於除本集團自身權益工具的市場價格以外的變量（例如利率、某種商品的價格或某項金融工具的價格）的變動而變動，該合同分類為金融負債。

simultaneously realise the financial asset and settle the financial liability.

(5) Distinction between and treatment of financial liabilities and equity instruments

The Group distinguishes between financial liabilities and equity instruments in accordance with the following principles: (1) A contractual obligation meets the definition of a financial liability if the Group cannot unconditionally avoid meeting that obligation by delivering cash or other financial assets. Some financial instruments do not explicitly contain terms and conditions for delivery of cash or other financial asset obligations, but it is possible that contractual obligations may arise indirectly through other terms and conditions. (2) If a financial instrument is required to be, or may be, settled with the Group's own equity instruments, it's needed to take into account whether the Group's own equity instruments used to settle the instrument in question are intended as a substitute for cash or other financial assets or are intended to give the holder of the instrument in question certain residual interest in the assets of the issuer net of all liabilities. If the former prevails, the instrument will be treated as a financial liability of the issuer; or if the latter prevails, the instrument will be treated as an equity instrument of the issuer. In certain circumstances, a financial instrument contract requires or allows the Group to settle the financial instrument with its own equity instruments, where the amount of the contractual right or contractual obligation is equal to the number of the Group's own equity instruments available for acquisition or required for delivery multiplied by their fair value at the time of settlement, then the contract is classified as a financial liability regardless of whether the amount of the contractual right or obligation is fixed or varies, in whole or in part, with variables other than the market price of the Group's own equity instruments (for example, interest rates, the price of a commodity or a financial instrument).

本集團在合併報表中對金融工具（或其組成部分）進行分類時，考慮了集團成員和金融工具持有方之間達成的所有條款和條件。如果集團作為一個整體由於該工具而承擔了交付現金、其他金融資產或者以其他導致該工具成為金融負債的方式進行結算的義務，則該工具應當分類為金融負債。

金融工具或其組成部分屬於金融負債的，相關利息、股利（或股息）、利得或損失，以及贖回或再融資產生的利得或損失等，本集團計入當期損益。

金融工具或其組成部分屬於權益工具的，其發行（含再融資）、回購、出售或註銷時，本集團作為權益的變動處理，不確認權益工具的公允價值變動。

11. 應收票據

基於應收票據的承兌人信用風險作為共同風險特徵，將其劃分為不同組合，並確定預期信用損失會計估計政策：

When classifying financial instruments (or their components) in the consolidated statements of operations, the Group takes into account all terms and conditions agreed between the members of the Group and holders of financial instruments. An instrument shall be classified as a financial liability if the Group as a whole has borne an obligation to deliver cash, other financial assets or to settle in a manner that otherwise results in the instrument becoming a financial liability.

Where a financial instrument or its component parts are financial liabilities, the related interest, dividend, gains or losses (including those arising from redemption or refinancing) shall be included in the Group's profit or loss for the current period.

Where a financial instrument or its components are an equity instrument, the Group will treat its issuance (including refinancing), repurchase, sale or cancellation as a change in equity and will not recognise changes in the fair value of the equity instrument.

11. Bills receivables

Bills receivables are divided into different portfolios and the accounting estimation policies for the expected credit loss thereof are determined, based on the shared characteristics of acceptors' credit risks:

| 組合分類 Category of portfolio | 預期信用損失會計估計政策 Accounting estimation policy for expected credit loss |
|--|---|
| 銀行承兌匯票組合 Bank acceptance bill portfolio | 管理層評價該類款項具有較低信用風險，一般不計提減值準備 Management evaluates that such payments have low credit risk and generally do not provide for impairment |
| 商業承兌匯票組合 Commercial draft portfolio | 按照預期損失率計提減值準備 Provision for impairment is made based on expected loss rate |

本集團在資產負債表日計算應收票據預期信用損失，如果該預期信用損失大於當前應收票據減值準備的賬面金額，本集團將其差額確認為應收票據減值損失，借記“信用減值損失”，貸計“應收票據-壞賬準備”。相反，本集團將差額確認為減值利得。

12.應收款項

本集團採用簡化方法於應收款項初始確認時確認預期存續期損失。本集團根據客戶的信用評級、業務規模、歷史回款與壞賬損失情況等分別採用以下兩種方式估計預期信用損失：

(1) 涉及金額重大、有長期合作關係或合作關係有異常情況等的應收款項，本集團不考慮減值矩陣，而是根據應收款項的具體信用風險特徵，如客戶信用評級、行業及業務特點、歷史回款與壞賬損失情況等，於應收款項初始確認時按照整個存續期內預期信用損失的金額確認損失準備。本集團於每個報告日重新評估應收賬款餘下的存續期內預期信用損失的金額變動，調整損失準備。

(2) 不屬於上述情況的其他應收款項，本集團以共同信用風險特徵為依據，將金融工具分為不同組別，在組合基礎上採用減值矩陣確定相關金融工具的信用損失。本集團採用的共同信用風險特徵包括：信用風險評級、初始確認日期、剩餘合同期限、債務人所處行業、擔保物類型及擔保物相

The Group calculates the expected credit loss for bills receivables on the balance sheet date. If the expected credit loss is higher than the book value of the current provision for the impairment of the bills receivables, the Group will recognize such difference as impairment loss of the bills receivables, which will be debited to “Impairment loss of credit” and credited to “Bills receivables – Provision for bad debt”. Otherwise, the Group will recognize such difference as impairment gain.

12.Receivables

The Group recognizes the lifetime expected loss for receivables at the initial recognition by using the simplified approach. The Group estimates the expected credit loss using the following two methods based on the customers’ credit ratings, business scales, historical collections and bad debt losses:

(1) For receivables of significant amounts and involving long-term cooperative relationships or abnormal situations in the cooperative relationship, etc., the Group, instead of using the impairment matrix, recognizes loss provisions for receivables at the initial recognition at an amount equal to the lifetime expected credit loss based on the specific credit risk characteristics of the receivables, such as customers’ credit ratings, industry and business characteristics, historical collections and bad debt losses. At each reporting date, the Group re-evaluates the changes in the amount of expected credit losses in the remaining duration of the receivables and adjusts the loss provisions accordingly.

(2) For other receivables that do not fall into the above circumstances, the Group divides financial instruments into different groups based on shared characteristics of credit risks, and uses the impairment matrix to determine the credit losses of related financial instruments on a grouping basis. The shared characteristics of credit risks adopted by the Group include: credit risk rating, initial recognition date, remaining contract term, industry of the debtor, type of collateral and value of the

對於金融資產的價值等。

本集團在組合基礎上對應收款項預期存續期內的歷史觀察違約率厘定減值矩陣，並就前瞻性估計做出調整。於每個報告日，本集團更新歷史觀察違約率和分析前瞻性估計的變動，如有需要調整減值矩陣，按變動情況調整減值矩陣並計提損失準備。

13.應收款項融資

分類為以公允價值計量且其變動計入其他綜合收益的應收票據、應收賬款，自取得起期限在一年內（含一年）的部分，列示為應收款項融資；自取得起期限在一年以上的，列示為其他債權投資。其相關會計政策參見本附註四、10“金融資產和金融負債”。

14.存貨

本集團存貨主要包括庫存商品和發出商品。

存貨實行永續盤存制，存貨在取得時按實際成本計價，領用或發出存貨，採用加權平均法確定其實際成本。低值易耗品採用一次轉銷法進行攤銷。

庫存商品、在產品和用於出售的材料等直接用於出售的商品存貨，其可變現淨值按該存貨的估計售價減去估計的銷售費用和相關稅費後的金額確

collateral relative to financial assets, etc.

The Group determines the impairment matrix based on the historically observed default rates over the expected duration of the receivables on a grouping basis, and makes adjustments in respect of forward-looking estimates. At each reporting date, the Group updates the historically observed default rates, analyzes the changes in forward-looking estimates, adjusts the impairment matrix according to the changes if the impairment matrix needs to be adjusted, and make loss provisions accordingly.

13.Accounts receivable financing

For bills and accounts receivable measured at fair value through other comprehensive income, the portion with a term of not more than one year since the day of acquisition is presented as receivables financing, and the rest is presented as other debt investments. See “Note IV. 10 to the Financial Statements: Financial Assets and Financial Liabilities” for relevant accounting policy.

14.Inventories

The Group’s inventories mainly include goods in stock and goods in delivery.

The Group maintains a perpetual inventory system, the inventories are recognized at the actual cost when acquired. Actual cost is determined using weighted average method when the inventories are consumed or issued. Low-value consumables are amortized using one-off write-off method.

The net realisable value of inventories of merchandise held for direct sale, such as goods in stock, goods sold and materials for sale, shall be determined as the estimated selling price of the inventory less estimated selling expenses and related taxes; the

定；用於生產而持有的材料存貨，其可變現淨值按所生產的產成品的估計售價減去至完工時估計將要發生的成本、估計的銷售費用和相關稅費後的金額確定。

資產負債表日，存貨按成本與可變現淨值孰低計價。如果由於存貨毀損、全部或部分陳舊過時或銷售價格低於成本等原因，使存貨成本高於可變現淨值的，按單個存貨項目可變現淨值低於成本的差額計提存貨跌價損失準備。

庫存商品在正常生產經營過程中，以該存貨的估計售價減去估計的銷售費用和相關稅費後的金額，確定其可變現淨值。

15. 合同資產

(1) 合同資產的確認方法及標準

合同資產，是指本集團已向客戶轉讓商品而有權收取對價的權利，且該權利取決於時間流逝之外的其他因素。

(2) 合同資產的預期信用損失的確定方法及會計處理方法

合同資產的預期信用損失的確定方法，參照上述 12. 應收款項相關內容描述。

會計處理方法，本集團在資產負債表日計算合同資產預期信用損失，如果該預期信用損失大於當前合同資產減值準備的賬面金額，本集團將其差額

net realisable value of inventories of materials held for production shall be determined as the estimated selling price of the finished goods less the estimated costs to be incurred upon completion, estimated selling expenses and related taxes.

At the balance sheet date, inventories are recognized at the lower of cost and net realizable value. If the cost of inventories is higher than the net realizable value for reasons like the inventories being damaged, becoming completely or partially obsolete or being sold at a price lower than cost, the provision for impairment loss of inventories shall be made at the difference between the net realizable value of the inventory and the cost on an item-by-item basis.

The net realizable value is determined based on the estimated selling price of such inventories after deducting its estimated selling costs and relevant taxes in the normal production and operation process of goods in stock.

15. Contractual assets

(1) Methods and criteria for recognition of contractual assets

Contractual assets refer to rights to receive consideration for goods that the Group has transferred to clients, and such rights are dependent on factors other than the passage of time.

(2) Methods for determining expected credit losses on contractual assets and for related accounting treatment

The methods for determining expected credit losses on contractual assets are described with reference to 12. Receivables above.

For accounting purposes, the Group will calculate the expected credit loss on contractual assets on the balance sheet date. If the expected credit loss is greater than the current carrying amount of the provision for impairment of contractual assets, the Group

確認為減值損失，借記“資產減值損失”，貸記“合同資產減值準備”。相反，本集團將差額確認為減值利得，做相反的會計記錄。

本集團實際發生信用損失，認定相關合同資產無法收回，經批准予以核銷的，根據批准的核銷金額，借記“合同資產減值準備”，貸記“合同資產”。若核銷金額大於已計提的損失準備，按其差額借記“資產減值損失”。

16.長期股權投資

本集團長期股權投資主要是對子公司的投資、對聯營企業的投資和對合營企業的投資。

本集團對共同控制的判斷依據是所有參與方或參與方組合集體控制該安排，並且該安排相關活動的政策必須經過這些集體控制該安排的參與方一致同意。

本集團直接或通過子公司間接擁有被投資單位 20%以上但低於 50%的表決權時，通常認為對被投資單位具有重大影響。持有被投資單位 20%以下表決權的，還需要綜合考慮在被投資單位的董事會或類似權力機構中派有代表、或參與被投資單位財務和經營政策制定過程、或與被投資單位之間發生重要交易、或向被投資單位派出管理人員、或向被投資單位提供關鍵技術資料等事實和情況判斷對被投資

will recognise the difference as an impairment loss by debiting “impairment loss on assets” and crediting “provision for impairment of contractual assets”. Conversely, the Group will recognise the difference as an impairment gain and make a reverse accounting entry.

If the Group incurs actual credit losses and the related contractual assets are deemed uncollectible and are approved for write-off, the Group will debit “provision for impairment of contractual assets” and credit “contractual assets” according to the approved write-off amount. If the write-off amount is greater than the provision for losses, the difference will be debited to “impairment loss on assets”.

16.Long-term equity investment

The long-term equity investment of the Group mainly refers to the investment in subsidiaries, investment in associates and investment in joint ventures.

The Group’s basis for judgement in respect of common control is that all participating parties or a group of participating parties control such arrangement, and that policies on related business of such arrangement have to obtain unanimous agreement from all participating parties that collectively control such arrangement.

The Group directly or indirectly through its subsidiaries owns more than 20% (inclusive) but less than 50% of the voting right of the investee, which is usually deemed to have significant influence on the investee. For voting rights of less than 20% in the investee, significant influence over the investee will be judged by comprehensively taking into consideration of such facts and circumstances as dispatching representative to the Board or similar authority of the investee, or participating in the formulation process of financial and operation policies of the investee, or having major transactions with the investee, or sending management personnel to the investee or providing key

單位具有重大影響。

對被投資單位形成控制的，為本集團的子公司。通過同一控制下的企業合併取得的長期股權投資，在合併日按照取得被合併方在最終控制方合併報表中淨資產的賬面價值的份額作為長期股權投資的初始投資成本。被合併方在合併日的淨資產賬面價值為負數的，長期股權投資成本按零確定。

通過多次交易分步取得同一控制下被投資單位的股權，最終形成企業合併的，應在取得控制權的報告期，補充披露在母公司財務報表中的長期股權投資的處理方法。例如：通過多次交易分步取得同一控制下被投資單位的股權，最終形成企業合併，屬於一攬子交易的，本集團將各項交易作為一項取得控制權的交易進行會計處理。不屬於一攬子交易的，在合併日，根據合併後享有被合併方淨資產在最終控制方合併財務報表中的賬面價值的份額作為長期股權投資的的初始投資成本。初始投資成本與達到合併前的長期股權投資賬面價值加上合併日進一步取得股份新支付對價的賬面價值之和的差額，調整資本公積，資本公積不足沖減的，沖減留存收益。

technical information to the investee.

An investee that is under the control of the Group shall be deemed as a subsidiary of the Group. For long-term equity investment acquired through business combination under common control, the share of the book value of net assets of the combined party in the combined statement of the ultimate controlling party on the combination date shall be accounted for as the initial investment cost of the long-term equity investment. If the book value of net assets of the combined party on the combination date is negative, the cost of the long-term equity investment is determined as nil.

For equity in an investee under common control obtained in stages through multiple transactions, which results in business combination, supplementary disclosure to treatment methods of the long-term equity investment in the financial statements of the parent company shall be made in the reporting period of acquiring the control. For instance, for equity in an investee under common control obtained in stages through multiple transactions, which results in business combination, the Group will conduct accounting treatment on each transaction as one transaction which obtains control if the transactions belong to a package deal; if the transactions do not belong to a package deal, the share of the book value of net assets of the combined party in the combined financial statements of the ultimate controlling party upon the combination shall be deemed as the initial investment cost of the long-term equity investment on the combination date. The difference between the initial investment cost and the sum of the book value of long-term equity investment before the combination and the book value of newly-paid consideration for further acquisition of shares on the combination date shall be applied to adjust capital reserve. If the capital reserve is insufficient for offsetting, the retained earnings shall be offset.

通過非同一控制下的企業合併取得的長期股權投資，以合併成本作為初始投資成本。

通過多次交易分步取得非同一控制下被投資單位的股權，最終形成企業合併的，應在取得控制權的報告期，補充披露在母公司財務報表中的長期股權投資成本處理方法。例如：通過多次交易分步取得非同一控制下被投資單位的股權，最終形成企業合併，屬於一攬子交易的，本集團將各項交易作為一項取得控制權的交易進行會計處理。不屬於一攬子交易的，按照原持有的股權投資賬面價值加上新增投資成本之和，作為改按成本法核算的初始投資成本。購買日之前持有的股權採用權益法核算的，原權益法核算的相關其他綜合收益暫不做調整，在處置該項投資時採用與被投資單位直接處置相關資產或負債相同的基礎進行會計處理。購買日之前持有的股權為指定以公允價值計量且其變動計入其他綜合收益的非交易性權益工具，原計入其他綜合收益的累計公允價值變動不得轉入當期損益。

除上述通過企業合併取得的長期股權投資外，以支付現金取得的長期股權投資，按照實際支付的購買價款作為投資成本；以發行權益性證券取得的

For long-term equity investment obtained through business combination not under common control, combined cost shall be recognized as initial investment cost.

For equity in an investee not under common control obtained in stages through multiple transactions, which results in business combination, supplementary disclosure to treatment methods for long-term equity investment in financial statements of the parent company shall be made in the report period for acquiring the control. For instance, for equity in an investee not under common control obtained in stages through multiple transactions, which results in the business combination, the Group will conduct accounting treatment on each transaction as one transaction which obtains the control right if the transactions belong to a package deal. If the transactions do not belong to a package deal, the sum of the book value of equity investment held originally and additional investment costs shall be the initial investment cost whose calculation method is changed to cost method. If the equity held before the acquisition date is calculated by equity method, the related other comprehensive income originally calculated by equity method shall not be adjusted; and the accounting treatment shall be conducted as per the same basis as that of directly disposing of related assets or liabilities of the investee when disposing of the investment. If the equity held before the acquisition date is a non-trading equity instrument specified to be measured at fair value and its changes are included in other comprehensive income, the accumulative changes in fair value originally included in other comprehensive income shall not be transferred into current profit and loss.

Apart from the long-term equity investments acquired through business combination mentioned above, for long-term equity investments acquired by cash payment, the investment cost is the actual amount of cash paid for the acquisition; for long-term

長期股權投資，按照發行權益性證券的公允價值作為投資成本；投資者投入的長期股權投資，按照投資合同或協定約定的價值作為投資成本。

本集團對子公司投資採用成本法核算，對合營企業及聯營企業投資採用權益法核算。

後續計量採用成本法核算的長期股權投資，在追加投資時，按照追加投資支付的成本額公允價值及發生的相關交易費用增加長期股權投資成本的賬面價值。被投資單位宣告分派的現金股利或利潤，按照應享有的金額確認為當期投資收益。

後續計量採用權益法核算的長期股權投資，隨著被投資單位所有者權益的變動相應調整增加或減少長期股權投資的賬面價值。其中在確認應享有被投資單位淨損益的份額時，以取得投資時被投資單位各項可辨認資產等的公允價值為基礎，按照本集團的會計政策及會計期間，並抵銷與聯營企業及合營企業之間發生的內部交易損益按照持股比例計算歸屬於投資企業的部分，對被投資單位的淨利潤進行調整後確認。

處置長期股權投資，其賬面價值與實際取得價款的差額，計入當期投資收

equity investments acquired by issuing equity securities, the cost of investment is the fair value of the equity securities issued; for long-term equity investments invested by the investor, the investment cost is the agreed consideration under the investment contract or agreement.

The Group's investments in subsidiaries are accounted for using the cost method, and the investments in joint ventures and associates are accounted for using equity method.

For long-term equity investments for which the subsequent measurement is accounted for using the cost method, when additional investment is made, the book value of the long-term equity investment cost will be added according to the fair value of cost paid for additional investment and the related expenses incurred by related transactions. For cash dividend or profit declared and paid by the investee, it shall be recognized as its investment income for the period at the amount to which it entitles.

For long-term equity investment for which the subsequent measurement is accounted for using the equity method, the book value of long-term equity investment shall be increased or decreased accordingly according to the change in the owners' equity of the investee. In which, the attributable net profit or loss in the investee is recognized on the basis of the fair value of various identifiable assets in the investee at the time of acquisition and in accordance with the accounting policies and accounting period of the Group, based on the share attributable to the investor as calculated according to shareholdings, after elimination of the profit or loss for intra-group transactions with associates and joint ventures and after adjustment to the net profits of the investee.

On disposal of a long-term equity investment, the difference between the book value and the proceeds actually received shall



益。採用權益法核算的長期股權投資，原權益法核算的相關其他綜合收益應當在終止採用權益法核算時採用與被投資單位直接處置相關資產或負債相同的基礎進行會計處理，因被投資方除淨損益、其他綜合收益和利潤分配以外的其他所有者權益變動而確認的所有者權益，應當在終止採用權益法核算時全部轉入當期投資收益。

因處置部分股權投資等原因喪失了對被投資單位的共同控制或重大影響的，處置後的剩餘股權適用《企業會計準則第 22 號——金融工具確認和計量（財會[2017]7 號）》核算的，剩餘股權在喪失共同控制或重大影響之日的公允價值與賬面價值之間的差額計入當期損益。原股權投資因採用權益法核算而確認的其他綜合收益，在終止採用權益法核算時採用與被投資單位直接處置相關資產或負債相同的基礎處理並按比例結轉，因被投資方除淨損益、其他綜合收益和利潤分配以外的其他所有者權益變動而確認的所有者權益，應當按比例轉入當期投資收益。

因處置部分長期股權投資喪失了對被投資單位控制的，處置後的剩餘股權能夠對被投資單位實施共同控制或施加大影響的，改按權益法核算，處

be included in investment income for the period. For a long-term equity investment measured with the equity method, the related other comprehensive income previously measured with such method shall be accounted for on the same basis as the direct disposal of the related assets or liabilities of the investee upon the termination of the equity method of accounting, and the owner's equity recognised as a result of changes in the owner's equity of the investee other than net profit or loss, other comprehensive income and profit distribution shall be entirely transferred to current investment income upon the termination of the equity method of accounting.

Where the common control or significant influence over the investee is lost due to the partial disposal of equity investment, and the residual equity after disposal is accounted as per the *Accounting Standards for Enterprises No. 24: Recognition and Measurement of Financial Instruments (Accounting [2017] No. 7)*, the balance between the fair value and book value of such residual equity on the date when the common control or significant influence is lost shall be included in profit or loss for the period. Other comprehensive income recognized as a result of calculating original equity investment by equity method shall be accounted for on the same basis as that used by the investee to directly dispose of the relevant assets or liabilities when ceasing to use the equity method, and carried forward proportionately. Owner's equity recognized as a result of changes in the owner's equity of the investee other than net profit or loss, other comprehensive income and profit distribution, shall be transferred to current investment yield on a proportionate basis.

When the control over the investee is lost due to the partial disposal of long-term equity investment, for residual equity which still has common control or significant influence over the investee after disposal, it shall be accounted for under the equity

置股權賬面價值和處置對價的差額計入投資收益，並對該剩餘股權視同自取得時即採用權益法核算進行調整；處置後的剩餘股權不能對被投資單位實施共同控制或施加重大影響的，適用《企業會計準則第 22 號——金融工具確認和計量（財會[2017]7 號）》進行會計處理，處置股權賬面價值和處置對價的差額計入投資收益，剩餘股權在喪失控制之日的公允價值與賬面價值間的差額計入當期損益。

本集團對於分步處置股權至喪失控股權的各項交易不屬於一攬子交易的，對每一項交易分別進行會計處理。屬於“一攬子交易”的，將各項交易作為一項處置子公司並喪失控制權的交易進行會計處理，但是，在喪失控制權之前每一次交易處置價款與所處置的股權對應的長期股權投資賬面價值之間的差額，確認為其他綜合收益，到喪失控制權時再一併轉入喪失控制權的當期損益。

17. 投資性房地產

投資性房地產是指本集團為賺取租金或資本增值，或兩者兼有而持有的房地產。本集團投資性房地產包括已出租的土地使用權、已出租的建築物等。本集團採用成本模式計量。

method. Difference between the book value of equity disposed and the disposal consideration shall be included in investment income. Such residual equity shall be adjusted assuming that it is treated as being accounted for under the equity method since acquisition. For residual equity which cannot exercise common control or impose significant influence over the investee after disposal, it shall be accounted for as per the *Accounting Standards for Enterprises No. 24: Recognition and Measurement of Financial Instruments (Accounting [2017] No. 7)*, and the difference between book value of equity disposed and the disposal consideration shall be included in investment income, and the difference between fair value and the book value of residual equity on the date of loss of control shall be included in profit or loss for the period.

For each transaction where equity is disposed by the Group in stages until loss of control and which does not belong to a package transaction, the accounting for each transaction shall be conducted separately. For the “package transaction”, the accounting treatment shall be conducted on each transaction as the transaction that disposes of subsidiary with loss of control. However, before loss of control, the difference between disposal price for each transaction and the book value of corresponding long-term investment of the equity disposed of, shall be recognized as other comprehensive income, and, upon loss of control, shall be transfer to the profit or loss for the period when the control is lost.

17. Investment property

Investment property refers to those held by the Group for the purpose of rentals or capital appreciation, or both. Investment property of the Group includes the rented land use rights and rented buildings, etc. The Group shall measure the investment property by using the cost mode.

本集團投資性房地產採用直線法計提折舊或攤銷。各類投資性房地產的預計使用壽命、淨殘值率及年折舊(攤銷)率如下：

The investment property of the Group shall be depreciated or amortized on straight-line basis. The estimated useful life, net residual value rate and annual depreciation (amortization) rate of various investment properties are as follows:

| 序號 No. | 類別 Category | 折舊年限(年) Depreciation Period (year) | 預計殘值率(%) Estimated Residual Value Rate (%) | 年折舊率(%) Annual Depreciation Rate (%) |
|-----------|-----------------------------------|---|---|---|
| 1 | 土地使用權 Land use rights | 出讓取得時剩餘年限 Remaining term upon transfer | 0 | - |
| 2 | 房屋建築物 Buildings and structures | 30 | 5 | 3.17 |

18. 固定資產

本集團固定資產是指同時具有以下特徵，即為生產商品、提供勞務、出租或經營管理而持有的，使用年限超過一年，單位價值超過 2,000 元的有形資產。

固定資產在與其有關的經濟利益很可能流入本集團、且其成本能夠可靠計量時予以確認。本集團固定資產包括房屋及建築物、機器設備、運輸設備、辦公設備等。

與固定資產有關的後續支出，如果與該固定資產有關的經濟利益很可能流入且其成本能可靠地計量，則計入固定資產成本，並終止確認被替換部分的賬面價值。除此以外的其他後續支出，在發生時計入當期損益。

除已提足折舊仍繼續使用的固定資產和單獨計價入帳的土地外，本集團對

18. Fixed assets

Fixed assets are tangible assets refer to the following characteristics at the same time, that are held for use in the production of goods, supply of labour, rental or operation management, with a unit value of more than RMB2,000 and have a useful life of more than one year.

Fixed assets are recognized only when its related economic benefits are likely to flow into the Group and its cost could be reliably measured. The Group's fixed assets include houses and buildings, machinery, transportation equipment, office equipment, etc.

For subsequent expenses related to fixed assets, if the economic benefits related to such fixed assets are likely to flow into the Group and its cost could be reliably measured, such expenses are included in the cost of fixed asset, and the book value of the replaced part will be derecognized. Save for the above, other subsequent expenses are included in profit or loss for the period in which they are incurred.

The Group depreciates all fixed assets, except for those that have been fully depreciated and continued to be used as well as

所有固定資產計提折舊。計提折舊時採用平均年限法（或其他方法）。本集團固定資產的分類折舊年限、預計淨殘值率、折舊率如下：

land that has been separately stated in the accounts. Depreciation is recognised using the average service life method (or other methods). The categorised depreciable service life, estimated net residual values and depreciation rates of the Group's fixed assets are shown as follows:

| 序號 No. | 類別 Category | 折舊年限(年) Depreciable Life (year) | 預計殘值率(%) Estimated Residual Value Rate (%) | 年折舊率(%) Annual Depreciation Rate (%) |
|-----------|-----------------------------------|---------------------------------------|--|--|
| 1 | 房屋建築物 Buildings and structures | 30 | 5 | 3.17 |
| 2 | 機器設備 Machinery and equipment | 10、13、15 | 0 | 10.00、7.69、6.67 |
| 3 | 運輸設備 Transportation facilities | 8 | 0 | 12.50 |
| 4 | 辦公設備 Office equipment | 3、5 | 0 | 33.33、20.00 |

本集團於每年年度終了，對固定資產的預計使用壽命、預計淨殘值和折舊方法進行覆核，如發生改變，則作為會計估計變更處理。

The Group shall review the expected useful life, estimated net residual value and the depreciation method of a fixed asset at the end of each year, and account for any change as a change in accounting estimate.

19. 在建工程

在建工程在達到預定可使用狀態之日起，根據工程預算、造價或工程實際成本等，按估計的價值結轉固定資產，次月起開始計提折舊，待辦理了竣工決算手續後再對固定資產原值差異進行調整。

19. Construction in progress

Construction in progress shall be transferred into fixed assets at the estimated value as per the project budget, construction prices or actual construction costs from the date when they are ready for intended use, and be depreciated from the next month and be adjusted for difference from the original value of fixed asset after the completion settlement procedures.

20. 借款費用

發生的可直接歸屬於需要經過 1 年以上的購建或者生產活動才能達到預定可使用或者可銷售狀態的固定資產、投資性房地產和存貨等的借款費用，在資產支出已經發生、借款費用已經發生、為使資產達到預定可使用或可銷售狀態所必要的購建或生產活動已

20. Borrowing costs

For borrowing costs incurred that are directly attributable to fixed asset, investment property and inventory which are ready for their intended use or sale after activities related to their acquisition, construction or production last for more than one year, capitalization shall commence when expenditures for the asset and borrowing costs have been incurred, and activities relating to the acquisition, construction or production of the

經開始時，開始資本化；當購建或生產符合資本化條件的資產達到預定可使用或可銷售狀態時，停止資本化，其後發生的借款費用計入當期損益。如果符合資本化條件的資產在購建或者生產過程中發生非正常中斷、且中斷時間連續超過 3 個月，暫停借款費用的資本化，直至資產的購建或生產活動重新開始。

專門借款當期實際發生的利息費用，扣除尚未動用的借款資金存入銀行取得的利息收入或進行暫時性投資取得的投資收益後的金額予以資本化；一般借款根據累計資產支出超過專門借款部分的資產支出加權平均數乘以所佔用一般借款的資本化率，確定資本化金額。資本化率根據一般借款加權平均利率計算確定。

21. 使用權資產

使用權資產，是指本集團作為承租人可在租賃期內使用租賃資產的權利。

(1) 初始計量

在租賃期開始日，本集團按照成本對使用權資產進行初始計量。該成本包括下列四項：①租賃負債的初始計量金額；②在租賃期開始日或之前支付的租賃付款額，存在租賃激勵的，扣除已享受的租賃激勵相關金額；③發

asset that are necessary for the asset to be ready for its intended use or sale have begun; and capitalization shall be ceased when the acquired, constructed or produced qualifying asset for capitalization is ready for its intended use or sale, and borrowing costs subsequently incurred shall be recognized in profit or loss for the period. If acquisition, construction or production of a qualifying asset for capitalization is interrupted abnormally, and the interruption lasts for more than 3 months, the capitalization of borrowing costs shall be suspended until the acquisition, construction or production activities of the asset are resumed.

Where borrowings are borrowed for a specific purpose, the actual interest expense incurred on that borrowing for the period less any bank interest earned from depositing the unutilized borrowed funds in banks or any investment income on the temporary investment of those borrowings shall be capitalized. Where borrowings are borrowed for general purpose, the amount to be capitalized is determined on multiplying the weighted average of the excess amount of accumulated asset expense over the amount of specific-purpose borrowings by capitalization rate of general-purpose borrowings occupied. The capitalization rate shall be determined based on the weighted average interest rates applicable to the general-purpose borrowings.

21. Right-of-use assets

The right-of-use assets are defined as the rights of the Group as a lessee to use the leased assets in the lease term.

(1) Initial recognition

At the commencement of the lease term, the Group initially measures the right-of-use assets at cost, which includes the following: ① the amount of the initial measurement of the lease liability; ② any lease payments made at or before the commencement date, less the amount of lease incentives received, if any; ③ any initial direct costs incurred, i.e. the

生的初始直接費用，即為達成租賃所發生的增量成本；④為拆卸及移除租賃資產、復原租賃資產所在場地或將租賃資產恢復至租賃條款約定狀態預計將發生的成本，屬於為生產存貨而發生的除外。

(2) 後續計量

在租賃期開始日後，本集團採用成本模式對使用權資產進行後續計量，即以成本減累計折舊及累計減值損失計量使用權資產。本集團按照租賃準則有關規定重新計量租賃負債的，相應調整使用權資產的賬面價值。

(3) 使用權資產的折舊

自租賃期開始日起，本集團對使用權資產計提折舊。使用權資產通常自租賃期開始的當月計提折舊。計提的折舊金額根據使用權資產的用途，計入相關資產的成本或者當期損益。

本集團在確定使用權資產的折舊方法時，根據與使用權資產有關的經濟利益的預期消耗方式做出決定，以直線法對使用權資產計提折舊。

本集團在確定使用權資產的折舊年限時，遵循以下原則：能夠合理確定租賃期屆滿時取得租賃資產所有權的，在租賃資產剩餘使用壽命內計提折舊；無法合理確定租賃期屆滿時能夠取得租賃資產所有權的，在租賃期與租賃資產剩餘使用壽命兩者孰短的期間內計提折舊。

incremental costs incurred for the execution of the lease; ④ the costs expected to be incurred for dismantling and removing the leased asset, restoring the site on which the leased asset is located or restoring it to the condition as agreed in the terms of the lease, except those incurred for the production of inventories.

(2) Subsequent measurement

After the commencement of the lease term, the Group adopts a cost model for the subsequent measurement of the right-of-use assets, where the right-of-use assets are measured at cost less accumulated depreciation and accumulated impairment losses. Where the Group re-measures the lease liability in accordance with the relevant provisions of the lease standards, the book value of the right-of-use assets shall be adjusted accordingly.

(3) Depreciation of right-of-use assets

The Group provides for the depreciation of the right-of-use assets from the commencement of the lease term. Right-of-use assets are usually depreciated from the month in which the lease term commences. The amount of the provision for depreciation is included in the cost of the relevant assets or the current profit or loss according to the use of the right-of-use assets.

When determining the depreciation method of the right-of-use assets, the Group makes decisions based on the expected methods of consuming the economic benefits related to the right-of-use assets, and provides for depreciation for the right-of-use assets on a straight-line basis.

When determining the depreciation period of the right-of-use assets, the Group adheres to the following principles: if it is reasonably certain that the ownership of the leased assets will be obtained at the end of the lease term, the provision for depreciation will be made within the remaining useful life of the leased assets; if it is not reasonably certain that the ownership of the leased assets will be obtained when the lease term expires, the provision for depreciation is made during the lease term or

(4) 使用權資產的減值

如果使用權資產發生減值，本集團按照扣除減值損失之後的使用權資產的賬面價值，進行後續折舊。

22.無形資產

本集團無形資產包括土地使用權、軟件及軟件使用權、客戶資源等，按取得時的實際成本計量，其中，購入的無形資產，按實際支付的價款和相關的其他支出作為實際成本；投資者投入的無形資產，按投資合同或協議約定的價值確定實際成本，但合同或協議約定價值不公允的，按公允價值確定實際成本；對非同一控制下合併中取得被購買方擁有的但在其財務報表中未確認的無形資產，在對被購買方資產進行初始確認時，按公允價值確認為無形資產。

土地使用權從出讓起始日起，按其出讓年限平均攤銷；軟件及軟件使用權、客戶資源按預計使用年限、合同規定的受益年限和法律規定的有效年限三者中最短者分期平均攤銷。攤銷金額按其受益對象計入相關資產成本和當期損益。對使用壽命有限的無形資產的預計使用壽命及攤銷方法於每年年度終了進行覆核，如發生改變，則作為會計估計變更處理。

the remaining useful life of the leased assets, whichever is the shortest.

(4) Impairment of right-of-use assets

If the right-of-use assets are impaired, the Group will make subsequent provision for depreciation based on the book value of the right-of-use assets after deducting the impairment losses.

22.Intangible assets

The Group's intangible assets include land use right, software and software license, customer resources, etc. Intangible assets are measured at the actual costs upon acquisition, of which the purchased intangible assets, actual paid cost and other relevant expenses are presented as the actual costs. For intangible assets invested by investors, the actual costs are determined according to the values specified in the investment contract or agreement, for the unfair values agreed in contract or agreement, the actual costs are determined at the fair value. For the intangible asset acquired from combination not under common control which is owned by the acquiree but is not recognized in the financial statements, it shall be recognized as intangible asset at its fair value upon the initial recognition of the acquiree's assets.

The land use right shall be evenly amortized when it is obtained from the date of transfer. The software and software use rights, customer resources are amortized evenly by stages over the shortest of estimated useful life, beneficial term stipulated by contract and legal effective term. The amortization amount is credited into relevant asset cost and profit or loss for the period according to its beneficiaries. The Group reviews the estimated useful life and amortization method of intangible assets with limited useful life at the end of each year, and any changes will be treated as changes on accounting estimates.

23.長期資產減值

本集團於每一資產負債表日對長期股權投資、採用成本模式計量的投資性房地產、固定資產、在建工程、使用權資產、使用壽命有限的無形資產、經營租賃資產等項目進行檢查，當存在減值跡象時，本集團進行減值測試。對商譽和使用壽命不確定的無形資產，無論是否存在減值跡象，每年末均進行減值測試。

減值測試後，若該資產的賬面價值超過其可收回金額，其差額確認為減值損失，上述資產的減值損失一經確認，在以後會計期間不予轉回。

24.長期待攤費用

本集團的長期待攤費用包括房屋裝修支出等。該等費用在受益期內平均攤銷，如果長期待攤費用項目不能使以後會計期間受益，則將尚未攤銷的該項目的攤餘價值全部轉入當期損益。

25.合同負債

合同負債反映本集團已收或應收客戶對價而應向客戶轉讓商品的義務。本集團在向客戶轉讓商品之前，客戶已經支付了合同對價或本集團已經取得了無條件收取合同對價權利的，在客戶實際支付款項與到期應支付款項孰早時點，按照已收或應收的金額確認合同負債。

23.Impairment of long term assets

The Company reviews items such as long term equity investments, investment properties, fixed assets, construction in progress and right-of-use assets measured by the cost model, intangible assets with definite useful life, etc. on each balance sheet date. The Group conducts impairment test when there is any indication of impairment. Goodwill and intangible assets with indefinite useful life are tested at the end of each year for impairment, whether indication of impairment exists or not.

If the book value of such asset exceeds its recoverable amount after impairment test, the difference is recognized as impairment loss. The above impairment losses shall not be reversed in subsequent accounting periods once recognized.

24.Long-term deferred expenses

Long-term deferred expenses of the Group include expenses for building renovation, etc. Such expenses are amortized evenly over periods in which benefits are derived. If the long-term deferred expenses are no longer beneficial in subsequent accounting periods, the amortized value of the unamortized item is transferred in full to profit or loss for the period.

25.Contract liabilities

Contract liabilities reflect the Group's obligation to transfer goods to a customer for which the Group has received consideration (or an amount of consideration is due) from the customer. Before the Group transfers goods to a customer, the customer has already paid the contract consideration, or the Group has obtained unconditional right to receive the contract consideration. At the earlier of the date of actual payment from the customer and the due date of payment, contract liabilities were recognized in accordance with the amount received or receivable.

26.職工薪酬

本集團職工薪酬包括短期薪酬、離職後福利、辭退福利和其他長期福利。

短期薪酬主要包括：職工工資、獎金、津貼和補貼，職工福利費，醫療保險費、工傷保險費和生育保險費等社會保險費，住房公積金，工會經費和職工教育經費，短期帶薪缺勤，短期利潤分享計劃，非貨幣性福利以及其他短期薪酬等。在職工提供服務的會計期間，將實際發生的短期薪酬確認為負債，並按照受益對象計入當期損益或相關資產成本。

離職後福利主要包括基本養老保險費、企業年金、失業保險費、內退福利以及其他離職後福利等，按照公司承擔的風險和義務，分類為設定提存計劃、設定受益計劃。對於設定提存計劃在根據在資產負債表日為換取職工在會計期間提供的服務而向單獨主體繳存的提存金確認為負債，並按照受益對象計入當期損益或相關資產成本。如果公司存在設定受益計劃，應說明具體會計處理方法。

辭退福利，是由於本集團在職工勞動合同到期之前解除與職工的勞動關係，或者為鼓勵職工自願接受裁減而

26. Staff remuneration

The Group's staff remuneration includes short-term remuneration, post-employment benefits, termination benefits and other long-term benefits.

Short-term remuneration mainly includes staff salaries, bonuses, allowances and subsidies, staff welfare payments, social insurance premiums including medical insurance premiums, work injury insurance premiums and maternity insurance premiums, housing provident fund, labour union expenses and staff education expenses, short-term paid leaves, short-term benefits sharing scheme, non-monetary welfare and other short-term remuneration etc. During the accounting period in which the employees render services, the Group recognizes the short-term remuneration actually incurred as a liability and includes it in the profit or loss or in the cost of the related asset for the current period, depending on the class of beneficiaries.

The post-employment benefits mainly include basic pension insurance premiums, enterprise annuity, unemployment insurance premiums, early retirement benefits and other post-employment benefits, etc. Defined contribution plans and defined benefit plans are classified according to the risks and obligations assumed by the company. Withdrawals from defined contribution plans are recognised as a liability on the balance sheet date based on the amount of contributions made to a separate entity in exchange for services rendered by employees during the accounting period, and are recognised as current profit or loss or as cost of related assets, depending on the beneficiary. If the company has a defined benefit plan, the specific accounting treatment shall be stated.

Termination benefits is due to the compensation to employees when the Group terminates the employment relationship with employees before the expiry of the employment contracts or as

給予職工的補償，在下列兩者孰早日確認辭退福利產生的負債，並計入當期損益：①本集團不能單方面撤回因解除勞動關係計劃或裁減建議所提供的辭退福利時。②本集團確認與涉及支付辭退福利的重組相關的成本或費用時。其中對超過一年予以支付的補償款，按折現率折現後計入當期損益。

其他長期福利，主要包括短期薪酬、離職後福利、辭退福利之外所有的職工薪酬等。

27.租賃負債

(1) 初始計量

本集團按照租賃期開始日尚未支付的租賃付款額的現值對租賃負債進行初始計量。

1) 租賃付款額

租賃付款額，是指本集團向出租人支付的與在租賃期內使用租賃資產的權利相關的款項，包括：①固定付款額及實質固定付款額，存在租賃激勵的，扣除租賃激勵相關金額；②取決於指數或比率的可變租賃付款額，該款項在初始計量時根據租賃期開始日的指數或比率確定；③本集團合理確定將行使購買選擇權時，購買選擇權的行權價格；④租賃期反映出本集團將行使終止租賃選擇權時，行使終止租賃選擇權需支付的款項；⑤根據本

an offer to encourage employees to accept voluntary redundancy. If the Group provides termination benefits to the employees, the liabilities arising from termination benefits will be recognized and included in profit or loss for the period at the earlier of the following dates: ① when the Group cannot unilaterally withdraw termination benefits for the employment termination plan or the redundancy offer; and ② when the Group recognizes the costs or expenses related to the reorganization involving in payment of termination benefits. Of these, compensation paid in excess of one year is discounted at a discount rate and credited to current profit or loss.

Other long-term benefits refer to the employee compensation mainly include short-term compensation, post-employment benefits and termination benefits, etc.

27. Lease liabilities

(1) Initial recognition

The Group initially measures lease liabilities based on the present value of the lease payments that have not been paid at the commencement date of the lease term.

1) Lease payments

Lease payments are defined as the payments made by the Group to the lessors related to the rights to use leased assets during the lease term, including: ① fixed payments and fixed payments in substance, net of lease incentives, if any; ② variable lease payments based on indexes or ratios, which are determined at the initial measurement based on the indexes or ratios on the commencement date of the lease term; ③ the exercise price of the purchase option when the Group is reasonably certain to exercise the purchase option; ④ the payments required to be paid for exercising the option to terminate the lease when the lease term reflects that the Group will exercise the option to terminate the lease; and ⑤ the amount expected to be paid



集團提供的擔保餘值預計應支付的款項。

2) 折現率

在計算租賃付款額的現值時，本集團因無法確定租賃內含利率的，採用增量借款利率作為折現率。該增量借款利率，是指本集團在類似經濟環境下為獲得與使用權資產價值接近的資產，在類似期間以類似抵押條件借入資金須支付的利率。該利率與下列事項相關：①本集團自身情況，即集團的償債能力和信用狀況；②“借款”的期限，即租賃期；③“借入”資金的金額，即租賃負債的金額；④“抵押條件”，即目標資產的性質和質量；⑤經濟環境，包括承租人所處的司法管轄區、計價貨幣、合同簽訂時間等。本集團以長期銀行貸款利率為基礎，考慮上述因素進行調整而得出該增量借款利率。

(2) 後續計量

在租賃期開始日後，本集團按以下原則對租賃負債進行後續計量：①確認租賃負債的利息時，增加租賃負債的賬面金額；②支付租賃付款額時，減少租賃負債的賬面金額；③因重估或租賃變更等原因導致租賃付款額發生變動時，重新計量租賃負債的賬面價值。

本集團按照固定的週期性利率計算租

based on the residual value of the guarantee provided by the Group.

2) Discount rate

In calculating the present value of lease payments, the Group uses the incremental borrowing rate as the discount rate when it is unable to determine the interest rate implicit in the lease. The incremental borrowing interest rate refers to the interest rate payable by the Group to borrow funds under similar mortgage conditions in similar periods in order to acquire the assets of an amount close to the value of the right-of-use assets in a similar economic environment. The interest rate is related to the following: ① the Group's own situation, that is, the Group's solvency and credit status; ② the term of the "borrowing", that is, the lease term; ③ the amount of "borrowed" funds, that is, the amount of lease liabilities; ④ "mortgage conditions", that is, the nature and quality of the underlying assets; ⑤ the economic environment, including the jurisdiction in which the lessee is located, the currency of denomination, and the time of signing the contract. Based on the long-term bank loan interest rate, the Group makes adjustments in respect of the above-mentioned factors to derive the incremental borrowing interest rate.

(2) Subsequent measurement

After the commencement date of the lease term, the Group conducts the subsequent measurement of the lease liabilities according to the following principles: ① increasing the book value of the lease liabilities when recognizing lease liabilities; ② reducing the book value of the lease liabilities when making lease payments; ③ re-measuring the book value of the lease liabilities in case of any change in the lease payments due to revaluation or lease variations.

The interest expenses of the lease liabilities in each period of the

質負債在租賃期內各期間的利息費用，並計入當期損益，但應當資本化的除外。週期性利率是指本集團對租賃負債進行初始計量時所採用的折現率，或者因租賃付款額發生變動或因租賃變更而需按照修訂後的折現率對租賃負債進行重新計量時，本集團所採用的修訂後的折現率。

(3) 重新計量

在租賃期開始日後，發生下列情形時，本集團按照變動後租賃付款額的現值重新計量租賃負債，並相應調整使用權資產的賬面價值。使用權資產的賬面價值已調減至零，但租賃負債仍需進一步調減的，本集團將剩餘金額計入當期損益。①實質固定付款額發生變動（該情形下，採用原折現率折現）；②擔保餘值預計的應付金額發生變動（該情形下，採用原折現率折現）；③用於確定租賃付款額的指數或比率發生變動（該情形下，採用修訂後的折現率折現）；④購買選擇權的評估結果發生變化（該情形下，採用修訂後的折現率折現）；⑤續租選擇權或終止租賃選擇權的評估結果或實際行使情況發生變化（該情形下，採用修訂後的折現率折現）。

28.收入確認原則和計量方法

本集團在履行了合同中的履約義務，即在客戶取得相關商品或服務的控制權時，確認收入。

lease term are calculated at fixed periodic interest rates and are included in the profit and loss for the current period, except those that shall be capitalized. Periodic interest rates refer to the discount rates used by the Group in the initial measurement of lease liabilities, or the revised discount rates adopted by the Group when lease liabilities need to be re-measured at revised discount rates due to changes in lease payments or lease variations.

(3) Re-measurement

After the commencement date of the lease term, when the following circumstances occur, the Group re-measures the lease liabilities at the present value calculated based on the lease payments, and adjusts the book value of the right-of-use assets accordingly. If the book value of the right-of-use assets has been reduced to zero, but the lease liabilities still need to be further reduced, the Group will include the balance in the current profit and loss. The circumstances include ① any change in the fixed payment in substance (In this case, the original discount rate is used); ② any change in the expected payable amount of the residual value of the guarantee (In this case, the original discount rate is used); ③ any change in the indexes or ratios used to determine the lease payments (In this case, the revised discount rate is used); ④ any change in the evaluation result of the purchase option (In this case, the revised discount rate is used); ⑤ any change in evaluation result or actual exercise of the option to renew or terminate the lease (In this case, the revised discount rate is used).

28. Recognition principle and measurement of income

Revenue is recognized when the Group satisfies the performance obligation in the contract by transferring the control over relevant goods or services to customers.

合同中包含兩項或多項履約義務的，本集團在合同開始日，按照各單項履約義務所承諾商品或服務的單獨售價的相對比例，將交易價格分攤至各單項履約義務，按照分攤至各單項履約義務的交易價格計量收入。

交易價格是本集團因向客戶轉讓商品或服務而預期有權收取的對價金額，不包括代第三方收取的款項。本集團確認的交易價格不超過在相關不確定性消除時累計已確認收入極可能不會發生重大轉回的金額。預期將退還給客戶的款項作為負債，不計入交易價格。合同中存在重大融資成分的，本集團按照假定客戶在取得商品或服務控制權時即以現金支付的應付金額確定交易價格。該交易價格與合同對價之間的差額，在合同期間內採用實際利率法攤銷。合同開始日，本集團預計客戶取得商品或服務控制權與客戶支付價款間隔不超過一年的，不考慮合同中存在的重大融資成分。

滿足下列條件之一時，本集團屬於在某一段時間內履行履約義務，否則，屬於在某一時點履行履約義務：
客戶在本集團履約的同時即取得並消耗本集團履約所帶來的經濟利益；客戶能夠控制本集團履約過程中提供的

Where two or more performance obligations are included in a contract, at the commencement date of the contract, the Group will allocate the transaction price to each performance obligation on the proportion of the standalone selling prices of each distinct good or service promised, and measure the revenue based on the transaction price being allocated to each performance obligation.

The transaction price is the amount of consideration to which the Group expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties. The transaction price recognized by the Group shall not exceed the amounts that are most unlikely to have a significant reversal for accumulated recognized income when the relevant uncertainties are resolved. The amount which the Group expects to refund to the customer is recognized as liabilities and excluded from transaction price. Where the contract contains a significant financing component, the Group determines the transaction price as the amount payable in cash by a customer when he/she obtains the control of the goods or services. The difference between the transaction price and the consideration of the contract is amortized using effective interest method over the contract term. The Group will not consider a significant financing component in a contract if it expects, on the inception date of the contract, that the period between the obtaining of the control of the goods or services by a customer and the payment by the customer will be one year or less.

The Group satisfies a performance obligation over time if one of the following criteria is met; or otherwise, a performance obligation is satisfied at a point in time:

The customer simultaneously receives and consumes the benefits provided by the Group's performance as the Group performs; the customer can control the services (or goods)

服務（或商品）；本集團履約過程中所提供的服務（或商品）具有不可替代用途，且本集團在整個合同期間內有權就累計至今已完成的履約部分收取款項。

對於在某一時段內履行的履約義務，本集團在該段時間內按照履約進度確認收入。履約進度不能合理確定時，本集團已經發生的成本預計能夠得到補償的，按照已經發生的成本金額確認收入，直到履約進度能夠合理確定為止。

對於在某一時點履行的履約義務，本集團在客戶取得相關商品或服務控制權時點確認收入。在判斷客戶是否已取得商品或服務控制權時，本集團會考慮下列跡象：

本集團就該商品或服務享有現時收款權利；本集團已將該商品的實物轉移給客戶；

本集團已將該商品的法定所有權或所有權上的主要風險和報酬轉移給客戶；客戶已接受該商品或服務等。

本集團已向客戶轉讓商品或服務而有權收取對價的權利（且該權利取決於時間流逝之外的其他因素）作為合同資產列示，合同資產以預期信用損失為基礎計提減值。本集團擁有的、無條件（僅取決於時間流逝）向客戶收

provided during the Group's performance; the services (or goods) provided during the Group's performance does not create an asset with an alternative use and the Group has a right to payment for performance completed to date in the contract period.

For performance obligation satisfied over time, the Group recognizes revenue over time by the progress of the satisfaction of that performance obligation. When the progress of that performance obligation cannot be measured reasonably, but the Group expects to recover the costs incurred in satisfying the performance obligation, the Group recognizes revenue as the costs incurred until such time that it can reasonably measure the progress of the performance obligation.

For performance obligation satisfied at a point in time, the Group recognizes revenue at the point in time at which the customer obtains the control of relevant goods or services. To determine whether a customer has obtained the control of goods or services, the Group considers the following indicators:

The Group has a present right to payment for the goods or services; the Group has transferred physical possession of the goods to the customer;

The Group has transferred the legal title of the goods or the significant risks and rewards of ownership of the goods to the customer; the customer has accepted the goods or services.

The rights of the Group to receive consideration from customers (depending on factors other than the passage of time) for the transferred goods or services is presented as contract assets which is provided for impairment on the basis of expected credit losses. The Group's unconditional right (only the passage of time is required) to consideration from customer is presented as



取對價的權利作為應收款項列示。本集團已收或應收客戶對價而應向客戶轉讓商品或服務的義務作為合同負債列示。

本集團的收入包括銷售商品收入、提供諮詢服務收入，其主要活動相關的具體會計政策描述如下：

本集團產品收入確認具體政策：本集團與客戶簽訂銷售合同約定，對方應於收貨後三日內，按商品質量要求及 GSP 驗收標準進行驗收，逾期未驗收視為商品合格。因所提供的商品與訂單不符、破損、污染、過期等情況，應於貨到 3 日內向本集團提出，並提供詳細資料，經查證後屬於公司責任的，確認後辦理退貨手續。基於以上條款，本集團出於謹慎性原則，於貨品發出 3 日後視同商品的控制權已轉移給客戶，予以確認收入。

本集團服務費收入確認具體政策：公司其他業務收入主要是公司為部分醫藥廠商和分銷商提供品牌推介、產品市場推廣等方面的諮詢服務收入。諮詢服務費按簽訂的《服務協定》，根據提供的具體服務內容進行收取，獨立於產品採購合同。公司在提供諮詢服務考核期結束後，收到客戶款項或確定款項完全可以收到的情況下確認

receivables. The Group's obligation to transfer goods or services to a customer for which the Group has received consideration (or an amount of consideration is due) from the customer is presented as contract liability.

The income of the Group includes income from the sales of goods, income from provision of advisory services. The following is the description of accounting policies regarding income from its principal activities:

The specific income recognition policy for the Group's products: the Group entered into a sales contract with the customer while the counterparty shall, within 3 days after receipt of the goods, inspect and accepts according to the product quality requirements and the GSP acceptance criteria. Overdue acceptance is deemed to constitute standard product. The fact that the goods provided are not in conformity with the order, damage, pollution, expiration, etc., shall be submitted to the Group within 3 days after the goods have been received, and detailed information shall be provided. If the responsibilities rest with the Company after verification, the return procedures will commence upon confirmation. Based on the above terms, the Group recognizes the income 3 days after the goods were shipped (which shall be deemed to have transferred the control thereof to the customer) for the sake of prudence.

The specific income recognition policies for the Group's service fees: income of the Company's other business is mainly the advisory service income from provision of brand promotion, product marketing, etc. for some pharmaceutical manufacturers and distributors. The advisory service fee is charged on the specific service content provided according to the service agreement signed, which is independent of the product procurement contract. The income will be recognized by the Company after the end of the evaluation period of provision of

收入。

29.政府補助

本集團的政府補助包括與資產相關的政府補助、與收益相關的政府補助。其中，與資產相關的政府補助，是指本集團取得的、用於購建或以其他方式形成長期資產的政府補助；與收益相關的政府補助，是指除與資產相關的政府補助之外的政府補助。如果政府文件中未明確規定補助對象，本集團按照上述區分原則進行判斷，難以區分的，整體歸類為與收益相關的政府補助。

政府補助為貨幣性資產的，按照實際收到的金額計量，對於按照固定的定額標準撥付的補助，或對年末有確鑿證據表明能夠符合財政扶持政策規定的相關條件且預計能夠收到財政扶持資金時，按照應收的金額計量；政府補助為非貨幣性資產的，按照公允價值計量，公允價值不能可靠取得的，按照名義金額(1元)計量。

與資產相關的政府補助確認為遞延收益，在相關資產使用壽命內平均分配計入當期損益，相關資產在使用壽命結束前被出售、轉讓、報廢或發生毀損的，將尚未分配的相關遞延收益餘額轉入資產處置當期的損益。

advisory service to the extent that payment from the customers is received or it is determined that the amount can be fully received.

29.Government grants

The government grants of the Group include the government subsidies related to the assets and the revenue. Of these, asset-related government subsidies refer to government subsidies obtained by the Group for the construction or, in other means, for the formation of long-term assets; revenue-related government subsidies refer to government subsidies other than those related to assets. If the targets of the subsidies are not specified in government documents, the Group shall make judgments in accordance with the above-mentioned distinction principles, and where distinctions are difficult to be made, the subsidies shall be classified as revenue-related government subsidies as a whole.

If a government grant is in the form of a monetary asset, it is measured at the amount received; If the grants are allocated in accordance with fixed quotas, or if there is sufficient evidence at the end of the year to show that the entity complies with the relevant conditions of financial supporting policies and it is expected to receive financial supporting funds, the grants shall be measured at the amount receivable; If a government grant is in the form of a non-monetary asset, it is measured at fair value, and if the fair value could not be reliably obtained, it is measured at its nominal amount (RMB1).

The government grants related to assets are recognized as deferred revenue and are amortized equally over the useful life of the relevant assets and included in the profit or loss for the period. If the relevant asset is sold, transferred, scrapped or destroyed before the end of its service life, the unallocated balance of the relevant deferred gain shall be transferred to

與收益相關的政府補助，用於補償以後期間的相關費用或損失的，確認為遞延收益，並在確認相關費用的期間計入當期損益；用於補償已發生的相關費用或損失的，直接計入當期損益。與企業日常活動相關的政府補助，應當按照經濟業務實質，計入其他收益或沖減相關成本費用。與企業日常活動無關的政府補助，應當計入營業外收支。

本集團取得政策性優惠貸款貼息的，區分財政將貼息資金撥付給貸款銀行和財政將貼息資金直接撥付給本集團兩種情況，分別按照以下原則進行會計處理：

(1) 財政將貼息資金撥付給貸款銀行，由貸款銀行以政策性優惠利率向本集團提供貸款的，本集團以實際收到的借款金額作為借款的入賬價值，按照借款本金和該政策性優惠利率計算相關借款費用（或以借款的公允價值作為借款的入賬價值並按照實際利率法計算借款費用，實際收到的金額與借款公允價值之間的差額確認為遞延收益。遞延收益在借款存續期內採用實際利率法攤銷，沖減相關借款費用）。

profit or loss in the period in which the asset is disposed of.

When the government grants related to the revenue are used to make up the relevant expenses or losses incurred in subsequent periods, they shall be recognized as deferred revenue and shall be included in the profit or loss for the period during the period in which relevant expenses are recognized. When the government grants are used to make up the relevant expenses or losses incurred, they shall be directly included in the profit or loss for the period. The government grants related to business activities of an enterprise are recognized as other income or a reduction of relevant costs and expenses in the light of the nature of such business. The government grants non-related to business activities of an enterprise are recognized as non-operating income or expense.

The Group accounts for interest subsidies of policy-based preferential loans it obtains on the following principles and under two circumstances:

(1) Where the finance allocates the interest subsidy to the lending bank and the lending bank loans to the Group at the policy-based preferential interest rate, the Group records the amount of loan it actually receives as the entry value of the loan, and calculates the related borrowing costs based on the principal amount of the loan and the policy-based preferential interest rate (or records the fair value of the loan as the entry value of the loan and calculates the borrowing costs based on the effective interest rate method; and recognises the difference between the actual amount received and the fair value of the loan in deferred income. The deferred income is amortised over the duration of the loan using the effective interest rate method and is used to offset the related borrowing costs.)

(2) 財政將貼息資金直接撥付給本集團，本集團將對應的貼息沖減相關借款費用。

本集團已確認的政府補助需要退回的，在需要退回的當期分情況按照以下規定進行會計處理：

- 1) 初始確認時沖減相關資產賬面價值的，調整資產賬面價值。
- 2) 存在相關遞延收益的，沖減相關遞延收益賬面餘額，超出部分計入當期損益。
- 3) 屬於其他情況的，直接計入當期損益。

30. 遞延所得稅資產和遞延所得稅負債

本集團遞延所得稅資產和遞延所得稅負債根據資產和負債的計稅基礎與其賬面價值的差額(暫時性差異)計算確認。對於按照稅法規定能夠於以後年度抵減應納稅所得額的可抵扣虧損，確認相應的遞延所得稅資產。對於商譽的初始確認產生的暫時性差異，不確認相應的遞延所得稅負債。對於既不影響會計利潤也不影響應納稅所得額(或可抵扣虧損)的非企業合併的交易中產生的資產或負債的初始確認形成的暫時性差異，不確認相應的遞延所得稅資產和遞延所得稅負債。於資產負債表日，遞延所得稅資產和遞延所得稅負債，按照預期收回該資產或清償該負債期間的適用稅率計量。

(2) Where the finance allocates the interest subsidy to the Group directly, the Group offsets the related borrowing costs with the subsidy.

When the Group has to return government grants it has already recognised, such grants are accounted for in the period in which they are required to be returned under different circumstances:

- 1) If the carrying value of the related assets is offset upon initial recognition, the carrying value of the assets is adjusted.
- 2) If there is related deferred income, the book balance of deferred income is offset, and the excess is included in the current profit or loss.
- 3) In other cases, the returned grants are directly included in the current profit or loss.

30. Deferred income tax assets and deferred income tax liabilities

Deferred income tax assets and deferred income tax liabilities of the Group are calculated and recognized based on the difference (temporary differences) between tax bases and carrying amounts of assets and liabilities. Deferred income tax asset is recognized for the deductible losses that are deductible against taxable profit in subsequent years in accordance with the requirements under tax laws. No deferred tax liability is recognized for temporary difference arising from initial recognition of goodwill. No deferred income tax assets or deferred income tax liabilities are recognized for a temporary difference arising from initial recognition of asset or liability due to a transaction other than a business combination, which affects neither accounting profit nor taxable profit (or deductible loss). At balance sheet date, deferred income tax assets and deferred income tax liabilities are measured at the applicable tax rates for the period when the asset is expected to be recovered or the liability is expected to be settled.

本集團以很可能取得用來抵扣可抵扣暫時性差異、可抵扣虧損和稅款抵減的未來應納稅所得額為限，確認遞延所得稅資產。

31.租賃

(1) 租賃的識別

租賃，是指在一定期間內，出租人將資產的使用權讓與承租人以獲取對價的合同。在合同開始日，本集團評估合同是否為租賃或者包含租賃。如果合同一方讓渡了在一定期間內控制一項或多項已識別資產使用的權利以換取對價，則該合同為租賃或者包含租賃。為確定合同是否讓渡了在一定期間內控制已識別資產使用的權利，本集團評估合同中的客戶是否有權獲得在使用期間內因使用已識別資產所產生的幾乎全部經濟利益，並有權在該使用期間主導已識別資產的使用。

合同中同時包含多項單獨租賃的，本集團將合同予以分拆，並分別對各項單獨租賃進行會計處理。合同中同時包含租賃和非租賃部分的，本集團將租賃和非租賃部分分拆後進行會計處理。

(2) 本集團作為承租人

1) 租賃確認

在租賃期開始日，本集團對租賃確認使用權資產和租賃負債。使用權資產和租賃負債的確認和計量參見附註四“21. 使用權資產”以及“27. 租賃負

The Group shall recognize the deferred income tax assets to the extent that it is probable that future taxable profit will be available against which any deductible temporary difference, deductible loss or tax deduction can be utilized.

31. Leasing

(1) Identification of lease

Lease refers to a contract in which a lessor assigns the right to use an asset to a lessee within a certain period of time in exchange for consideration. On the commencement date of a contract, the Group assesses whether the contract is a lease or contains a lease. A contract is a lease or contains a lease if one party to the contract transfers the right to control the use of one or more identified assets within a certain period of time in exchange for consideration. In order to determine whether a contract transfers the right to control the use of the identified assets within a certain period of time, the Group assesses whether the customers in the contract are entitled to receive almost all of the economic benefits arising from the use of the identified assets during the period of use and have the right to direct the use of the identified assets during the period of use.

If a contract contains multiple separate leases, the Group will split the contract and account for each separate lease. Where a contract contains both lease and non-lease components, the Group will account for the lease and non-lease components separately.

(2) The Group as a lessee

1) Lease confirmation

At the commencement date of the lease term, the Group recognizes the right-of-use assets and lease liabilities for the lease. For the recognition and measurement of right-of-use assets and lease liabilities, see Note 4, “21. Right-of-use assets”

債”。

2) 租賃變更

租賃變更，是指原合同條款之外的租賃範圍、租賃對價、租賃期限的變更，包括增加或終止一項或多項租賃資產的使用權，延長或縮短合同規定的租賃期等。租賃變更生效日，是指雙方就租賃變更達成一致的日期。

租賃發生變更且同時符合下列條件的，本集團將該租賃變更作為一項單獨租賃進行會計處理：①該租賃變更通過增加一項或多項租賃資產的使用權而擴大了租賃範圍或延長了租賃期限；②增加的對價與租賃範圍擴大部分或租賃期限延長部分的單獨價格按該合同情況調整後的金額相當。

租賃變更未作為一項單獨租賃進行會計處理的，在租賃變更生效日，本集團按照租賃準則有關規定對變更後合同的對價進行分攤，重新確定變更後的租賃期；並採用修訂後的折現率對變更後的租賃付款額進行折現，以重新計量租賃負債。在計算變更後租賃付款額的現值時，本集團採用剩餘租賃期間的租賃內含利率作為折現率；無法確定剩餘租賃期間的租賃內含利率的，本集團採用租賃變更生效日的承租人增量借款利率作為折現率。就上述租賃負債調整的影響，本集團區分以下情形進行會計處理：①租賃變更導致租賃範圍縮小或租賃期縮短的，承租人應當調減使用權資產的賬

and “27. Lease liabilities”.

2) Lease variations

Lease variations refer to the variations of the lease scope, lease consideration and lease duration beyond the original contract terms, including the addition or termination of the right to use one or more leased assets, and the extension or shortening of the lease term stipulated in the contract. The effective date of a lease variation is the date on which the parties agree on such lease variation.

When there is a lease variation and the following conditions are simultaneously met, the Group accounts for the lease variation as a separate lease: ① the lease variation expands the scope of the lease or extends the lease term by adding the right to use one or more leased assets; ② the additional consideration is equal to the price of the enlarged part of the lease or the extended part of the lease term after being adjusted as per the contract.

Where the lease variation is not accounted for as a separate lease, on the effective date of the lease variation, the Group allocates the consideration of the contract after the variation in accordance with the relevant provisions of the lease standards, and re-determines the lease term after the variation; and re-measures the lease liabilities by applying the revised discount rate to discount the lease payments after the variation. When calculating the present value of lease payments after the variation, the Group uses the interest rate implicit in the lease for the remaining duration of the lease as the discount rate; where the interest rate implicit in the lease for the remaining duration of the lease cannot be determined, the Group uses the incremental borrowing rate of the lessee on the effective date of the lease variation as the discount rate. As for the effect of the aforesaid adjustments to lease liabilities, the Group applies different accounting treatments according to the following: ①

面價值，並將部分終止或完全終止租賃的相關利得或損失計入當期損益。

②其他租賃變更導致租賃負債重新計量的，承租人相應調整使用權資產的賬面價值。

3) 短期租賃和低價值資產租賃

對於租賃期不超過 12 個月的短期租賃和單項租賃資產為全新資產時價值較低的低價值資產租賃，本集團選擇不確認使用權資產和租賃負債。本集團將短期租賃和低價值資產租賃的租賃付款額，在租賃期內各個期間按照直線法或其他系統合理的方法計入相關資產成本或當期損益。

(3) 本集團為出租人

在(1)評估的該合同為租賃或包含租賃的基礎上，本集團作為出租人，在租賃開始日，將租賃分為融資租賃和經營租賃。

如果一項租賃實質上轉移了與租賃資產所有權有關的幾乎全部風險和報酬，出租人將該項租賃分類為融資租賃，除融資租賃以外的其他租賃分類為經營租賃。

一項租賃存在下列一種或多種情形的，本集團通常將其分類為融資租賃：①在租賃期屆滿時，租賃資產的所有權轉移給承租人；②承租人有購買租賃資產的選擇權，所訂立的購買

where the lease variation reduces the lease scope or lease term, the lessee shall reduce the book value of the right-of-use assets, and include the gains or losses resulting from the partial or complete termination of the lease in the current profit and loss;

② where the lease liabilities are re-measured due to other lease variations, the lessee shall adjust the book value of the right-of-use assets accordingly.

3) Short-term lease and lease of low-value assets

For the short-term leases with a lease term of less than 12 months, and the leases of low-value assets where the single leased assets are brand new assets, the Group chooses not to recognize right-of-use assets and lease liabilities. The Group includes the lease payments for short-term leases and leases of low-value assets in the relevant costs of assets or current profit or loss using the straight-line method or other systematic and reasonable methods in each period of the lease term.

(3) The Group as a lessor

On the basis that the contract is a lease or contains a lease as evaluated in (1), the Group, as a lessor, divides the lease into a finance lease or operating lease on the commencement date of the lease.

If a lease transfers almost all of the risks and rewards related to the ownership of the leased assets in substance, the lessor classifies the lease as a finance lease and those other than finance leases as operating leases.

A lease is generally classified as a finance lease by the Group if one or more of the following conditions are met: ① upon the expiration of the lease term, the ownership of the leased assets is transferred to the lessee; ② the lessee has the option to purchase the leased assets, and the purchase price as agreed is

價款與預計行使選擇權時租賃資產的公允價值相比足夠低，因而在租賃開始日就可以合理確定承租人將行使該選擇權；③資產的所有權雖然不轉移，但租賃期佔租賃資產使用壽命的大部分（不低於租賃資產使用壽命的75%）；④在租賃開始日，租賃收款額的現值幾乎相當於租賃資產的公允價值（不低於租賃資產公允價值的90%。）；⑤租賃資產性質特殊，如果不作較大改造，只有承租人才能使用。一項租賃存在下列一項或多項跡象的，本集團也可能將其分類為融資租賃：①若承租人撤銷租賃，撤銷租賃對出租人造成的損失由承租人承擔；②資產餘值的公允價值波動所產生的利得或損失歸屬於承租人；③承租人有能力以遠低於市場水準的租金繼續租賃至下一期間。

1) 融資租賃會計處理

初始計量

在租賃期開始日，本集團對融資租賃確認應收融資租賃款，並終止確認融資租賃資產。本集團對應收融資租賃款進行初始計量時，以租賃投資淨額作為應收融資租賃款的入賬價值。

租賃投資淨額為未擔保餘值和租賃期開始日尚未收到的租賃收款額按照租賃內含利率折現的現值之和。租賃收款額，是指出租人因讓渡在租賃期內使用租賃資產的權利而應向承租人收取的款項，包括：①承租人需支付的固定付款額及實質固定付款額；存在租賃激勵的，扣除租賃激勵相關金

sufficiently low compared to the fair value of the leased assets when the option is expected to be exercised, so it can be reasonably determined at the commencement date of the lease that the lessee will exercise the option; ③ although the ownership of the assets is not transferred, the lease term represents most of the useful life of the assets (not less than 75% of the useful life of the leased assets); ④ at the commencement date of the lease, the present value of the lease receipts is almost equal to the fair value of the leased assets (not less than 90% of the fair value of the leased assets); ⑤ the leased assets are of a special nature and can only be used by the lessee with any major modification. A lease may be classified as a finance lease by the Group if there are one or more of the following signs: ① if the lessee cancels the lease, the loss caused to the lessor by the cancellation of the lease shall be borne by the lessee; ② the gains or losses resulting from the fluctuations of the fair value of the residual value of the assets belong to the lessee; ③ the lessee has the ability to continue the lease to the next period at a rent far below the market level.

1) Accounting of financial leases

Initial recognition

At the commencement date of the lease term, the Group recognizes finance lease receivables for financial leases and derecognizes finance lease assets. When performing the initial measurement of financial lease receivables, the Group accounts for the finance lease receivables at the net lease investment.

The net lease investment is the sum of the unguaranteed residual value and the present value of the lease payments that have not been received at the commencement date of the lease, discounted at the interest rate implicit in the lease. The lease receipt refers to the amount that the lessor should collect from the lessee for transferring its right to use the leased assets during the lease term, including: ① the fixed payments and the fixed payments in substance to be paid by the lessee, net of lease

額；②取決於指數或比率的可變租賃付款額，該款項在初始計量時根據租賃期開始日的指數或比率確定；③購買選擇權的行權價格，前提是合理確定承租人將行使該選擇權；④承租人行使終止租賃選擇權需支付的款項，前提是租賃期反映出承租人將行使終止租賃選擇權；⑤由承租人、與承租人有關的一方以及有經濟能力履行擔保義務的第三方向出租人提供的擔保餘值。

後續計量

本集團按照固定的週期性利率計算並確認租賃期內各個期間的利息收入。該週期性利率，是指確定租賃投資淨額採用內含折現率（轉租情況下，若轉租的租賃內含利率無法確定，採用原租賃的折現率（根據與轉租有關的初始直接費用進行調整）），或者融資租賃的變更未作為一項單獨租賃進行會計處理，且滿足假如變更在租賃開始日生效，該租賃會被分類為融資租賃條件時按相關規定確定的修訂後的折現率。

租賃變更的會計處理

融資租賃發生變更且同時符合下列條件的，本集團將該變更作為一項單獨租賃進行會計處理：①該變更通過增加一項或多項租賃資產的使用權而擴大了租賃範圍；②增加的對價與租賃範圍擴大部分的單獨價格按該合同情況調整後的金額相當。

incentives received, if any; ② variable lease payments depending on indexes or ratios, which are determined at the initial measurement based on the indexes or ratios at the commencement date of the lease; ③ the exercise price of the purchase option, provided that it is reasonably certain that the lessee will exercise this option; ④ the payments that the lessee needs to make for exercising the option to terminate the lease, provided that the lease term reflects that the lessee will exercise the option to terminate the lease; ⑤ the residual value of the guarantee provided to the lessor by the lessee, a party related to the lessee and an independent third party with the financial ability to fulfill the obligation of the guarantee.

Subsequent measurement

The Group calculates and recognizes interest income for each period of the lease term at a fixed periodic interest rate. The periodic interest rate refers to the implicit discount rate used to determine the net lease investment (in the case of a sublease, if the interest rate implicit in the sublease cannot be determined, the discount rate of the original lease will be used (as adjusted based on the initial direct costs relating to the sublease)), or the revised discount rate as determined according to relevant requirements when the variation of the financial lease is not accounted for as a separate lease, and the condition is satisfied that the lease will be classified as a finance lease if the variation becomes effective at the commencement date of the lease.

Accounting of lease variations

When there is a variation of the finance lease and the following conditions are simultaneously met, the Group accounts for the variation as a separate lease: ① the variation extends the scope of the lease by adding the right to use one or more leased assets; ② the additional consideration is equal to the separate price of the enlarged scope of the lease as adjusted for the circumstances of the contract.

如果融資租賃的變更未作為一項單獨租賃進行會計處理，且滿足假如變更後在租賃開始日生效，該租賃會被分類為經營租賃條件的，本集團自租賃變更生效日開始將其作為一項新租賃進行會計處理，並以租賃變更生效日前的租賃投資淨額作為租賃資產的賬面價值。

2) 经营租赁的会计处理

租金的處理

在租賃期內各個期間，本集團採用直線法將經營租賃的租賃收款額確認為租金收入。

提供的激勵措施

提供免租期的，本集團將租金總額在不扣除免租期的整個租賃期內，按直線法進行分配，免租期內應當確認租金收入。本集團承擔了承租人某些費用的，將該費用自租金收入總額中扣除，按扣除後的租金收入餘額在租賃期內進行分配。

初始直接費用

本集團發生的與經營租賃有關的初始直接費用應當資本化至租賃標的資產的成本，在租賃期內按照與租金收入相同的確認基礎分期計入當期損益。

折舊

對於經營租賃資產中的固定資產，本集團採用類似資產的折舊政策計提折

If a variation of a finance lease is not accounted for as a separate lease, and the condition is satisfied that the lease will be classified as an operating lease if the variation becomes effective at the commencement date of the lease, the Group will account for it as a new lease from the effective date of the lease variation, and use the net lease investment before the effective date of the lease variation as the book value of the leased assets.

2) Accounting of operating leases

Accounting of rentals

In each period of the lease term, the Group uses the straight-line method to recognize lease receipts from operating leases as rental income.

Incentives provided

Where a rental-free period is provided, the Group allocates the total rent over the entire lease term without deducting the rent-free period on a straight-line basis, and recognizes rental income in the rent-free period. If the Group bears certain expenses of the lessee, the expenses shall be deducted from the total rental income, and the balance of the rental income after deduction shall be allocated during the lease term.

Initial direct costs

The initial direct costs incurred by the Group related to operating leases shall be capitalized to the costs of the underlying assets of the lease, and shall be charged to the current profit and loss in installments over the lease term on the same basis as the rental income.

Depreciation

For the fixed assets under operating leases, the Group adopts the depreciation policies for similar assets to provide for

舊；對於其他經營租賃資產，採用系統合理的方法進行攤銷。

可變租賃付款額

本集團取得的與經營租賃有關的未計入租賃收款額的可變租賃付款額，在實際發生時計入當期損益。

經營租賃的變更

經營租賃發生變更的，本集團自變更生效日開始，將其作為一項新的租賃進行會計處理，與變更前租賃有關的預收或應收租賃收款額視為新租賃的收款額。

32.終止經營

終止經營，是指本集團滿足下列條件之一的、能夠單獨區分的組成部分，且該組成部分已經處置或劃分為持有待售類別：（1）該組成部分代表一項獨立的主要業務或一個單獨的主要經營地區；（2）該組成部分是擬對一項獨立的主要業務或一個單獨的主要經營地區進行處置的一項相關聯計劃的一部分；（3）該組成部分是專為轉售而取得的子公司。

33.重要會計政策和會計估計變更

（1）重要會計政策變更

本報告期本集團主要會計政策未發生變更。

depreciation. For other assets under operating leases, systematic and reasonable methods are used for amortization.

Variable lease payments

The variable lease payments received by the Group related to operating leases and not included in the lease receipts are included in the current profit and loss when they are actually incurred.

Variation of operating lease

When there is a variation of an operating lease, the Group will account for it as a new lease from the effective date of the variation, and the lease receipts received in advance or receivable related to the lease before the variation will be treated as the receipts for the new lease.

32. Discontinued operation

Discontinued operation refers to a component of the Group which meets one of the following requirements and can be distinguish separately and has been already disposed of or classified as held-for-sale: (1) the component represents an independent major line of business or a major independent geographical area of operations; (2) the component is part of a plan for the contemplated disposal of an independent major line of business or a major independent geographical area of operations; (3) the component is a subsidiary acquired exclusively for the purpose of resale.

33. Changes of significant accounting policies and accounting estimates

(1) Changes of significant accounting policies

There is no change in significant accounting policies of the Group for the reporting period.

(2) 重要會計估計變更

本報告期本集團主要會計估計未發生變更。

(2) Changes of significant accounting estimates

There is no change in the significant accounting estimates of the Group for the reporting period.

五、稅項

V. TAXATION

1. 主要稅種及稅率

1. Main types of tax and tax rates

| 稅種 Type of tax | 計稅依據 Tax basis | 稅率 Tax rate |
|---|---|---------------------------|
| 增值稅 VAT | 應稅收入 Taxable income | 0%、3%、6%、9%、13% |
| 城市維護建設稅 Urban maintenance and construction tax | 實際繳納流轉稅額 Amount of actual payable turnover tax | 7% |
| 教育費附加 Education surcharge | 實際繳納流轉稅額 Amount of actual payable turnover tax | 3% |
| 地方教育費附加 Local education surcharge | 實際繳納流轉稅額 Amount of actual payable turnover tax | 2% |
| 土地使用稅 Tax on land use | 土地面積 Land area | 定額徵收 Fixed rate |
| 房產稅 Property taxes | 房屋原值的 70% 或租金收入 70% of original value of the properties or rental income | 1.2% 或 12% 1.2% or 12% |
| 企業所得稅 Enterprise income tax | 應納稅所得額 Amount of taxable income | 25% |

六、合併財務報表主要項目
註釋

VI. NOTES TO MAJOR ITEMS IN THE
CONSOLIDATED FINANCIAL
STATEMENTS

1. 貨幣資金

1. Monetary funds

| 項目 Items | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|--------------------------------|-------------------------|--|
| 庫存現金 Cash on hand | 408,835.92 | 343,374.54 |
| 銀行存款 Cash in bank | 67,573,319.84 | 143,883,349.87 |
| 其他貨幣資金 Other monetary funds | 375,626,036.26 | 485,941,302.10 |
| 合計 Total | 443,608,192.02 | 630,168,026.51 |

| 項目 Items | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|--|-------------------------|--|
| 其中：存放在境外的款項總額 Including: the total amount of money deposited abroad | 381,530.32 | 365,285.32 |

使用受到限制的货币资金

Use of restricted monetary funds

| 項目 Items | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|---------------------|-------------------------|--|
| 銀行承兌匯票保證金、借款保證金 | 375,626,036.26 | 485,941,302.10 |
| 合計 Total | 375,626,036.26 | 485,941,302.10 |

2. 應收票據

2. Bills receivables

(1) 應收票據種類

(1) Classification of bills receivables

| 項目 Items | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|--|-------------------------|--|
| 商業承兌匯票 Commercial drafts | 900,000.00 | 15,000,000.00 |
| 小計 Subtotal | 900,000.00 | 15,000,000.00 |
| 減：壞賬準備 Less: Provision for bad debt | 3,330.00 | 52,500.00 |
| 合計 Total | 896,670.00 | 14,947,500.00 |

(2) 於 2022 年 6 月 30 日已用於質

(2) Pledged bills receivables as at 30 June 2022

押的應收票據

| 項目 Items | 期末已質押金額 Pledged amount as at the end of the period |
|-----------------------------|---|
| 商業承兌匯票 Commercial drafts | 900,000.00 |
| 合計 Total | 900,000.00 |

(3) 於 2022 年 6 月 30 日已經背書或貼現且在資產負債表日尚未到期的應收票據

(3) Bills receivables endorsed or discounted as at 30 June 2022 but not mature at the balance sheet date.

| 項目 Items | 期末終止確認金額 Amount derecognised as at the end of the period | 期末未終止確認金額 Amount not derecognised as at the end of the period |
|---------------------------------|--|---|
| 商業承兌匯票 Commercial drafts | - | - |
| 銀行承兌匯票 Bank acceptance bills | - | - |
| 合計 Total | - | - |

(4) 於 2022 年 6 月 30 日未存在因出票人未履約而將其轉應收賬款的票據。

(4) As at 30 June 2022, no bills were reclassified to trade receivables due to inability of the issuers to settle the bills.

(5) 按壞賬計提方法分類列示

(5) Classification by the methods for making provisions for bad debt

| 類別 Classification | 期末餘額 Closing balance | | | | 賬面價值 Book value |
|--|-------------------------|--------------------------|--------------------------------|---------------------------------|--------------------|
| | 賬面餘額 Book balance | | 壞賬準備 Provision for bad debt | | |
| | 金額 Amount | 比例 (%) Percentage (%) | 金額 Amount | 計提比例 (%) Provision ratio (%) | |
| 按單項計提壞賬準備 Bad debt provision made on individual basis | - | - | - | - | - |
| 按組合計提壞賬準備 Bad debt provision made on a collective basis | 900,000.00 | 100.00 | 3,330.00 | 0.37% | 896,670.00 |
| 其中：賬齡組合 Aging portfolio | 900,000.00 | 100.00 | 3,330.00 | 0.37% | 896,670.00 |
| 低風險組合 Low risk portfolio | - | - | - | - | - |
| 合計 Total | 900,000.00 | 100.00 | 3,330.00 | — | 896,670.00 |

(續)

(continued)

| 類別 Classification | 上年年末餘額 Closing balance of last year | | | | 賬面價值 Book value |
|--|--|--------------------------|--------------------------------|---------------------------------|----------------------|
| | 賬面餘額 Book balance | | 壞賬準備 Provision for bad debt | | |
| | 金額 Amount | 比例 (%) Percentage (%) | 金額 Amount | 計提比例 (%) Provision ratio (%) | |
| 按單項計提壞賬準備 Bad debt provision made on individual basis | - | - | - | - | - |
| 按組合計提壞賬準備 Bad debt provision made on a collective basis | 15,000,000.00 | 100.00 | 52,500.00 | 0.35 | 14,947,500.00 |
| 其中：賬齡組合 Aging portfolio | 15,000,000.00 | 100.00 | 52,500.00 | 0.35 | 14,947,500.00 |
| 低風險組合 Low risk portfolio | - | - | - | - | - |
| 合計 Total | 15,000,000.00 | 100.00 | 52,500.00 | — | 14,947,500.00 |

1) 按組合計提應收票據壞賬準備

1) Bad debt provision for bills receivables made on a collective basis

| 賬齡 Age | 期末餘額 Closing balance | | |
|------------------------|-------------------------|--------------------------------|---------------------------------|
| | 賬面餘額 Book balance | 壞賬準備 Provision for bad debt | 計提比例 (%) Provision ratio (%) |
| 1 年以內 Within 1 year | 900,000.00 | 3,330.00 | 0.37 |
| 合計 Total | 900,000.00 | 3,330.00 | 0.37 |

註 1: 對於期末持有的商業承兌匯票及期末已貼現且在資產負債表日未到期的商業承兌匯票的金額作為賬齡組合, 參照應收賬款的預期信用損失計提比例計提信用減值損失。

Note 1: For the aging portfolio comprising the amounts of the commercial drafts held as at the end of the period and the commercial drafts discounted as at the end of the period but not mature at the balance sheet date, the impairment losses of credit are provided for with reference to the expected credit loss rates for trade receivables.

註 2: 本集團上述期末應收票據的賬齡均在 1 年之內。

Note 2: The age of the aforementioned bills receivables of the Group as at the end of the period was within 1 year.

(6) 本期計提、收回、轉回的應收票據壞賬準備

(6) Provisions for bad debt accrued, recovered and reversed for bills receivables in the period

| 類別 Category | 上年年末餘額 Closing balance of last year | 本期變動金額 Current movement | | | | 期末餘額 Closing balance |
|-----------------------------|--|----------------------------|--------------------------------|--------------------------------------|-------------|-------------------------|
| | | 計提 Accrued | 收回或轉回 Recovered or reversed | 轉銷或核銷 Written back or written off | 其他 Other | |
| 商業承兌匯票 Commercial drafts | 52,500.00 | - | 49,170.00 | - | - | 3,330.00 |
| 合計 Total | 52,500.00 | - | 49,170.00 | - | - | 3,330.00 |

3. 應收賬款

3. Trade receivables

| 項目名稱 Name of Items | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|---|-------------------------|--|
| 應收賬款 Trade receivables | 775,820,627.87 | 745,187,896.34 |
| 減: 壞賬準備 Less: Provision for bad debt | 29,142,743.12 | 28,874,948.91 |
| 淨額 Net amount | 746,677,884.75 | 716,312,947.43 |

(1) 應收賬款按壞賬計提方法分類
列示

(1) Accounts receivable by the method of provisioning for bad
debt

| 類別 Classification | 期末餘額 Closing balance | | | | 賬面價值 Book value |
|--|-------------------------|--------------------------------|--------------------------------|---------------------------------------|-----------------------|
| | 賬面餘額 Book balance | | 壞賬準備 Provision for bad debt | | |
| | 金額 Amount | 比例 (%) Percentage (%) | 金額 Amount | 計提比例 (%) Provision ratio (%) | |
| 按單項計提壞賬準備 Bad debt provision made on individual basis | 24,768,105.72 | 3.19 | 24,057,622.48 | 97.13 | 710,483.24 |
| 按組合計提壞賬準備 Bad debt provision made on a collective basis | 751,052,522.15 | 96.81 | 5,085,120.64 | 0.68 | 745,967,401.51 |
| 其中：賬齡組合 Aging portfolio | 751,052,522.15 | 96.81 | 5,085,120.64 | 0.68 | |
| 合計 Total | 775,820,627.87 | 100.00 | 29,142,743.12 | — | 746,677,884.75 |

(續)

(Continued)

| 類別 Classification | 上年年末餘額 Closing balance of last year | | | | 賬面價值 Book value |
|--|--|--------------------------------|--------------------------------|---------------------------------------|-----------------------|
| | 賬面餘額 Book balance | | 壞賬準備 Provision for bad debt | | |
| | 金額 Amount | 比例 (%) Percentage (%) | 金額 Amount | 計提比例 (%) Provision ratio (%) | |
| 按單項計提壞賬準備 Bad debt provision made on individual basis | 24,983,111.84 | 3.35 | 24,182,656.80 | 96.80 | 800,455.04 |
| 按組合計提壞賬準備 Bad debt provision made on a collective basis | 720,204,784.50 | 96.65 | 4,692,292.11 | 0.65 | 715,512,492.39 |
| 其中：賬齡組合 Aging portfolio | 720,204,784.50 | 96.65 | 4,692,292.11 | 0.65 | 715,512,492.39 |
| 合計 Total | 745,187,896.34 | 100.00 | 28,874,948.91 | — | 716,312,947.43 |

1) 按組合計提應收賬款壞賬準備

1) Bad debt provision for trade receivables made on a collective basis

| 賬齡 Age | 期末餘額 Closing balance | | |
|------------------------|---------------------------|--------------------------------|---------------------------------|
| | 應收賬款 Trade receivables | 壞賬準備 Provision for bad debt | 計提比例 (%) Provision ratio (%) |
| 1 年以內 Within 1 year | 727,110,581.67 | 2,656,812.11 | 0.37 |
| 1-2 年 1 to 2 years | 23,723,651.26 | 2,261,098.99 | 9.53 |
| 2-3 年 2 to 3 years | 218,289.22 | 167,209.54 | 76.6 |
| 3 年以上 Over 3 years | - | - | - |
| 合計 Total | 751,052,522.15 | 5,085,120.64 | 0.68 |

(2) 應收賬款按賬齡列示

在接納新客戶之前，本集團應用內部信貸評估政策來評估潛在客戶的信用質量並制定信用額度。本集團區別客戶制定不同的信用政策。信用期一般為六個月。對於商品銷售，以控制權轉移給購貨方作為應收賬款及營業收入的確認時點，並開始計算賬齡。

(2) Accounts receivable by aging

Before accepting new customers, the Group assessed the credit worthiness of potential clients and set corresponding credit limits according to the internal credit assessment policies. The Group applies different credit policies to different customers. Credit period is generally six months. As for commodity sales, the trade receivables and operating revenue are recognized and the age of the same is calculated after the control right has been transferred to the buyers.

| 賬齡 Age | 期末餘額 Closing balance | | | 上年年末餘額 Closing balance of last year | | |
|----------------------------|-------------------------|--------------------------|--------------------------------|--|--------------------------|--------------------------------|
| | 賬面餘額 Book balance | 比例 (%) Percentage (%) | 壞賬準備 Provision for bad debt | 賬面餘額 Book balance | 比例 (%) Percentage (%) | 壞賬準備 Provision for bad debt |
| 1 年以內 Within 1 year | 728,335,235.35 | 93.88 | 3,293,303.27 | 698,261,162.04 | 93.70 | 3,069,424.63 |
| 1-2 年 1 to 2 years | 24,314,536.68 | 3.13 | 2,813,659.40 | 23,963,529.50 | 3.22 | 2,934,764.53 |
| 2-3 年 2 to 3 years | 1,887,764.45 | 0.24 | 1,836,684.77 | 3,785,724.58 | 0.51 | 3,777,272.03 |
| 3 年以上 More than 3 years | 21,283,091.39 | 2.74 | 21,199,095.68 | 19,177,480.22 | 2.57 | 19,093,487.72 |
| 合計 Total | 775,820,627.87 | 100.00 | 29,142,743.12 | 745,187,896.34 | 100.00 | 28,874,948.91 |

(3) 本期應收賬款壞賬準備情況

(3) Provisions for bad debts accounts receivable in the period

| 上年年末餘額 Closing balance of last year | 本期變動金額 Current movement | | | | 期末餘額 Closing balance |
|--|----------------------------|--------------------------------|--------------------------------------|--------------|-------------------------|
| | 計提 Accrued | 收回或轉回 Recovered or reversed | 轉銷或核銷 Written back or written off | 其他 Others | |
| 28,874,948.91 | 392,828.53 | 125,034.32 | - | - | 29,142,743.12 |

(4) 本期未有核銷的應收賬款。

(4) No trade receivables were written off in the period.

4. 應收款項融資

4. Accounts receivable financing

| 項目 Item | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|---------------------------------|-------------------------|--|
| 銀行承兌匯票 Bank acceptance bills | 14,216,386.49 | - |
| 合計 Total | 14,216,386.49 | - |

5. 預付款項

5. Prepayments

(1) 預付款項賬齡

(1) Aging of prepayments

| 項目 Items | 期末餘額 Closing balance | | 上年年末餘額 Closing balance of last year | |
|---------------------------|-------------------------|--------------------------|--|--------------------------|
| | 金額 Amount | 比例 (%) Proportion (%) | 金額 Amount | 比例 (%) Proportion (%) |
| 1年以內 Within 1 year | 325,862,917.19 | 98.08 | 306,956,890.05 | 98.33 |
| 1-2年 1 to 2 years | 5,778,299.85 | 1.74 | 5,143,311.04 | 1.65 |
| 2-3年 2 to 3 years | 9,452.41 | - | 800.98 | - |
| 3年以上 More than 3 years | 591,471.34 | 0.18 | 59,692.12 | 0.02 |
| 合計 Total | 332,242,140.79 | 100.00 | 312,160,694.19 | 100.00 |

6. 其他應收款

6. Other receivables

| 項目 Items | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|------------------------------|-------------------------|--|
| 應收利息 Interests receivable | - | - |
| 應收股利 Dividend receivable | - | - |
| 其他應收款 Other receivables | 11,989,545.20 | 32,249,707.83 |
| 合計 Total | 11,989,545.20 | 32,249,707.83 |

6.1 其他應收款

6.1 Other receivables

(1) 其他應收款按款項性質分類

(1) Classification of other receivables by nature

| 款項性質 Nature of amounts | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|--|-------------------------|--|
| 保證金 Deposit | 10,941,336.00 | 11,587,520.15 |
| 往來款 Current accounts | 523,181.25 | 20,000,000.00 |
| 備用金 Reserve | 600,027.95 | 732,187.68 |
| 其他 Others | 898.20 | 5,898.20 |
| 合計 Total | 12,065,443.40 | 32,325,606.03 |
| 減：壞賬準備 Less: Provision for bad debt | 75,898.20 | 75,898.20 |
| 淨額 Net amount | 11,989,545.20 | 32,249,707.83 |

(2) 其他應收款壞賬準備計提情況

(2) Provisions for bad debt of other receivables

| 壞賬準備 Provision for bad debt | 第一階段 First stage | 第二階段 Second stage | 第三階段 Third stage | 合計 Total |
|---|---|---|--|------------------|
| | 未來 12 個月預期 信用損失 12-month expected credit loss | 整個存續期預期信用損 失(未發生信用減值) Lifetime expected credit loss (not credit-impaired) | 整個存續期預期信用損 失(已發生信用減值) Lifetime expected credit loss (credit- impaired) | |
| 2022 年 1 月 1 日餘額 Balance of 1 January 2022 | - | 70,000.00 | 5,898.20 | 75,898.20 |
| 2022 年 1 月 1 日其他應收款 賬面餘額在本期 Book balance of other receivables on 1 January 2022 in the period | - | - | - | - |
| --轉入第二階段 --Transfer to the second stage | - | - | - | - |
| --轉入第三階段 -- Transfer to the third stage | - | - | - | - |
| --轉回第二階段 -- Reversed to the second stage | - | - | - | - |
| --轉回第一階段 -- Reversed to the first stage | - | - | - | - |
| 本期計提 Accrued for the period | - | - | - | - |
| 本期轉回 Reversed in the period | - | - | - | - |
| 本期轉銷 Written off in the period | - | - | - | - |

| 壞賬準備 Provision for bad debt | 第一階段 First stage | 第二階段 Second stage | 第三階段 Third stage | 合計 Total |
|--|---|---|--|------------------|
| | 未來 12 個月預期 信用損失 12-month expected credit loss | 整個存續期預期信用損 失(未發生信用減值) Lifetime expected credit loss (not credit-impaired) | 整個存續期預期信用損 失(已發生信用減值) Lifetime expected credit loss (credit- impaired) | |
| 本期核銷 Cancelled in the period | - | - | - | - |
| 其他變動 Other changes | - | - | - | - |
| 2022 年 6 月 30 日餘額 Balance on 30 June 2022 | - | 70,000.00 | 5,898.20 | 75,898.20 |

7.存貨

7.Inventories

(1) 存貨分類

(1) Classification of inventories

| 項目 Items | 期末餘額 Closing balance | | | 上年年末餘額 Closing balance of last year | | |
|---------------------------|-------------------------|--|-----------------------|--|--|-----------------------|
| | 賬面餘額 Book balance | 存貨跌價準備 Provision for inventory impairment | 賬面價值 Book value | 賬面餘額 Book balance | 存貨跌價準備 Provision for inventory impairment | 賬面價值 Book value |
| 庫存商品 Goods in stock | 560,887,804.00 | -2,845,084.18 | 558,042,719.82 | 479,288,059.64 | 3,102,249.84 | 476,185,809.80 |
| 發出商品 Goods sold | - | - | - | 32,970,616.57 | - | 32,970,616.57 |
| 合計 Total | 560,887,804.00 | -2,845,084.18 | 558,042,719.82 | 512,258,676.21 | 3,102,249.84 | 509,156,426.37 |

8.其他流動資產

8.Other current assets

| 項目 Items | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|-------------------------------------|-------------------------|--|
| 待抵扣進項稅額 Input tax to be credited | 29,734,598.45 | 22,870,078.17 |
| 待攤費用 Deferred expenses | 366,658.28 | 356,902.33 |
| 合計 Total | 30,101,256.73 | 23,226,980.50 |

9.固定資產

9.Fixed assets

| 項目 Items | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|---------------------------------------|-------------------------|--|
| 固定資產 Fixed assets | 324,213,328.70 | 334,925,145.94 |
| 固定資產清理 Liquidation of fixed assets | - | - |
| 合計 Total | 324,213,328.70 | 334,925,145.94 |

9.1 固定資產

9.1 Fixed assets

(1) 固定資產明細表

(1) Breakdown of fixed assets

| 項目 Items | 房屋建築物 Buildings and structures | 機器設備 Machinery and equipment | 運輸設備 Transportation facilities | 辦公設備 Office equipment | 合計 Total |
|--|-----------------------------------|---------------------------------|-----------------------------------|--------------------------|----------------|
| 一、賬面原值 I. Original book value | | | | | |
| 1.上年年末餘額 1.Closing balance of last year | 329,708,003.81 | 92,147,844.52 | 16,679,754.04 | 9,570,125.51 | 448,105,727.88 |
| 2.本期增加金額 2. Addition for the period | - | 32,670.44 | 1,518,671.72 | 72,720.10 | 676,894.08 |
| (1) 購置 (1) Purchase | - | 32,670.44 | 571,503.54 | 72,720.10 | 676,894.08 |
| (2) 其他增加 (2) Other addition | | | 947,168.18 | | |
| 3.本期減少金額 3. Reduction for the period | - | 979,089.58 | 1,588,711.39 | 82,250.00 | 1,702,882.79 |
| (1) 處置或報廢 (1) Disposal or retirement | - | 31,921.40 | 1,588,711.39 | 82,250.00 | 1,702,882.79 |
| (2) 其他減少 (2) Other deduction | - | 947,168.18 | - | - | - |
| 4.期末餘額 4.Closing balance | 329,708,003.81 | 91,201,425.38 | 16,609,714.37 | 9,560,595.61 | 447,079,739.17 |
| 二、累計折舊 II. Accumulated depreciation | | | | | |
| 1.上年年末餘額 1.Closing balance of last year | 55,115,300.08 | 40,705,973.13 | 9,009,031.80 | 8,350,276.93 | 113,180,581.94 |
| 2.本期增加金額 2. Addition for the period | 5,493,811.27 | 4,344,436.86 | 814,288.64 | 493,794.38 | 11,146,331.15 |
| (1) 計提 (1) Accrue | 5,493,811.27 | 4,344,436.86 | 814,288.64 | 493,794.38 | 11,146,331.15 |
| 3.本期減少金額 3. Reduction for the period | - | 25,227.87 | 1,353,024.75 | 82,250.00 | 1,460,502.62 |
| (1) 處置或報廢 (1) Disposal or retirement | - | 25,227.87 | 1,353,024.75 | 82,250.00 | 1,460,502.62 |
| (2) 其他減少 (2) Other deduction | - | - | - | - | - |
| 4.期末餘額 4.Closing balance | 60,609,111.35 | 45,025,182.12 | 8,470,295.69 | 8,761,821.31 | 122,866,410.47 |
| 三、減值準備 III. Impairment provision | | | | | |
| 1.上年年末餘額 1.Closing balance of last year | - | - | - | - | - |
| 2.本期增加金額 2. Addition for the period | - | - | - | - | - |
| 3.本期減少金額 3. Reduction for the period | - | - | - | - | - |
| 4.期末餘額 4.Closing balance | - | - | - | - | - |
| 四、賬面價值 IV. Book value | | | | | |
| 1.期末賬面價值 1.Closing balance of book value | 269,098,892.46 | 46,176,243.26 | 8,139,418.68 | 798,774.30 | 324,213,328.70 |
| 2.上年年末賬面價值 2.Closing balance of last year of book value | 274,592,703.73 | 51,441,871.39 | 7,670,722.24 | 1,219,848.58 | 334,925,145.94 |

註 1：本期增加的累計折舊中，本期計提人民幣 11,146,331.15 元。本期減少主要系固定資產處置。期末已提足折舊仍繼續使用的固定資產原值人民幣 10,936,573.26 元。

註 2：固定資產抵押情況見附註六、45。

(2) 本集團不存在暫時閑置的固定資產。

(3) 本集團不存在通過經營租賃租出的固定資產。

Note 1: Of the increase in accumulated depreciation for the period, RMB 11,146,331.15 was recognized in the current period. The decrease in the current period was mainly due to the disposal of fixed assets. At the end of the period, the original value of fully depreciated fixed assets still in use was RMB10,936,573.26.

Note 2: For the fixed assets mortgage, see Note VI. 45.

(2) The Group has no fixed assets that are temporarily idle.

(3) The Group has no fixed assets leased out through operating leases.

10. 使用權資產

10. Right-of-use assets

| 項目 Items | 房屋建築物 Buildings and structures | 合計 Total |
|--|-----------------------------------|----------------------|
| 一、賬面原值 I. Original book value | | |
| 1. 上年年末餘額 1. Closing balance of last year | 23,594,134.98 | 23,594,134.98 |
| 2. 本期增加金額 2. Addition for the period | - | - |
| (1) 租入 (1) New lease | - | - |
| 3. 本期減少金額 3. Reduction for the period | - | - |
| (1) 處置 (1) Disposal | - | - |
| 4. 期末餘額 4. Closing balance | 23,594,134.98 | 23,594,134.98 |
| 二、累計折舊 II. Accumulated depreciation | - | - |
| 1. 上年年末餘額 1. Closing balance of last year | 10,082,951.37 | 10,082,951.37 |
| 2. 本期增加金額 2. Addition for the period | 1,470,228.70 | 1,470,228.70 |
| (1) 計提 (1) Addition for the period | 1,470,228.70 | 1,470,228.70 |
| 3. 本期減少金額 3. Reduction for the period | - | - |
| (1) 處置 (1) Disposal | - | - |
| 4. 期末餘額 4. Closing balance | 11,553,180.07 | 11,553,180.07 |
| 三、賬面價值 III. Book value | - | - |
| 1. 期末賬面價值 1. Closing balance of book value | 12,040,954.91 | 12,040,954.91 |
| 2. 上年年末賬面價值 2. Closing balance of last year of book value | 13,511,183.61 | 13,511,183.61 |

11. 無形資產

11. Intangible assets

(1) 無形資產明細

(1) Details of intangible assets

| 項目 Items | 土地使用權 Land use rights | 計算機軟件 Computer software | 客戶資源 Customer resources | 合計 Total |
|--|--------------------------|----------------------------|----------------------------|----------------|
| 一、賬面原值 I. Original book value | | | | |
| 1. 上年年末餘額 1. Closing balance of last year | 164,253,763.65 | 18,814,928.89 | 2,697,830.16 | 185,766,522.70 |
| 2. 本期增加金額 2. Addition for the period | | | | |
| (1) 購置 (1) Purchase | | | | |

| 項目 Items | 土地使用權 Land use rights | 計算機軟件 Computer software | 客戶資源 Customer resources | 合計 Total |
|--|--------------------------|----------------------------|----------------------------|-----------------------|
| 3.本期減少金額 3.Reduction for the period | | | | |
| (1) 其他減少 (1) Other reduction | | | | |
| 4.期末餘額 4.Closing balance | 164,253,763.65 | 18,814,928.89 | 2,697,830.16 | 185,766,522.70 |
| 二、累計攤銷 II.Accumulated amortization | | | | |
| 1.上年年末餘額 1.Closing balance of last year | 33,101,467.42 | 9,327,602.24 | 303,628.14 | 42,732,697.80 |
| 2.本期增加金額 2.Addition for the period | 2,160,139.66 | 920,426.63 | 134,891.51 | 3,215,457.80 |
| (1) 計提 (1) Addition for the period | 2,160,139.66 | 920,426.63 | 134,891.51 | 3,215,457.80 |
| 3.本期減少金額 3.Reduction for the period | | | | |
| (1) 其他減少 (1) Other reduction | | | | |
| 4.期末餘額 4.Closing balance | 35,261,607.08 | 10,248,028.87 | 438,519.65 | 45,948,155.60 |
| 三、減值準備 III. Impairment provision | | | | |
| 1.上年年末餘額 1.Balance as at 31December 2021 | | | | |
| 2.本年增加金額 2.Addition for the period | | | | |
| 3.本年減少金額 3.Reduction for the period | | | | |
| 4.期末餘額 4.Closing balance | | | | |
| 四、賬面價值 IV. Book value | | | | |
| 1.期末賬面價值 1.Closing balance of book value | 128,992,156.57 | 8,566,900.02 | 2,259,310.51 | 139,818,367.10 |
| 2.上年年末賬面價值 2.Closing balance of last year of book value | 131,152,296.23 | 9,487,326.65 | 2,394,202.02 | 143,033,824.90 |

註 1：截至 2022 年 6 月 30 日，本集團未存在內部研發形成的無形資產。

註 2：無形資產抵押情況見附註六、45。

Note 1: As at 30 June 2022, no intangible asset arose through the internal research and development of the Group.

Note 2: For the pledge of intangible assets, please refer to Note VI. 45.

12. 商譽

(1) 商譽原值

12. Goodwill

(1) Original value of goodwill

| 被投資單位名稱 Name of the investee | 上年年末餘額 Closing balance of last year | 本期增加 Addition for the period | | 本期減少 Reduction for the period | | 期末餘額 Closing balance |
|---|---|---|--------------|-------------------------------------|--------------|----------------------------|
| | | 企業合併形成的 As a result of business combination | 其他 Others | 處置 Disposal | 其他 Others | |
| 珠海創美公司 Zhuhai Charmacy Company | 4,567,297.19 | - | - | - | - | 4,567,297.19 |
| 廣州創美公司 Guangzhou Charmacy Company | 26,328.12 | - | - | - | - | 26,328.12 |
| 惠州創美公司 Huizhou Charmacy Company | 2,896,416.16 | - | - | - | - | 2,896,416.16 |
| 合計 Total | 7,490,041.47 | - | - | - | - | 7,490,041.47 |

(2) 商譽減值準備

(2) Provision for impairment of goodwill

| 被投資單位名稱 Name of the investee | 上年年末餘額 Closing balance of last year | 本期增加 Addition for the period | | 本期減少 Reduction for the period | | 期末餘額 Closing balance |
|---|---|------------------------------------|--------------|-------------------------------------|--------------|-------------------------|
| | | 計提 Accrued | 其他 Others | 處置 Disposal | 其他 Others | |
| 珠海創美公司 Zhuhai Charmacy Company | 1,465,937.31 | - | - | - | - | 1,465,937.31 |
| 廣州創美公司 Guangzhou Charmacy Company | - | - | - | - | - | - |
| 惠州創美公司 Huizhou Charmacy Company | - | - | - | - | - | - |
| 合計 Total | 1,465,937.31 | - | - | - | - | 1,465,937.31 |

註：公司於 2017 年 2 月、2017 年 6 月、2020 年 7 月分別收購珠海創美公司、廣州創美公司、惠州創美公司的股權，並形成了人民幣 456.73 萬元、人民幣 2.63 萬元、人民幣 289.64 萬元的商譽。商譽所在的資產組與該商譽初始確認時保持一致。本集團期末對商譽進行了減值測試，經測試，本期不存在減值情況。

Note: The Company acquired Zhuhai Charmacy Company, Guangzhou Charmacy Company and Huizhou Charmacy Company in February 2017, June 2017 and July 2020 respectively, resulting in a goodwill of RMB4.5673 million, RMB0.0263 million and RMB2.8964 million. The asset group a goodwill belongs to is the same with that at initial recognition of the goodwill. The Group carried out an impairment test of goodwill at the end of the period, finding no impairment in the period.

13. 長期待攤費用

13. Long-term expenses to be amortized

| 項目 Item | 上年年末餘額 Closing balance of last year | 本期增加 Addition for the period | 本期攤銷 Amortization for the period | 本期其他減少 Other reduction for the period | 期末餘額 Closing balance |
|--------------------------|--|---------------------------------|-------------------------------------|--|-------------------------|
| 裝修費用 Renovation costs | 19,214,660.88 | - | 1,443,002.26 | - | 17,771,658.62 |
| 合計 Total | 19,214,660.88 | - | 1,443,002.26 | - | 17,771,658.62 |

14. 遞延所得稅資產和遞延所得稅負債

14. Deferred income tax assets and deferred income tax liabilities

(1) 未經抵銷的遞延所得稅資產

(1) Deferred income tax assets not offset

| 項目 Items | 期末餘額 Closing balance | | 上年年末餘額 Closing balance of last year | |
|--|---------------------------------------|--|--|--|
| | 遞延所得稅資產 Deferred income tax assets | 可抵扣暫時性差異 Deductible temporary differences | 遞延所得稅資產 Deferred income tax assets | 可抵扣暫時性差異 Deductible temporary differences |
| 資產減值準備 Provision for asset Impairment | 8,028,953.61 | 32,115,814.36 | 8,026,399.26 | 32,105,596.95 |
| 政府補助 Government grants | 19,044.19 | 76,176.74 | 76,176.75 | 304,706.99 |
| 可抵扣虧損 Deductible losses | 597,888.65 | 2,391,554.60 | 57,743.53 | 230,974.12 |
| 合計 Total | 8,645,886.45 | 34,583,545.70 | 8,160,319.54 | 32,641,278.06 |

(2) 未經抵銷的遞延所得稅負債

(2) Deferred income tax liabilities not offset

| 項目 Items | 期末餘額 Closing balance | | 上年年末餘額 Closing balance of last year | |
|---|--|---|--|---|
| | 遞延所得稅負債 Deferred income tax liabilities | 應納稅暫時性差異 Taxable temporary differences | 遞延所得稅負債 Deferred income tax liabilities | 應納稅暫時性差異 Taxable temporary differences |
| 未實現的內部銷售損益 Unrealized internal sales gains and losses | - | - | 390,019.44 | 1,560,077.77 |
| 非同一控制企業合併資產評估增值 Asset assessment gains arising from business combinations not under common control | 12,890.18 | 51,560.69 | 12,890.18 | 51,560.69 |
| 合計 Total | 12,890.18 | 51,560.69 | 402,909.62 | 1,611,638.46 |

15.短期借款

(1) 短期借款分類

| 借款類別 Types of borrowings | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|---|-------------------------|--|
| 信用借款 Credit borrowings | 60,107,687.51 | 60,115,981.25 |
| 保證借款 Guaranteed borrowings | 229,759,868.06 | 265,327,763.35 |
| 抵押借款 Secured borrowings | 138,676,799.21 | 138,710,365.07 |
| 質押借款 Pledged borrowings | 55,629,279.45 | 70,266,291.68 |
| 應收票據貼現借款 Borrowings from discounted bills receivables | 31,313,082.47 | 133,618,874.72 |
| 合計 Total | 515,486,716.70 | 668,039,276.07 |

(2) 本集團期末未存在已逾期未償還的短期借款。

15.Short-term borrowings

(1) Types of borrowings

(2) The Group had no overdue short-term borrowings at the end of the period.

16.應付票據

| 票據種類 Classification of bills | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|---------------------------------|-------------------------|--|
| 銀行承兌匯票 Bank acceptance bills | 818,410,573.01 | 809,768,308.81 |
| 合計 Total | 818,410,573.01 | 809,768,308.81 |

註：本集團上述期末應付票據的賬齡均在1年之內。

16.Bills payables

Note: As at the end of the period, the age of the aforementioned bills payables of the Group was within 1 year.

17.應付賬款

(1) 應付賬款

| 項目 Items | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|------------------------|-------------------------|--|
| 貨款 Loans | 508,622,108.61 | 525,003,330.09 |
| 設備款 Equipment costs | 6,246,735.49 | 7,856,953.98 |
| 合計 Total | 514,868,844.10 | 532,860,284.07 |

17.Trade payables

(1) Trade payables

(2) 應付賬款賬齡分析

於 2022 年 6 月 30 日，應付賬款按交易日期的賬齡分析如下：

(2) Aging analysis of trade payables

Below is an aging analysis of trade payables based on transaction date as at 30 June 2022:

| 賬齡 Age | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|----------------------------|-------------------------|--|
| 1 年以內 Within 1 year | 495,324,187.12 | 530,047,558.14 |
| 1-2 年 1 to 2 years | 18,339,006.57 | 2,040,818.31 |
| 2-3 年 2 to 3 years | 673,750.48 | 308,387.62 |
| 3 年以上 More than 3 years | 531,899.93 | 463,520.00 |
| 合計 Total | 514,868,844.10 | 532,860,284.07 |

註：本集團賬齡超過一年的應付帳款，主要為尚未結算的應付貨款。

Note: Accounts payable aged over one year of the Group are mainly unsettled trade payables.

18. 合同負債

(1) 合同負債情況

18. Contract liabilities

(1) Contract liabilities

| 項目 Items | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|-------------------------|-------------------------|--|
| 貨款 Payment for goods | 67,641,555.74 | 46,664,141.17 |
| 合計 Total | 67,641,555.74 | 46,664,141.17 |

註：於 2022 年 6 月 30 日，本集團無賬齡超過 1 年以上的重大合同負債。

Note: As at 30 June 2022, the Group had no significant contract liabilities aged over 1 year.

19. 應付職工薪酬

19. Salaries payable to employees

(1) 應付職工薪酬分類

(1) Classification of salaries payable to employees

| 項目 Items | 上年年末餘額 Closing balance of last year | 本期增加 Addition for the period | 本期減少 Reduction for the period | 期末餘額 Closing balance |
|---|--|---------------------------------|----------------------------------|-------------------------|
| 短期薪酬 Short-term remuneration | 5,180,138.03 | 35,830,834.29 | 36,340,819.95 | 4,670,152.37 |
| 離職後福利-設定提存計劃 Post-employment benefits – Defined contribution plan | - | 2,885,300.50 | 2,885,300.50 | - |
| 辭退福利 Termination benefits | - | - | - | - |
| 一年內到期的其他福利 Other benefits due within one year | - | - | - | - |
| 合計 Total | 5,180,138.03 | 38,716,134.79 | 39,226,120.45 | 4,670,152.37 |

(2) 短期薪酬

(2) Short-term remuneration

| 項目 Items | 上年年末餘額 Closing balance of last year | 本期增加 Addition for the period | 本期減少 Reduction for the period | 期末餘額 Closing balance |
|---|--|---------------------------------|----------------------------------|-------------------------|
| 工資、獎金、津貼和補貼 Salaries, bonuses, allowances and subsidies | 5,123,511.67 | 29,648,354.58 | 30,154,451.44 | 4,617,414.81 |
| 職工福利費 Staff welfare payments | - | 2,398,125.02 | 2,398,125.02 | - |
| 社會保險費 Social insurance premiums | - | 1,334,784.72 | 1,334,784.72 | - |
| 其中：醫療保險費 Of which: medical insurance premium | - | 1,315,259.96 | 1,315,259.96 | - |
| 工傷保險費 Industrial injury insurance premium | - | 19,524.76 | 19,524.76 | - |
| 住房公積金 Housing provident fund | - | 784,974.00 | 784,974.00 | - |
| 工會經費和職工教育經費 Labor union expenses and staff education expenses | 56,626.36 | 329,811.25 | 333,700.05 | 52,737.56 |
| 短期帶薪缺勤 Short-term paid absences | - | - | - | - |
| 短期利潤分享計劃 Short-term profit sharing program | - | - | - | - |
| 其他 Others | - | - | - | - |
| 合計 Total | 5,180,138.03 | 35,830,834.29 | 36,340,819.95 | 4,670,152.37 |

(3) 設定提存計劃

本集團按規定參加政府機構設立的社會保險計劃。根據計劃，本集團按照當地政府的有關規定向該等計劃繳存費用。除上述繳存費用外，本集團不再承擔進一步支付義務。相應的支出於發生時計入當期損益或相關資產成本。本集團本期應分別向養老保險、失業保險計劃繳存費用如下：

(3) Defined contribution plan

The Group participated in social insurance plans operated by the government authorities according to the regulations. Pursuant to the plans, the Group made contributions to those plans in compliance with the relevant provisions of local government authorities. Apart from the aforesaid contributions, the Group assumed no further payment obligations. The corresponding expenses shall be credited to the profit or loss for the period or the cost of related assets when incurred. The Group's contributions payable to pension insurance plan and unemployment insurance plan for the period are respectively as follows:

| 項目 Items | 上年年末餘額 Closing balance of last year | 本期增加 Addition for the period | 本期減少 Reduction for the period | 期末餘額 Closing balance |
|---|--|---------------------------------|----------------------------------|-------------------------|
| 基本養老保險 Basic pension insurance | - | 2,838,472.80 | 2,838,472.80 | - |
| 失業保險費 Unemployment insurance premium | - | 46,827.70 | 46,827.70 | - |
| 合計 Total | - | 2,885,300.50 | 2,885,300.50 | - |

註 1：本集團本年度應向參與的設定提存計劃繳存費用人民幣 2,885,300.50 元。於 2022 年 6 月 30 日，本集團計劃繳納的養老保險和失業保險已經全部支付完畢。

Note 1: The Group's contribution payable to the defined contribution plan that the Group participated in amounted to RMB2,885,300.50. The pension insurance and unemployment insurance, which was fully paid as at 30 June 2022.

註 2：於截至 2022 年 6 月 30 日止六個月，本集團無界定供款計劃項下的沒收供款（由僱主代表於完全歸屬該供款前離開計劃的僱員）可供本集團以降低現有的供款水平。

Note 2: For six month end 30 June 2022, the Group has no forfeited contribution (for employers on behalf of employees who leave the plan before fully attributing the contribution) under the defined contribution plan are available to the Group to reduce the existing level of contributions.

20.應交稅費

20.Tax payables

| 項目 Items | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|---|-------------------------|--|
| 增值稅 VAT | 53,787,167.39 | 37,521,680.24 |
| 企業所得稅 Enterprise income tax | 5,081,472.51 | 6,407,752.76 |
| 個人所得稅 Individual income tax | 58,946.16 | 83,035.55 |
| 房產稅 Property taxes | 2,015,781.41 | 34,695.43 |
| 土地使用稅 land use tax | 164,079.77 | - |
| 印花稅 Stamp duty | 364,980.30 | 373,372.52 |
| 城市維護建設稅 Urban maintenance and construction tax | 143,605.21 | 79,444.38 |
| 教育費附加 Education surcharge | 102,638.44 | 56,968.58 |
| 其他稅費 Local education surcharge | 1,050.00 | 1,050.00 |
| 合計 Total | 61,719,721.19 | 44,557,999.46 |

21.其他應付款

21.Other payables

| 項目 Items | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|---------------------------|-------------------------|--|
| 應付利息 Interest payables | - | - |
| 應付股利 Dividend payables | - | - |
| 其他應付款 Other payables | 12,875,096.44 | 11,030,236.31 |
| 合計 Total | 12,875,096.44 | 11,030,236.31 |

21.1 其他應付款

21.1 Other payables

(1) 其他應付款按款項性質分類

(1) Classification of other payables by nature of payment

| 單位名稱 Nature of payment | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|-------------------------------|-------------------------|--|
| 保證金 Margin | 5,000,120.28 | 5,293,212.78 |
| 中介費用 Intermediary expenses | 3,393,009.00 | 4,386,817.89 |
| 股權轉讓款 Equity transfers | 407,535.18 | 407,535.18 |
| 運輸費 Transportation costs | 6,660.00 | 207,748.72 |
| 其他 Others | 4,067,771.98 | 734,921.74 |
| 合計 Total | 12,875,096.44 | 11,030,236.31 |

22.一年內到期的非流動負債

22.Non-current liabilities due within one year

| 項目 Item | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|--|-------------------------|--|
| 一年內到期的長期借款 Long-term borrowings due within one year | 31,751,186.98 | 31,783,826.75 |
| 一年內到期的租賃負債 Lease liabilities due within one year | 2,877,501.20 | 2,974,226.92 |
| 合計 Total | 34,628,688.18 | 34,758,053.67 |

註：本集團自資產負債表日起一年內到期應予以清償的租賃負債的期末賬面價值，在“一年內到期的非流動負債”項目反映。

Note: The closing book value of the Group's lease liabilities due for settlement within one year from the balance sheet date is reflected in the item "Non-current liabilities due within one year".

23.其他流動負債

23. Other current liabilities

| 項目 Item | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|--|-------------------------|--|
| 待轉銷項稅額 The amount of tax to be resold | 8,793,402.24 | 6,066,338.36 |
| 合計 Total | 8,793,402.24 | 6,066,338.36 |

24.長期借款

24.Long-term borrowings

(1) 長期借款分類

(1) Classification of long-term borrowings

| 借款類別 Types of borrowings | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|--|-------------------------|--|
| 抵押借款 Secured borrowings | 102,824,524.32 | 118,651,241.79 |
| 小計 Subtotal | 102,824,524.32 | 118,651,241.79 |
| 減：一年內到期的長期借款 Less: long-term borrowings due within one year | 31,751,186.98 | 31,783,826.75 |
| 合計 Total | 71,073,337.34 | 86,867,415.04 |

註：2018年8月15日，創美藥業股份有限公司與中國工商銀行股份有限公司廣東自由貿易試驗區南沙分行簽

Note: On 15 August 2018, Charmacy Pharmaceutical Co., Ltd. signed the Fixed Assets Loan Contract (《固定資產借款合同》) with the Nansha Branch in Guangdong Pilot Free Trade

署《固定資產借款合同》，協議約定貸款資金主要用於廣州南沙分揀配送中心項目建設。

Zone of Industrial and Commercial Bank of China Limited. The loan funds agreed in the agreement are mainly used for the construction of Guangzhou Nansha Sorting and Delivery Centre project.

(2) 長期借款到期日分析

(2) Analysis of long-term borrowings' maturity date

| 項目 Items | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|--|-------------------------|--|
| 資產負債表日後一年內 Within one year after the balance sheet date | 31,751,186.98 | 31,783,826.75 |
| 資產負債表日後超過一年，但不超過兩年 Over one year but not more than two years after the balance sheet date | 39,485,191.65 | 31,588,152.92 |
| 資產負債表日後超過兩年，但不超過五年 Over two years but not more than five years after the balance sheet date | 31,588,145.69 | 55,279,262.12 |
| 資產負債表日後超過五年 Over five years after the balance sheet date | - | - |
| 減：流動負債項下所示一年內到期的款項 Less: Current liabilities due within one year | 31,751,186.98 | 31,783,826.75 |
| 非流動負債項下所示款項 Amounts shown under non-current liabilities | 71,073,337.34 | 86,867,415.04 |

註：一年內到期的長期借款已重分類至“一年內到期的非流動負債”，參見本附註六、22。

Note: The long-term borrowings due within one year have been reclassified to “non-current liabilities due within one year” as shown in Note VI. 22.

25.租賃負債

25. Lease liabilities

| 項目 Items | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|---|-------------------------|--|
| 資產負債表日後第1年 First year after the balance sheet date | 2,877,501.20 | 3,726,243.13 |
| 資產負債表日後第2年 Second year after the balance sheet date | 3,412,339.21 | 3,736,689.52 |
| 資產負債表日後第3年 Third year after the balance sheet date | 2,517,061.72 | 3,300,800.04 |
| 以後年度 Subsequent years | 5,361,233.81 | 6,900,760.13 |
| 最低租賃付款額合計 Total minimum lease payments | 15,978,272.43 | 17,664,492.82 |
| 減：未確認融資費用 Less: finance costs not recognized | 1,810,136.49 | 2,200,531.27 |
| 最低租賃付款額現值 Present value of minimum lease payments | 14,168,135.94 | 15,463,961.55 |
| 其中：一年內到期的租賃負債 Including: lease liabilities due within one year | 2,877,501.20 | 2,974,226.92 |
| 一年後到期的租賃負債 Lease liabilities due after one year | 11,290,634.74 | 12,489,734.63 |

註：一年內到期的租賃負債已重分類至“一年內到期的非流動負債”，參見本附註六、22。

Note: The lease liabilities due within one year have been reclassified to “non-current liabilities due within one year” as shown in Note VI.22.

26.遞延收益

26. Deferred income

(1) 遞延收益分類

(1) Classification of deferred income

| 項目 Item | 上年年末餘額 Closing balance of last year | 本期增加 Addition for the period | 本期減少 Reduction for the period | 期末餘額 Closing balance | 形成原因 Reason for formation |
|---------------------------|--|---------------------------------|----------------------------------|-------------------------|------------------------------|
| 政府補助 Government grants | 304,706.99 | - | 228,530.25 | 76,176.74 | 與資產相關 Related to assets |
| 合計 Total | 304,706.99 | - | 228,530.25 | 76,176.74 | — |

(2) 政府補助項目

(2) Government grant program

| 政府補助項目 Government grant program | 上年年末餘額 Closing balance of last year | 本期新增補助金額 Addition of grant for the period | 本期計入營業外收入金額 Included in Non-operating income for the period | 本期計入其他收益金額 Included in other income for the period | 本期沖減成本費用金額 Amount of costs offset in the period | 其他變動 Other changes | 期末餘額 Closing balance | 與資產相關 / 與收益相關 Asset-related/ Revenue-related |
|--|--|--|--|---|--|-----------------------|-------------------------|---|
| 物流標準化項目政府補助 Government grants for logistics standardization program | 304,706.99 | - | - | 228,530.25 | - | - | 76,176.74 | 與資產相關 Related to assets |
| 合計 Total | 304,706.99 | - | - | 228,530.25 | - | - | 76,176.74 | — |

27.股本

27.Share capital

| 項目 Item | 上年年末餘額 Closing balance of last year | 本期變動增減 (+、-) Increase/decrease in the period (+, -) | | | | | 期末餘額 Closing balance |
|--------------------------------|--|--|--------------------|--|--------------|----------------|-------------------------|
| | | 發行新股 Issuance of new shares | 送股 Bonus shares | 公積金轉股 Shares transferred from surplus reserve | 其他 Others | 小計 Subtotal | |
| 股份總額 Total number of shares | 108,000,000.00 | - | - | - | - | - | 108,000,000.00 |
| 合計 Total | 108,000,000.00 | - | - | - | - | - | 108,000,000.00 |

28.資本公積

28.Capital reserve

| 項目 Items | 上年年末餘額 Closing balance of last year | 本期增加 Addition for the period | 本期減少 Reduction for the period | 期末餘額 Closing balance |
|---------------------------------|--|---------------------------------|----------------------------------|-------------------------|
| 股本溢價 Share premium | 278,001,901.04 | - | - | 278,001,901.04 |
| 其他資本公積 Other capital reserve | 988,928.00 | - | - | 988,928.00 |
| 合計 Total | 278,990,829.04 | - | - | 278,990,829.04 |

29.盈餘公積

29.Surplus reserve

| 項目 Item | 上年年末餘額 Closing balance of last year | 本期增加 Addition for the period | 本期減少 Reduction for the period | 期末餘額 Closing balance |
|--|---|------------------------------------|-------------------------------------|-------------------------|
| 法定盈餘公積 Statutory surplus reserve | 21,080,432.34 | - | - | 21,080,432.34 |
| 合計 Total | 21,080,432.34 | - | - | 21,080,432.34 |

30.未分配利潤

30.Undistributed profits

| 項目 Items | 本期金額 Closing balance | 上年度金額 Closing balance of last year |
|---|-------------------------|--|
| 上年年末餘額 Balance at the end of last year | 96,030,718.25 | 97,118,259.82 |
| 加：年初未分配利潤調整數 Add: Adjustment to the balance of undistributed profit at the beginning of the year | - | - |
| 本年年初餘額 Balance at the beginning of the year | 96,030,718.25 | 97,118,259.82 |
| 加：本期歸屬於母公司所有者的淨利潤 Add: Net profit attributable to the owners of the parent company for the period | 20,639,327.13 | 23,153,060.07 |
| 減：提取法定盈餘公積 Less: Appropriation of statutory surplus reserve | - | 2,640,601.64 |
| 應付普通股股利 Dividends payable on ordinary shares | - | 21,600,000.00 |
| 轉作股本的普通股股利 Dividends on ordinary shares converted to share capital | - | - |
| 本期期末餘額 Ending balance of current period | 116,670,045.38 | 96,030,718.25 |

31.營業收入、營業成本

31.Operating revenue and operating cost

(1) 營業收入和營業成本情況

(1)Basic information on business revenue and business expenses

| 項目 Items | 本期金額 Current period | | 上期金額 Prior period | |
|------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| | 收入 Revenue | 成本 Cost | 收入 Revenue | 成本 Cost |
| 主營業務 Principal businesses | 1,868,014,100.74 | 1,762,707,467.23 | 1,978,105,883.41 | 1,857,967,782.94 |
| 其他業務 Other businesses | 19,065,285.48 | - | 14,908,237.18 | - |
| 合計 Total | 1,887,079,386.22 | 1,762,707,467.23 | 1,993,014,120.59 | 1,857,967,782.94 |

32. 税金及附加

32. Taxes and surcharges

| 項目 Items | 本期金額 Current period | 上期金額 Prior period |
|--|------------------------|----------------------|
| 印花稅 Stamp duty | 1,449,731.63 | 1,494,035.83 |
| 房產稅 Property tax | 2,011,345.80 | 2,028,693.54 |
| 城市維護建設稅 Urban maintenance and construction tax | 706,449.96 | 403,447.11 |
| 教育費附加 Education surcharge | 303,096.50 | 172,998.49 |
| 地方教育費附加 Local education surcharge | 202,064.30 | 115,332.32 |
| 土地使用稅 Tax on land use | 164,079.78 | 164,079.78 |
| 車船稅 Vehicle and vessel tax | 4,689.60 | 6,156.00 |
| 環境保護稅 Environment protection tax | 2,100.00 | 2,100.00 |
| 合計 Total | 4,843,557.57 | 4,386,843.07 |

33. 銷售費用

33. Selling expenses

| 項目 Items | 本期金額 Current period | 上期金額 Prior period |
|--|------------------------|----------------------|
| 職工薪酬 Staff remuneration | 26,299,677.32 | 26,346,332.08 |
| 運輸費 Transportation costs | 6,332,864.29 | 6,673,975.85 |
| 辦公費用 Office expenses | 2,876,508.51 | 3,561,236.17 |
| 折舊與攤銷 Depreciation and amortization | 13,196,627.76 | 13,198,893.14 |
| 宣傳廣告費 Promotion and advertising expenses | 55,890.48 | 224,180.34 |
| 業務招待費 Business entertainment expenses | 298,284.92 | 423,099.42 |
| 差旅費 Travelling expenses | 108,046.49 | 150,265.72 |
| 其他 Others | 4,641,220.46 | 1,706,925.45 |
| 合計 Total | 53,809,120.23 | 52,284,908.17 |

34.管理費用

34.Management expenses

| 項目 Items | 本期金額 Current period | 上期金額 Prior period |
|--|------------------------|----------------------|
| 職工薪酬 Staff remuneration | 10,574,008.72 | 11,319,863.19 |
| 辦公費 Office expenses | 2,651,942.93 | 3,454,009.11 |
| 折舊與攤銷 Depreciation and amortization | 3,724,133.56 | 3,227,085.27 |
| 聘請中介機構費 Expenses on engaging intermediary agencies | 1,263,849.39 | 814,981.29 |
| 其中：審計師酬金 Of which: Auditor's remuneration | 41,499.52 | 70,012.34 |
| -審計服務費用 - Audit service expenses | 41,499.52 | 70,012.34 |
| 差旅費 Travelling expenses | 29,028.77 | 60,993.65 |
| 業務招待費 Business entertainment expenses | 64,846.52 | 56,525.36 |
| 宣傳廣告費 Promotion and advertising expenses | 88,264.53 | 33,543.24 |
| 存貨損失 Loss on inventory | - | - |
| 其他 Others | 5,600.00 | 21,948.18 |
| 合計 Total | 18,401,674.42 | 18,988,949.29 |

35.財務費用

35.Finance costs

| 項目 Items | 本期金額 Current period | 上期金額 Prior period |
|--|------------------------|----------------------|
| 利息支出 Interest expenses | 17,152,560.51 | 20,300,388.76 |
| 減：利息收入 Less: Interest income | 2,641,344.75 | 1,921,670.20 |
| 加：匯兌損失 Add: Loss on foreign exchange | 766,124.39 | -240,579.13 |
| 加：手續費 Add: Handling fees | 3,389,516.20 | 3,190,283.75 |
| 加：租賃負債利息 Add: Interest on lease liabilities | 393,620.01 | 467,673.23 |
| 合計 Total | 19,060,476.36 | 21,796,096.41 |

36.其他收益

36.Other gains

| 項目 Items | 本期金額 Current period | 上期金額 Prior period |
|--|------------------------|----------------------|
| 物流標準化項目政府補助 Government grants for logistics standardization program | 228,530.25 | 228,530.25 |
| 代扣代繳個人所得稅手續費返還 Individual income tax fee refund | 67,031.95 | 66,654.59 |
| 合計 Total | 295,562.20 | 295,184.84 |

37.信用減值損失

37.Impairment loss of credit

| 項目 Items | 本期金額 Current period | 上期金額 Prior period |
|---|------------------------|----------------------|
| 應收票據壞賬損失 Loss of bad debts in bills receivable | 49,170.00 | - |
| 應收賬款壞賬損失 Loss of bad debts in accounts receivable | -278,256.87 | - |
| 其他應收款壞賬損失 Loss of bad debts in bills receivable in other receivables | - | - |
| 壞賬損失 Loss of bad debts | - | -247,245.69 |
| 合計 Total | -229,086.87 | -247,245.69 |

38.資產減值損失

38.Impairment loss of assets

| 項目 Item | 本期金額 Current period | 上期金額 Prior period |
|---|------------------------|----------------------|
| 存貨跌價損失 Loss on impairment of inventories | -2,845,084.18 | -3,136,215.98 |
| 合計 Total | -2,845,084.18 | -3,136,215.98 |

39. 資產處置收益

39. Gains on disposal of assets

| 項目 Items | 本期金額 Current period | 上期金額 Prior period | 計入本期非經常性損益的金額 Amount charged to non-recurring profit or loss for the period |
|---|------------------------|----------------------|--|
| 非流動資產處置收益 Gains on disposal of noncurrent assets | 20,894.19 | -11,149.73 | 20,894.19 |
| 其中：未劃分為持有待售的非流動資產處置收益 Of which: Gains on disposal of non-current assets that are not classified as held for sale | 20,894.19 | -11,149.73 | 20,894.19 |
| 固定資產處置收益 Gains on disposal of fixed assets | 20,894.19 | -11,149.73 | 20,894.19 |
| 合計 Total | 20,894.19 | -11,149.73 | 20,894.19 |

40. 營業外收入

40. Non-operating revenue

(1) 營業外收入明細

(1) Breakdown of non-operating income

| 項目 Items | 本期金額 Current period | 上期金額 Prior period | 計入本期非經常性損益的金額 Amounts included in non-recurring profit and loss for the period |
|---------------------------|------------------------|----------------------|---|
| 政府補助 Government grants | 588,642.63 | 40,526.40 | 588,642.63 |
| 其他 Others | 150.81 | 28,865.64 | 150.81 |
| 合計 Total | 588,793.44 | 69,392.04 | 588,793.44 |

41. 營業外支出

41. Non-operating expenses

| 項目 Items | 本期金額 Current period | 上期金額 Prior period | 計入本期非經常性損益的金額 Amounts included in non-recurring profit and loss for the period |
|--|------------------------|----------------------|---|
| 非流動資產毀損報廢損失 Loss of non-current assets due to destruction and scrapping | - | - | - |
| 對外捐贈 External donation | 240,289.95 | 28,920.00 | 240,289.95 |
| 其他 Others | 3.85 | 117.34 | 3.85 |
| 合計 Total | 240,293.80 | 29,037.34 | 240,293.80 |

42. 所得稅費用

42. Income tax expenses

(1) 所得稅費用

(1) Income tax expenses

| 項目 Items | 本期金額 Current period | 上期金額 Prior period |
|--|------------------------|----------------------|
| 按稅法及相關規定計算的當期所得稅 Current income tax calculated according to the tax law and related regulations | 6,367,110.46 | 9,664,994.87 |
| -中國大陸企業所得稅 Corporate income tax in the Chinese mainland | 6,367,110.46 | 9,664,994.87 |
| -中國香港利得稅 Profit tax in Hong Kong, PRC | - | - |
| 遞延所得稅費用 Deferred income tax expenses | -1,158,562.20 | -1,095,906.07 |
| 合計 Total | 5,208,548.26 | 8,569,088.80 |

由於本集團截至 2021 年及 2022 年 6 月 30 日止六個月在香港無應納稅收入，故並無香港所得稅。

The Group had no Hong Kong income tax, since it had no taxable income in Hong Kong for the six months ended 30 June 2021 and 2022.

(2) 會計利潤與所得稅費用調整過程

(2) Reconciliation between accounting profit and income tax expenses

| 項目 Items | 本期金額 Current period |
|--|------------------------|
| 本期合併利潤總額 Combined total profit for the period | 25,847,875.39 |
| 按法定/適用稅率計算的所得稅費用 Income tax expenses calculated at statutory/applicable tax rate | 6,367,110.46 |
| 子公司適用不同稅率的影響 The impact of different tax rates applied to subsidiaries | - |
| 調整以前期間所得稅的影響 Adjust the impact of income taxes for previous periods | - |
| 非應稅收入的影響 Impact of non-taxable income | - |
| 不可抵扣的成本、費用和損失的影響 Effect of non-deductible costs, expenses and losses | - |
| 使用前期未確認遞延所得稅資產的可抵扣虧損的影響 Use of deductible losses that have not been previously confirmed for deferred EIT assets | - |
| 本期未確認遞延所得稅資產的可抵扣暫時性差異或可抵扣虧損的影響 Effect of deductible temporary differences or deductible losses on deferred income tax assets not recognized in the current period | -1,158,562.20 |
| 所得稅費用 Income tax expenses | 5,208,548.26 |

43. 淨資產收益率及每股收益

按照中國證券監督管理委員會《公開發行證券的公司信息披露編報規則第9號—淨資產收益率和每股收益的計算及披露（2010年修訂）》的規定，本集團加權平均淨資產收益率、基本每股收益和稀釋每股收益如下：

43. Return On Net Assets And Earnings Per Share

In accordance with the requirements of the “Preparation Rules for Information Disclosures by Companies Offering Shares to the Public No.9 – Calculations and Disclosures for Return on Net Assets and Earnings Per Share (Revised in 2010)” (《公開發行證券的公司信息披露編報規則第9號—淨資產收益率和每股收益的計算及披露（2010年修訂）》) issued by the China Securities Regulatory Commission, the weighted average return on net assets, basic earnings per share and diluted earnings per share of the Group are as follows:

| 報告期利潤 Profit for the reporting period | 加權平均 淨資產收益率 Weighted average return on net asset (%) | 每股收益 Earnings per share | |
|---|---|---------------------------------------|---|
| | | 基本每股收益 Basic earnings per share | 稀釋每股收益 Diluted earnings per share |
| 歸屬於母公司股東的淨利潤 Net profit attributable to the shareholders of parent company | 4.04 | 0.1911 | 0.1911 |
| 扣除非經常性損益後歸屬於母 公司股東的淨利潤 Net profit attributable to the shareholders of parent company (excluding non-recurring profit and loss) | 3.94 | 0.1865 | 0.1865 |

44. 合併現金流量表補充資料

44. Supplementary information to the Consolidated Statement of Cash Flows

| 項目 Items | 本期金額 Current period | 上期金額 Prior period |
|--|------------------------|----------------------|
| 1.將淨利潤調節為經營活動現金流量： 1. Reconciliation of net profit to cash flows from operating activities: | | |
| 淨利潤 Net profit | 20,639,327.13 | 25,961,380.05 |
| 加：資產減值準備 Add: Provision for impairment on assets | 229,086.87 | 3,136,215.98 |
| 信用資產減值損失 Impairment loss of credit assets | 2,845,084.18 | 247,245.69 |

| 項目 Items | 本期金額 Current period | 上期金額 Prior period |
|--|------------------------|------------------------|
| 固定資產折舊、油氣資產折耗、生產性生物資產折舊 Depreciation of fixed assets, depletion of petroleum and natural gas properties, depreciation of productive biological assets | 10,677,060.85 | 10,463,957.87 |
| 使用權資產折舊 Depreciation of right-of-use assets | 1,470,228.70 | 1,470,228.70 |
| 無形資產攤銷 Amortization of intangible assets | 3,215,457.82 | 3,227,554.98 |
| 長期待攤費用攤銷 Amortization of long-term expenses to be amortized | 1,896,362.57 | 1,264,236.86 |
| 處置固定資產、無形資產和其他長期資產的損失（收益以「-」填列） Loss on disposal of fixed assets, intangible assets and other long-term assets ("-" for gain) | -20,894.19 | 11,149.73 |
| 固定資產報廢損失（收益以「-」填列） Loss on scrapped fixed assets ("-" for gain) | - | - |
| 公允價值變動損失（收益以「-」填列） loss arising from changes in fair value ("-" for gain) | - | - |
| 財務費用（收益以「-」填列） Finance costs ("-" for gain) | 13,183,277.97 | 21,796,096.41 |
| 投資損失（收益以「-」填列） Investment loss ("-" for gain) | - | - |
| 遞延所得稅資產的減少（增加以「-」填列） Decrease in deferred income tax assets ("-" for increase) | 18,165.93 | -797,339.12 |
| 遞延所得稅負債的增加（減少以「-」填列） Increase in deferred income tax liabilities ("-" for decrease) | - | -298,566.95 |
| 存貨的減少（增加以「-」填列） Decrease in inventories ("-" for increase) | -49,904,395.01 | -5,329,080.99 |
| 經營性應收項目的減少（增加以「-」填列） Decrease in receivables from operating activities ("-" for increase) | -240,954,501.25 | -153,733,582.43 |
| 經營性應付項目的增加（減少以「-」填列） Increase in payables from operating activities ("-" for decrease) | 205,265,013.79 | -17,221,770.42 |
| 其他 Others | | |
| 經營活動產生的現金流量淨額 Net cash flow from operating activities | -31,440,724.64 | -109,802,273.64 |
| 2.不涉及現金收支的重大投資和籌資活動： 2. Non-cash significant investing and financing activities: | | |
| 債務轉為資本 Conversion of debt into capital | | |

| 項目 Items | 本期金額 Current period | 上期金額 Prior period |
|---|------------------------|----------------------|
| 一年內到期的可轉換公司債券 Convertible corporate bonds due within one year | | |
| 融資租入固定資產 Fixed assets under finance lease | | |
| 3.現金及現金等價物淨變動情況: 3. Net change in cash and cash equivalents: | | |
| 現金的期末餘額 Cash balance as at the end of the period | 72,852,099.15 | 35,410,806.58 |
| 減：現金的期初餘額 Less: cash balance as at the beginning of the period | 149,096,068.30 | 113,771,300.25 |
| 加：現金等價物的期末餘額 Add: balance of cash equivalents as at the end of the period | | |
| 減：現金等價物的期初餘額 Less: balance of cash equivalents as at the beginning of the period | | |
| 現金及現金等價物淨增加額 Net increase in cash and cash equivalents | -76,243,969.15 | -78,360,493.67 |

45.所有權或使用權受到限制的資產

45.Assets with restricted ownership and rights of use

| 項目 Items | 期末賬面價值 Book value at the end of the period | 受限原因 Reasons of Restriction |
|---|---|---|
| 貨幣資金 Monetary funds | 375,626,036.26 | 銀行承兌匯票保證金、借款保證金 Bank acceptance bills deposits, borrowing deposits |
| 應收票據 Bills receivables | 896,670.00 | 質押以及票據貼現 Pledge and bills discounting |
| 應收款項融資 Account receivables financing | 499,200.00 | 質押以及票據貼現 Pledge and bills discounting |
| 存貨 Inventories | 350,000,000.00 | 抵押 Security |
| 固定資產 Fixed assets | 263,268,766.11 | 抵押 Security |
| 無形資產 Intangible assets | 128,992,156.57 | 抵押 Security |
| 合計 Total | 1,119,282,828.94 | — |

46. 外幣貨幣性項目

46. Monetary items in foreign currencies

| 項目 Items | 期末外幣餘額 Balance in foreign currency at the end of the period | 折算匯率 Exchange rate | 期末折算人民幣餘額 Equivalent RMB balance at the end of the period |
|--------------------------------------|--|-----------------------|--|
| 貨幣資金 Monetary funds | 441,915.52 | 0.8552 | 377,921.74 |
| 其中：港幣 Of which: Hong Kong Dollars | 441,915.52 | 0.8552 | 377,921.74 |

47. 政府補助

47. Government grants

(1) 政府補助基本情況

(1) Basic information about government grants

| 種類 Type | 金額 Amount | 列報項目 Item reported | 計入當期損益的金額 Amount included in profit and loss for the period |
|--|--------------|--------------------------------|---|
| 與資產相關的政府補助 the government subsidies related to the assets | 228,530.25 | 其他收益 Other gains | 228,530.25 |
| 與收益相關的政府補助 the government subsidies related to the revenue | 588,642.63 | 營業外收入 Non-operating revenue | 588,642.63 |
| 合計 Total | 817,172.88 | — | 817,172.88 |

(2) 本集團本期無政府補助退回情況。

(2) There were no returns of government subsidies in the Group during the period.

七、合併範圍的變化

VII. CHANGES IN SCOPE OF CONSOLIDATION

報告期內，本集團無合併範圍的變化情況。

During the reporting period, the Group had no changes in scope of consolidation.

八、在其他主體中的權益

1. 在子公司中的權益

(1) 企業集團的構成

VIII. INTERESTS IN OTHER ENTITIES

1. Interests in subsidiaries

(1) Composition of the corporation

| 子公司名稱 Name of subsidiary | 主要經營地 Place of principal operation | 註冊地 Place of registration | 法律地位類別 Type of legal status | 業務性質 Nature of business | 註冊資本 Registered Capital (RMB) | 持股比例(%) Proportion of shareholding (%) | | 取得方式 Method of acquisition |
|--------------------------------------|---------------------------------------|------------------------------|--------------------------------|---------------------------------------|-----------------------------------|---|----------------|--|
| | | | | | | 直接 Direct | 間接 Indirect | |
| 廣東創美公司 Guangdong Charmacy Company | 珠三角 Pearl River Delta | 佛山 Foshan | 有限責任 Limited liability | 醫藥產品分銷 Pharmaceutical distribution | 15,000.00 萬元 150.00 million | 100.00 | | 投資設立 Established by investment |
| 珠海創美公司 Zhuhai Charmacy Company | 珠三角 Pearl River Delta | 珠海 Zhuhai | 有限責任 Limited liability | 醫藥產品分銷 Pharmaceutical distribution | 360.00 萬元 3.60 million | 100.00 | | 非同一控制下的企業合併 Business combination not under common control |
| 廣州創美公司 Guangzhou Charmacy Company | 珠三角 Pearl River Delta | 廣州 Guangzhou | 有限責任 Limited liability | 醫藥產品分銷 Pharmaceutical distribution | 2,000.00 萬元 20.00 million | 100.00 | | 非同一控制下的企業合併 Business combination not under common control |
| 深圳創美公司 Shenzhen Charmacy Company | 珠三角 Pearl River Delta | 深圳 Shenzhen | 有限責任 Limited liability | 醫藥產品分銷 Pharmaceutical distribution | 2,080.00 萬元 20.80 million | 100.00 | | 投資設立 Established by investment |
| 惠州創美公司 Huizhou Charmacy Company | 珠三角 Pearl River Delta | 惠州 Huizhou | 有限責任 Limited liability | 醫藥產品分銷 Pharmaceutical distribution | 1,500.00 萬元 15.00 million | 100.00 | | 非同一控制下的企業合併 Business combination not under common control |

九、與金融工具相關風險

本集團的主要金融工具包括借款、應收款項、應付款項、交易性金融資產、交易性金融負債等，各項金融工具的詳細情況說明見本附註六。與這些金融工具有關的風險，以及本集團為降低這些風險所採取的風險管理政策如下所述。本集團管理層對這些風險敞口進行管理和監控以確保將上述風險控制在限定的範圍之內。

IX. RISKS RELATED TO FINANCIAL INSTRUMENTS

The Group's major financial instruments include borrowings, receivables, payables, financial assets held for trading, financial liabilities held for trading, etc. Details of these financial instruments are set out in Note VI. The risks associated with these financial instruments and the risk management policies adopted by the Group on how to mitigate these risks are set out below. The management of the Group manages and monitors these exposures to ensure such risks are contained within a prescribed scope.

1.各類風險管理目標和政策

本集團從事風險管理的目標是在風險和收益之間取得適當的平衡，將風險對本集團經營業績的負面影響降低到最低水準，使股東及其它權益投資者的利益最大化。基於該風險管理目標，本集團風險管理的基本策略是確定和分析本集團所面臨的各種風險，建立適當的風險承受底線並進行風險管理，並及時可靠地對各種風險進行監督，將風險控制在限定的範圍之內。

(1)市場風險**1) 匯率風險**

外匯風險是指金融工具的公允價值或未來現金流量因外匯匯率變動而發生波動的風險。本集團承受外匯風險主要與港幣有關，除本集團 H 股募集資金、H 股支付股利及少部分發生在香港特別行政區的費用外，本集團的其他主要業務活動以人民幣計價結算。於 2022 年 6 月 30 日，下表所述港幣賬戶餘額的資產和負債因匯率變動產生的公允價值或未來現金流量變動可能對本集團的經營業績產生影響：

1.Objective and policies of various risks management

The Group engages in risk management with the aim of achieving an appropriate balance between risk and return, where the negative effects of risks against the operating results of the Group are minimized, and to maximize the interest of Shareholders and other stakeholders. Based on such risk management objectives, the fundamental strategy of risk management of the Group is to ascertain and analyse all types of risk exposures of the Group, establish appropriate risk tolerance thresholds, carry out risk management procedures and perform risk monitoring on all kinds of risks in a timely and reliable manner, thus containing risk exposures within a prescribed scope.

(1) Market risk**1) Foreign exchange risk**

Foreign exchange risk is the risk arising from changes in fair value or future cash flows of financial instrument resulted from changes in exchange rate. The Group's foreign exchange risk relates mainly to Hong Kong Dollars. Except for the proceeds from the H Share offering, payment of H Share dividends and minor expenses incurred in the Hong Kong Special Administrative Region, other main business activities of the Group are settled in RMB. As at 30 June 2022, the changes in the fair value or future cash flows from the assets and liabilities of the balance of the account denominated in HK\$ due to changes in exchange rates may have impact on the Group's operating results as set out in the following table:

| 項目 Item | 期末餘額（折合人民幣） Closing balance (RMB equivalent) | 上年末餘額（折合人民幣） Closing balance of last year (RMB equivalent) |
|---------------------------------|--|--|
| 貨幣資金-港幣 Monetary fund – HK\$ | 441,915.52 | 368,083.50 |

本集團密切關注匯率變動對本集團的影響。

2) 利率風險

本集團存在利率風險的主要負債有短期借款和長期借款等，本集團無外幣借款。

3) 其他價格風險

本集團未持有其他債權投資和交易性金融資產，本集團無此類價格風險。

(2) 信用風險

於 2022 年 6 月 30 日，可能引起本集團財務損失的最大信用風險敞口主要來自於合同另一方未能履行義務而導致本集團金融資產產生的損失，具體包括：

合併資產負債表中已確認的金融資產的賬面金額；對於以公允價值計量的金融工具而言，賬面價值反映了其風險敞口，但並非最大風險敞口，其最大風險敞口將隨著未來公允價值的變化而改變。

為降低信用風險，本集團成立專門部門確定信用額度、進行信用審批，並執行其它監控程序以確保採取必要的措施回收過期債權。此外，本集團於每個資產負債表日審核每一單項應收款的回收情況，以確保就無法回收的款項計提充分的壞賬準備。因此，本集團管理層認為本集團所承擔的信用風險已經大為降低。

The Group closely monitors the effect of exchange rate on the Group.

2) Interest rate risk

The major liabilities of the Group with interest rate risk include short-term borrowings and long-term borrowings. The Group has no foreign currency borrowings.

3) Other price risks

The Group holds no other debt investments and trading financial assets, and it has no such price risk.

(2) Credit risk

As at 30 June 2022, the maximum credit risk exposure that might incur financial losses to the Group was mainly attributable to the losses of financial assets due to a contractual failure of counterparty to perform its obligations. Specifically, such losses include:

The carrying amount of financial assets recognized in the consolidated balance sheet. For financial assets at fair value, the carrying amount reflects the risk exposure, but not the maximum risk exposure, which will vary with the changes in future fair value.

In order to mitigate credit risk, the Group established special departments to determine credit limits and perform credit approval, and carries out other monitoring procedures to ensure necessary measures are taken to collect overdue debts. Besides, the Group reassesses the recovery of each receivable items on an individual basis at each balance sheet date, so as to ensure sufficient provision for doubtful debts is made for amounts that are not recoverable. As such, the management of the Group believes that the credit risks assumed by the Group has been

significantly mitigated.

本集團的流動資金存放在信用評級較高的銀行，故流動資金的信用風險較低。

本集團採用了必要的政策確保所有銷售客戶均具有良好的信用記錄。

The Group's liquidity is deposited in banks with higher credit rating, so the credit risk of the liquidity is lower.

The Group has adopted necessary policies to ensure that all the trade customers have good credit history.

(3) 流動風險

流動風險為本集團在到期日無法履行其財務義務的風險。本集團管理流動性風險的方法是確保有足夠的資金流動性來履行到期債務，而不至於造成不可接受的損失或對企業信譽造成損害。本集團定期分析負債結構和期限，以確保有充裕的資金。本集團管理層對銀行借款的使用情況進行監控並確保遵守借款協議。同時與金融機構進行融資磋商，以保持一定的授信額度，減低流動性風險。

本集團持有的金融資產和金融負債按未折現的合同現金流的到期期限分析如下：

(3) Liquidity risk

Liquidity risk is the risk that the Group will not be able to meet its financial obligations at maturity. The Group manages liquidity risk by ensuring that it has ample liquidity to meet its obligations as they fall due without incurring unacceptable losses or causing damage to its reputation. The Group regularly analyses the structure and maturity of its liabilities to ensure that sufficient funds are available. The Group's management monitors the use of bank loans and ensures compliance with loan agreements. It also negotiates with financial institutions on financing to maintain a certain credit limit and reduce liquidity risk.

Analysis of financial assets and financial liabilities of the Group by maturity of undiscounted contractual cash flows is set out as follows:

| 項目 Items | 賬面價值 Book value | 1年以內 Within 1 year | 1-5年 1 to 5 years | 5年以上 Over 5 years | 合計 Total |
|--|--------------------|-----------------------|----------------------|----------------------|----------------|
| 貨幣資金 Monetary funds | 443,608,192.02 | 443,608,192.02 | - | - | 443,608,192.02 |
| 應收票據 Bills receivables | 896,670.00 | 896,670.00 | - | - | 896,670.00 |
| 應收賬款 Trade receivables | 746,677,884.75 | 746,677,884.75 | - | - | 746,677,884.75 |
| 應收款項融資 Account receivables financing | 14,216,386.49 | 14,216,386.49 | - | - | 14,216,386.49 |
| 其他應收款 Other receivables | 11,989,545.20 | 11,989,545.20 | - | - | 11,989,545.20 |

| 項目 Items | 賬面價值 Book value | 1年以內 Within 1 year | 1-5年 1 to 5 years | 5年以上 Over 5 years | 合計 Total |
|--|--------------------|-----------------------|----------------------|----------------------|----------------|
| 其他流動資產 Other current assets | 30,101,256.73 | 30,101,256.73 | - | - | 30,101,256.73 |
| 短期借款 Short-term borrowings | 515,486,716.70 | 515,486,716.70 | - | - | 515,486,716.70 |
| 應付票據 Bills payables | 818,410,573.01 | 818,410,573.01 | - | - | 818,410,573.01 |
| 應付賬款 Trade payables | 576,254,966.43 | 576,254,966.43 | - | - | 576,254,966.43 |
| 應付職工薪酬 Salaries payable to employees | 4,670,152.37 | 4,670,152.37 | - | - | 4,670,152.37 |
| 其他應付款 Other payables | 12,875,096.44 | 12,875,096.44 | - | - | 12,875,096.44 |
| 一年內到期的非流動負債 Non-current liabilities due within one year | 35,996,199.36 | 35,996,199.36 | - | - | 35,996,199.36 |
| 長期借款 Long-term borrowings | 71,073,337.34 | - | 71,073,337.34 | - | 71,073,337.34 |
| 合同負債 Contract liabilities | 67,641,555.74 | 67,641,555.74 | - | - | 67,641,555.74 |

2.公允價值

金融資產和金融負債的公允價值按照下述方法確定：

具有標準條款及條件並存在活躍市場的金融資產及金融負債的公允價值分別參照相應的活躍市場現行出價及現行要價確定；

其他金融資產及金融負債(不包括衍生工具)的公允價值按照未來現金流量折現法為基礎的通用定價模型確定或採用可觀察的現行市場交易價格確認；

衍生工具的公允價值採用活躍市場的公開報價確定。

本集團管理層認為，財務報表中按攤

2.Fair value

The fair value of financial assets and financial liabilities is determined in accordance with the following methods:

The fair value of financial assets and financial liabilities with standard terms and conditions and in active markets are determined by reference to the prevailing bid and ask prices in the corresponding active market;

The fair value of other financial assets and financial liabilities (other than derivative instruments) are determined by the general pricing model based on the discounted future cash flow method or recognized by observable current market transaction prices;

The fair value of the derivative instruments is determined by quoted price in active markets.

The management of the Group considers that the carrying

余成本計量的金融資產及金融負債的賬面價值接近該等資產及負債的公允價值。

amounts of financial assets and financial liabilities measured at amortized cost in the financial statements approximate to the fair value of such assets and liabilities.

十、關聯方及關聯交易

X. RELATED PARTIES AND RELATED PARTY TRANSACTIONS

(一) 關聯方關係

(I). Relationship with related parties

1. 控股股東及最終控制方

1. Controlling shareholder and ultimate controller

(1) 控股股東及最終控制方

(1) Controlling shareholder and ultimate controller

| 控股股東及最終控制方名稱 Name of controlling shareholder and ultimate controller | 註冊地 Nationality | 對本公司的持股比例(%) Percentage of shareholding in the Company(%) | 對本公司的表決權比例(%) Percentage of voting rights in the Company(%) |
|---|--------------------|--|--|
| 姚創龍 Yao Chuanglong | 中國 Chinese | 40.97 | 40.97 |

(2) 控股股東的註冊資本及其變化

(2) Registered capital of controlling shareholder and its changes

| 控股股東 Controlling shareholder | 上年年末餘額 Closing balance of last year | 本期增加 Increase in this period | 本期減少 Decrease in this period | 期末餘額 Closing balance |
|---------------------------------|--|---------------------------------|---------------------------------|-------------------------|
| 姚創龍 Yao Chuanglong | 44,250,000.00 | - | - | 44,250,000.00 |

(3) 控股股東的所持股份或權益及其變化

(3) Shares or interests held by controlling shareholder and its changes

| 控股股東 Controlling shareholder | 持股金額 Shareholding amount | | 持股比例(%) Percentage of shareholding(%) | |
|---------------------------------|-----------------------------|--|---|--|
| | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year | 期末比例 Percentage at the end of the period | 上年年末比例 Percentage at the end of last year |
| 姚創龍 Yao Chuanglong | 44,250,000.00 | 44,250,000.00 | 40.97 | 40.97 |

2. 子公司

2. Subsidiaries

子公司情況詳見本附註“八、1.

For details of subsidiaries, please see “VIII. 1. (1) Composition of the corporation” under these notes.

(1) 企業集團的構成”相關內容。

3.其他關聯方

3.Other related parties

| 其他關聯方名稱 Name of other related parties | 與本公司關係 Relationship with the Company |
|---|---|
| 汕頭市悠然投資管理合夥企業（有限合夥） Youran Investment | 持有公司 1.57% 股權，為主要由公司員工構成的持股平台 Holding 1.57% equity interest in the Company, a shareholding platform that is mainly consisted of employees of the Company |
| 汕頭市智創投資管理合夥企業（有限合夥） Zhichuang Investment | 持有公司 1.67% 股權，為主要由公司員工構成的持股平台 Holding 1.67% equity interest in the Company, a shareholding platform that is mainly consisted of employees of the Company |
| 汕頭市美智投資管理合夥企業（有限合夥） Meizhi Investment | 持有公司 2.96% 股權，為主要由公司員工構成的持股平台 Holding 2.96% equity interest in the Company, a shareholding platform that is mainly consisted of employees of the Company |
| 江西江中醫藥商業運營有限責任公司 Jiangxi Jiangzhong Pharmaceutical Commercial Operation Co., Ltd. | 持有公司 26.90% 股權，為非執行董事嚴京斌擔任董事及法定代表人、付征擔任副總經理的企業 Holding 26.90% equity interest in the Company, An enterprise in which Yanjingbin, the non-executive Director, serves as the director and the legal representative and Fuzheng, the non-executive Director, serves as the deputy general manager |
| 廣州白雲山醫藥集團股份有限公司（以下簡稱“白雲山股份”）及其下屬控股子公司及合營公司註 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. (hereinafter referred to as "Baiyunshan" and its holding subsidiaries and joint ventures Note | 廣藥白雲山香港有限公司（以下簡稱“白雲山香港”）持有本公司 H 股 790.65 萬股，佔本公司股本總額 7.32%，其為白雲山股份下屬公司，是本公司戰略投資者。由於本公司與白雲山股份及其下屬公司存在緊密的商業往來，其控制的白雲山香港對本公司持股比例超過 5%，且於 2017 年向公司委派了董事李偉生。按照實質重於形式的原則，本公司將白雲山股份及其下屬控股公司和合營公司認定為本公司的關聯方 Guangzhou Pharmaceutical Baiyunshan Hong Kong Company Limited (hereinafter referred to as "Baiyunshan Hong Kong"), a subsidiary of Baiyunshan and a strategic investor of the Company, holds 7,906,500 H shares of the Company, representing 7.32% of the total share capital of the Company. Due to the close business association between the Company and Baiyunshan and its subsidiaries, the shareholding percentage of Baiyunshan Hong Kong controlled by it in the Company has exceeded 5%, and it has appointed a Director, Li Weisheng in 2017 to the Company. Based on the principle of substance over form, the Company deemed Baiyunshan and its holding subsidiaries and joint ventures as related parties of the Company |
| 廣藥白雲山澳門有限公司 Guangzhou Pharmaceutical Baiyunshan Macau Company Limited | 非執行董事李偉生擔任董事長的企業 An enterprise in which Li Weisheng, the non-executive Director, serves as the chairman of the board |
| 廣藥（珠海橫琴）中醫藥產業有限公司 Guangzhou Pharmaceutical (Zhuhai Hengqin) TCM Industry Co., Ltd. | 非執行董事李偉生擔任監事的企業 An enterprise in which our non-executive Director Li Weisheng serves as a supervisor |
| 廣藥（珠海橫琴）醫藥產業園有限公司 Guangzhou Pharmaceutical (Zhuhai Hengqin) Industrial Park Co., Ltd. | 非執行董事李偉生擔任監事的企業 An enterprise in which our non-executive Director Li Weisheng serves as a supervisor |
| 鄭玉燕、張寒孜、李偉生、嚴京斌、付征、尹智偉、周濤、關鍵、張玲、鄭禧玥、林志傑、劉映玉 Zheng Yuyan, Zhang Hanzi, Li Weisheng, Yan Jing bin, Fu Zheng, Wan Chi Wai Anthony, Zhou Tao, Guan Jian, Zhang Ling, Zheng Xiyue, Lin Zhijie, Liu Yingyu | 公司董事、監事及高級管理人員 Directors, Supervisors and Senior Management of the Company |
| 北京市金杜律師事務所 King & Wood Mallesons | 獨立非執行董事尹智偉擔任合夥人的企業 An enterprise in which Wan Chi Wai Anthony, the independent non-executive Director, serves as partner |
| 北京國楓律師事務所 Grandway Law Offices | 獨立非執行董事周濤擔任合夥人的企業 An enterprise in which Zhou Tao, the independent non-executive Director, serves as partner |

| 其他關聯方名稱 Name of other related parties | 與本公司關係 Relationship with the Company |
|---|--|
| HM International Holdings Limited | 獨立非執行董事尹智偉擔任獨立非執行董事的企業 An enterprise in which Wan Chi Wai Anthony, the independent non-executive Director, serves as the independent non-executive Director |
| 豐展控股有限公司 FDB HOLDINGS LIMITED | 獨立非執行董事尹智偉擔任獨立非執行董事的企業 An enterprise in which Wan Chi Wai Anthony, the independent non-executive Director, serves as the independent non-executive director |
| 江蘇坤奕環境技術股份有限公司 Jiangsu Kunyee Environmental Technology Co.,Ltd | 監事張玲擔任財務總監的企業 An enterprise in which Zhang Ling, the Supervisor, serves as the chief financial officer |
| 上海新關點教育科技有限公司 Shanghai New Focus Education Technology Limited | 獨立非執行董事關鍵持股 70% 並擔任企業法人的企業 An enterprise in which Guan Jian, the independent non-executive Director, holds 70% of shares and serves as the legal representative of the enterprise |
| 上海百教龍場企業管理服務中心（有限合夥） Shanghai Baidu Longchang Enterprise Management and Service Center (limited partnership) | 獨立非執行董事關鍵持股 99% 並擔任執行合夥人的企業 An enterprise in which Guan Jian, the independent non-executive Director, holds 99% of shares and serves as the general partner |
| 湖北富邦科技股份有限公司 Hubei Forbon Technology Co., Ltd. | 獨立非執行董事關鍵擔任獨立非執行董事的企業 An enterprise in which Guan Jian, the independent non-executive Director, serves as an independent non-executive director |

註：廣州白雲山醫藥集團股份有限公司（以下簡稱“白雲山股份”）及其下屬控股子公司及合營公司下屬公司關聯方關係明細：

Note: The details of the relationship among Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. (hereinafter referred to as “Baiyunshan”) and its holding subsidiaries and joint ventures are as follows:

| 公司名稱 Company name | 白雲山關聯方關係 Related party relationships with Baiyunshan |
|---|---|
| 佛山市廣藥健擇醫藥有限公司 Foshan GPC Jianze Pharmaceutical Co., Ltd. | 白雲山之控股公司 A holding company of Baiyunshan |
| 廣東百源堂醫藥連鎖有限公司 Guangdong Baiyuantang Medicine Chainstore Co.,Ltd. | 白雲山之聯營企業 An associate of Baiyunshan |
| 廣西白雲山盈康藥業有限公司 Guangxi Baiyunshan Yingkang Pharmaceutical Co., Ltd | 白雲山之控股公司 A holding company of Baiyunshan |
| 廣西鴻翔一心堂藥業有限責任公司 Guangxi Hongxiang Yi Xin Tang Pharmaceutical Co., Ltd. | 白雲山之聯營企業 An associate of Baiyunshan |
| 廣州白雲山陳李濟藥廠有限公司 Guangzhou Baiyunshan Chen Li Ji Pharmaceutical Factory Co., Ltd. | 白雲山之控股公司 A holding company of Baiyunshan |
| 廣州白雲山光華製藥股份有限公司 Guangzhou Baiyunshan Guang Hua Pharmacy Co., Ltd. | 白雲山之控股公司 A holding company of Baiyunshan |
| 廣州白雲山和黃醫藥有限公司 Hutchison Whamoa Guangzhou Baiyunshan Pharmaceutical Co., Ltd. | 白雲山之合營企業 A joint venture of Baiyunshan |
| 廣州白雲山和記黃埔中藥有限公司 Guangzhou Baiyunshan Hutchison Whamoa Chinese Medicine Co., Ltd. | 白雲山之合營企業 A joint venture of Baiyunshan |
| 廣州白雲山敬修堂藥業股份有限公司 Guangzhou Baiyunshan Jing Xiu Tang Pharmaceutical Co., Ltd. | 白雲山之控股公司 A holding company of Baiyunshan |
| 廣州白雲山明興製藥有限公司 Guangzhou Baiyunshan Ming Xing Pharmaceutical Co., Ltd. | 白雲山之控股公司 A holding company of Baiyunshan |

| 公司名稱 Company name | 白雲山關聯方關係 Related party relationships with Baiyunshan |
|---|---|
| 廣州白雲山潘高壽藥業股份有限公司 Guangzhou Baiyunshan Pan Gao Shou Pharmaceutical Co., Ltd. | 白雲山之控股公司 A holding company of Baiyunshan |
| 廣州白雲山奇星藥業有限公司 Guangzhou Baiyunshan Qi Xing Pharmaceutical Co., Ltd. | 白雲山之控股公司 A holding company of Baiyunshan |
| 廣州白雲山天心製藥股份有限公司 Guangzhou Baiyunshan Tian Xin Pharmaceutical Co., Ltd. | 白雲山之控股公司 A holding company of Baiyunshan |
| 廣州白雲山醫藥集團股份有限公司白雲山何濟公制藥廠 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Guangzhou Baiyunshan He Ji Gong Pharmaceutical Factory | 白雲山之控股公司 A holding company of Baiyunshan |
| 廣州白雲山醫藥集團股份有限公司白雲山製藥總廠 Guangzhou Baiyunshan Pharmaceutical Co., Ltd. Guangzhou Baiyunshan Pharmaceutical General | 白雲山之控股公司 A holding company of Baiyunshan |
| 廣州白雲山醫藥銷售有限公司 Guangzhou Baiyunshan Pharmaceutical Marketing Co., Ltd. | 白雲山之控股公司 A holding company of Baiyunshan |
| 廣州白雲山中一藥業有限公司 Guangzhou Baiyunshan Zhong Yi Pharmaceutical Company Limited | 白雲山之控股公司 A holding company of Baiyunshan |
| 廣州采芝林國醫館有限公司北商大藥房 Guangzhou Caizhilin Traditional Chinese Medical Hall Co., Ltd. Beishang Pharmacy | 白雲山之控股公司 A holding company of Baiyunshan |
| 廣州采芝林國醫館有限公司花地灣分店 Guangzhou Caizhilin Traditional Chinese Medical Center Co., Ltd. Huadiwan Branch | 白雲山之控股公司 A holding company of Baiyunshan |
| 廣州采芝林藥業有限公司 Guangzhou Cai Zhi Lin Pharmaceutical Co., Ltd. | 白雲山之控股公司 A holding company of Baiyunshan |
| 廣州國盈醫藥有限公司 Guangzhou Guo Ying Pharmaceutical Co., Ltd. | 白雲山之控股公司 A holding company of Baiyunshan |
| 廣州健民醫藥有限公司 Guangzhou Jianmin Pharmaceutical Company Limited | 白雲山之控股公司 A holding company of Baiyunshan |
| 廣州神農草堂大藥房有限公司 Guangzhou Shennong Caotang Pharmacy Co., Ltd. | 白雲山之合營企業 A joint venture of Baiyunshan |
| 廣州王老吉藥業股份有限公司 Guangzhou Wang Lao Ji Pharmaceutical Co., Ltd. | 白雲山之控股公司 A holding company of Baiyunshan |
| 廣州欣特醫藥有限公司 Guangzhou Xin Te Pharmaceutical Co., Ltd. | 白雲山之控股公司 A holding company of Baiyunshan |
| 廣州醫藥大藥房有限公司 Guangzhou Pharmaceutical Pharmacy Co., Ltd. | 白雲山之控股公司 A holding company of Baiyunshan |
| 廣州醫藥股份有限公司 Guangzhou Pharmaceutical Co., Ltd. | 白雲山之控股公司 A holding company of Baiyunshan |
| 廣州醫藥股份有限公司大眾藥品銷售分公司 Guangzhou Pharmaceuticals Co., Ltd. Da Zhong Drug Sales Branch | 白雲山之控股公司 A holding company of Baiyunshan |
| 海南鴻翔一心堂醫藥連鎖有限公司 Hainan Hongxiang Yi Xin Tang Pharmaceutical Chain Co., Ltd. | 白雲山之聯營企業 An associate of Baiyunshan |
| 四川一心堂醫藥連鎖有限公司 Sichuan Yi Xin Tang Gurative Gatenation Co., Ltd. | 白雲山之聯營企業 An associate of Baiyunshan |
| 一心堂藥業集團股份有限公司 Yixintang Pharmaceutical Group Co., Ltd. | 白雲山之聯營企業 An associate of Baiyunshan |
| 珠海廣藥康鳴醫藥有限公司 Zhuhai Guang Yao Kangming Pharmaceutical Co., Ltd. | 白雲山之控股公司 A holding company of Baiyunshan |

(二) 關聯交易

(II). Related party transactions

1、關聯交易情況

1.Details of related party transactions

| 關聯方名稱 Name of related party | 關聯方交易 類型 Types of related party transactions | 關聯交易定價方式及決 策程式 Pricing method and decision making procedure for related party transactions | 本期金額 Current period | 上期金額 Prior period |
|--|--|---|---------------------------|----------------------|
| 1、銷售與提供勞務 | | | | |
| 1.Sales and rendering of services | | | | |
| 廣東百源堂醫藥連鎖有限公司 Guangdong Baiyuantang Medicine Chainstore Co.,Ltd. | 銷售商品 Sales of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 2,923,264.88 | 1,833,596.98 |
| 廣西鴻翔一心堂藥業有限責任公司 Guangxi Hongxiang Yi Xin Tang Pharmaceutical Co., Ltd. | 銷售商品 Sales of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | - | 1,647,871.08 |
| 廣州采芝林藥業有限公司 Guangzhou Cai Zhi Lin Pharmaceutical Co., Ltd. | 銷售商品 Sales of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | - | -4,500,253.17 |
| 廣州國盈醫藥有限公司 Guangzhou Guo Ying Pharmaceutical Co., Ltd. | 銷售商品 Sales of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | - | 161,092.67 |
| 廣州健民醫藥有限公司 Guangzhou Jianmin Pharmaceutical Company Limited | 銷售商品 Sales of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 4,460,783.85 | 4,667,907.39 |
| 廣州醫藥大藥房有限公司 Guangzhou Pharmaceutical Pharmacy Co., Ltd. | 銷售商品 Sales of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 272,503.37 | 96,141.67 |
| 廣州醫藥股份有限公司 Guangzhou Pharmaceutical Co., Ltd. | 銷售商品 Sales of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 104,684.51 | 17,649,954.38 |

| 關聯方名稱 Name of related party | 關聯方交易 類型 Types of related party transactions | 關聯交易定價方式及決 策程式 Pricing method and decision making procedure for related party transactions | 本期金額 Current period | 上期金額 Prior period |
|---|--|---|---------------------------|----------------------|
| 廣州醫藥股份有限公司大眾藥品銷售 分公司 Guangzhou Pharmaceuticals Co., Ltd. Da Zhong Drug Sales Branch | 銷售商品 Sales of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | -26,360.28 | 48,916.72 |
| 海南鴻翔一心堂醫藥連鎖有限公司 Hainan Hongxiang Yi Xin Tang Pharmaceutical Chain Co., Ltd. | 銷售商品 Sales of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 1,428,979.96 | 1,947,100.78 |
| 四川一心堂醫藥連鎖有限公司 Sichuan Yi Xin Tang Gurative Gatenation Co.,Ltd. | 銷售商品 Sales of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 136,586.09 | 292,726.30 |
| 一心堂藥業集團股份有限公司 Yixintang Pharmaceutical Group Co., Ltd. | 銷售商品 Sales of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | - | 201,604.75 |
| 珠海廣藥康鳴醫藥有限公司 Zhuhai Guang Yao Kangming Pharmaceutical Co., Ltd. | 銷售商品 Sales of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 142,618.73 | 104,520.29 |
| 廣州欣特醫藥有限公司 Guangzhou Xin Te Pharmaceutical Co., Ltd. | 銷售商品 Sales of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 1,106,356.02 | - |
| 廣州神農草堂大藥房有限公司 Guangzhou Shennong Caotang Pharmacy Co., Ltd | 銷售商品 Sales of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 4,078.46 | - |
| 廣州采芝林國醫館有限公司北商大藥 房 Guangzhou Caizhilin Traditional Chinese Medical Hall Co., Ltd. Beishang Pharmacy | 銷售商品 Sales of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 16,952.97 | - |

| 關聯方名稱 Name of related party | 關聯方交易 類型 Types of related party transactions | 關聯交易定價方式及決 策程式 Pricing method and decision making procedure for related party transactions | 本期金額 Current period | 上期金額 Prior period |
|---|--|---|---------------------------|----------------------|
| 廣州采芝林國醫館有限公司花地灣分店 Guangzhou Caizhilin Traditional Chinese Medical Center Co., Ltd. Huadiwan Branch | 銷售商品 Sales of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 2,846.42 | - |
| 2、採購與接受勞務 | | | | |
| 2. Procurement and acceptance of services | | | | |
| 廣州白雲山光華製藥股份有限公司 Guangzhou Baiyunshan Guang Hua Pharmacy Co., Ltd. | 採購商品 Procurement of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 1,697,256.64 | 1,263,000.00 |
| 廣州白雲山和記黃埔中藥有限公司 Guangzhou Baiyunshan Hutchison Whampoa Chinese Medicine Co., Ltd. | 採購商品 Procurement of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 2,122,973.52 | 7,072,317.60 |
| 廣州白雲山天心製藥股份有限公司 Guangzhou Baiyunshan Tian Xin Pharmaceutical Co., Ltd. | 採購商品 Procurement of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 6,297,812.05 | 8,831,380.59 |
| 廣州白雲山陳李濟藥廠有限公司 Guangzhou Baiyunshan Chen Li Ji Pharmaceutical Factory Co., Ltd. | 採購商品 Procurement of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 7,957,603.71 | 10,520,892.36 |
| 廣州白雲山潘高壽藥業股份有限公司 Guangzhou Baiyunshan Pan Gao Shou Pharmaceutical Co., Ltd. | 採購商品 Procurement of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 11,093,177.86 | 33,689,754.11 |
| 廣州白雲山奇星藥業有限公司 Guangzhou Baiyunshan Qi Xing Pharmaceutical Co., Ltd. | 採購商品 Procurement of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 2,859,982.04 | 3,862,200.31 |
| 廣州王老吉藥業股份有限公司 Guangzhou Wang Lao Ji Pharmaceutical Co., Ltd. | 採購商品 Procurement of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 21,509,260.86 | 28,963,221.47 |

| 關聯方名稱 Name of related party | 關聯方交易 類型 Types of related party transactions | 關聯交易定價方式及決 策程式 Pricing method and decision making procedure for related party transactions | 本期金額 Current period | 上期金額 Prior period |
|--|--|---|---------------------------|----------------------|
| 廣州白雲山中一藥業有限公司 Guangzhou Baiyunshan Zhong Yi Pharmaceutical Company Limited | 採購商品 Procurement of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 51,536,012.97 | 29,904,722.57 |
| 廣州白雲山醫藥集團股份有限公司白 雲山何濟公制藥廠 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Guangzhou Baiyunshan He Ji Gong Pharmaceutical Factory | 採購商品 Procurement of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 14,650,152.08 | 18,091,253.20 |
| 廣州白雲山醫藥銷售有限公司 Guangzhou Baiyunshan Pharmaceutical Marketing Co., Ltd. | 採購商品 Procurement of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 37,343,065.33 | 37,354,157.61 |
| 廣西白雲山盈康藥業有限公司 Guangxi Baiyunshan Yingkang Pharmaceutical Co., Ltd | 採購商品 Procurement of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 193,161.07 | 191,472.00 |
| 廣州采芝林藥業有限公司 Guangzhou Cai Zhi Lin Pharmaceutical Co., Ltd. | 採購商品 Procurement of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 5,242,477.87 | 159,786.60 |
| 廣州國盈醫藥有限公司 Guangzhou Guo Ying Pharmaceutical Co., Ltd. | 採購商品 Procurement of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 2,147,921.42 | 5,905,955.88 |
| 廣州醫藥股份有限公司 Guangzhou Pharmaceutical Co., Ltd. | 採購商品 Procurement of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 79,241,435.09 | 49,179,885.68 |
| 佛山市廣藥健擇醫藥有限公司 Foshan GPC Jianze Pharmaceutical Co., Ltd. | 採購商品 Procurement of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | - | 66,600.00 |

| 關聯方名稱 Name of related party | 關聯方交易 類型 Types of related party transactions | 關聯交易定價方式及決 策程式 Pricing method and decision making procedure for related party transactions | 本期金額 Current period | 上期金額 Prior period |
|---|--|---|---------------------------|----------------------|
| 廣州欣特醫藥有限公司 Guangzhou Xin Te Pharmaceutical Co., Ltd. | 採購商品 Procurement of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 2,494,555.77 | 5,208,014.20 |
| 廣州白雲山和黃醫藥有限公司 Hutchison Whampoa Guangzhou Baiyunshan Pharmaceutical Co., Ltd. | 採購商品 Procurement of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | - | 398,200.00 |
| 江西江中醫藥商業運營有限責任公司 Jiangxi Jiangzhong Pharmaceutical Commercial Operation Co., Ltd. | 採購商品 Procurement of goods | 參考市場價格協商 確定 Determined after negotiation by reference to market rates | 210,221.41 | - |

註：上述採購商品金額剔除上游廠
商、供應商返利。

Note :The above amount of procurement excludes rebates from
the upstream manufacturers and suppliers.

(三) 關聯方往來餘額

(III).Related party balances

| 項目 Item | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|--|-------------------------|---|
| 應收賬款 Trade receivables | | |
| 廣州醫藥股份有限公司 Guangzhou Pharmaceutical Co., Ltd. | 118,552.54 | 20,019,532.00 |
| 廣東百源堂醫藥連鎖有限公司 Guangdong Baiyuantang Medicine Chainstore Co.,Ltd. | 774,482.39 | 490,887.32 |
| 海南鴻翔一心堂醫藥連鎖有限公司 Hainan Hongxiang Yi Xin Tang Pharmaceutical Chain Co., Ltd. | 1,021,015.74 | 1,084,529.03 |
| 廣西鴻翔一心堂藥業有限責任公司 Guangxi Hongxiang Yi Xin Tang Pharmaceutical Co., Ltd. | 8,551.07 | 620,022.69 |
| 廣州國盈醫藥有限公司 Guangzhou Guo Ying Pharmaceutical Co., Ltd. | - | 137,040.00 |
| 四川一心堂醫藥連鎖有限公司 Sichuan Yi Xin Tang Gurative Gatenation Co.,Ltd. | 48,766.91 | 44,593.52 |
| 珠海廣藥康鳴醫藥有限公司 Zhuhai Guang Yao Kangming Pharmaceutical Co., Ltd. | 26,505.21 | 12,840.85 |
| 廣州醫藥大藥房有限公司 Guangzhou Pharmaceutical Pharmacy Co., Ltd. | 65,552.95 | 46,080.00 |
| 廣州健民醫藥有限公司 Guangzhou Jianmin Pharmaceutical Company Limited | 2,331,540.06 | 1,576,356.50 |
| 廣州欣特醫藥有限公司 Guangzhou Xin Te Pharmaceutical Co., Ltd. | 1,252,920.00 | - |

| 項目 Item | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|---|-------------------------|--|
| 廣州白雲山陳李濟藥廠有限公司 Guangzhou Baiyunshan Chen Li Ji Pharmaceutical Factory Co., Ltd. | 294,521.63 | - |
| 廣州神農草堂大藥房有限公司 Guangzhou Shennong Caotang Pharmacy Co., Ltd. | 635.00 | - |
| 預付賬款 Prepayments | | |
| 廣州白雲山陳李濟藥廠有限公司 Guangzhou Baiyunshan Chen Li Ji Pharmaceutical Factory Co., Ltd. | 5,835,414.63 | 2,195,689.93 |
| 廣州白雲山光華製藥股份有限公司 Guangzhou Baiyunshan Guang Hua Pharmacy Co., Ltd. | 1,390,292.92 | 165,663.71 |
| 廣州白雲山和黃醫藥有限公司 Hutchison Whampoa Guangzhou Baiyunshan Pharmaceutical Co., Ltd. | 3,209.72 | 153,000.00 |
| 廣州白雲山和記黃埔中藥有限公司 Guangzhou Baiyunshan Hutchison Whampoa Chinese Medicine Co., Ltd. | 794,638.51 | 3,227,217.46 |
| 廣州白雲山潘高壽藥業股份有限公司 Guangzhou Baiyunshan Pan Gao Shou Pharmaceutical Co., Ltd. | 15,848,958.93 | 11,976,993.34 |
| 廣州白雲山奇星藥業有限公司 Guangzhou Baiyunshan Qi Xing Pharmaceutical Co., Ltd. | 346,954.46 | 998,183.07 |
| 廣州白雲山醫藥集團股份有限公司白雲山何濟公制藥廠 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Guangzhou Baiyunshan He Ji Gong Pharmaceutical Factory | 3,941,281.98 | 1,071,856.00 |
| 廣州白雲山醫藥集團股份有限公司白雲山製藥總廠 Guangzhou Baiyunshan Pharmaceutical Co., Ltd. Guangzhou Baiyunshan Pharmaceutical General | 424.78 | 424.78 |
| 廣州白雲山醫藥銷售有限公司 Guangzhou Baiyunshan Pharmaceutical Marketing Co., Ltd. | 16,815,216.05 | 17,144,366.03 |
| 廣州白雲山中一藥業有限公司 Guangzhou Baiyunshan Zhong Yi Pharmaceutical Company Limited | 16,019,277.10 | 24,720,611.60 |
| 廣州采芝林藥業有限公司 Guangzhou Cai Zhi Lin Pharmaceutical Co., Ltd. | - | 2,432.20 |
| 廣州國盈醫藥有限公司 Guangzhou Guo Ying Pharmaceutical Co., Ltd. | - | 5,205.54 |
| 廣州王老吉藥業股份有限公司 Guangzhou Wang Lao Ji Pharmaceutical Co., Ltd. | 3,950,537.27 | 3,085,114.94 |
| 廣州白雲山明興製藥有限公司 Guangzhou Baiyunshan Ming Xing Pharmaceutical Co., Ltd. | 218,623.30 | - |
| 廣州白雲山天心製藥股份有限公司 Guangzhou Baiyunshan Tian Xin Pharmaceutical Co., Ltd. | 195,700.97 | - |
| 其他應收款 Other receivables | | |
| 廣州白雲山和記黃埔中藥有限公司 Guangzhou Baiyunshan Hutchison Whampoa Chinese Medicine Co., Ltd. | 20,000.00 | 20,000.00 |
| 廣州白雲山敬修堂藥業股份有限公司 Guangzhou Baiyunshan Jing Xiu Tang Pharmaceutical Co., Ltd. | 20,000.00 | 20,000.00 |
| 廣州王老吉藥業股份有限公司 Guangzhou Wang Lao Ji Pharmaceutical Co., Ltd. | - | 100,000.00 |
| 應付帳款 Trade payables | | |
| 佛山市廣藥健擇醫藥有限公司 Foshan GPC Jianze Pharmaceutical Co., Ltd. | - | 35,840.71 |

| 項目 Item | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|---|-------------------------|--|
| 廣西白雲山盈康藥業有限公司 Guangxi Baiyunshan Yingkang Pharmaceutical Co., Ltd | - | 1,844.25 |
| 廣州白雲山和記黃埔中藥有限公司 Guangzhou Baiyunshan Hutchison Whampoa Chinese Medicine Co., Ltd. | - | 64,340.71 |
| 廣州白雲山天心製藥股份有限公司 Guangzhou Baiyunshan Tian Xin Pharmaceutical Co., Ltd. | 584,861.93 | 469,308.46 |
| 廣州白雲山醫藥集團股份有限公司白雲山何濟公制藥廠 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Guangzhou Baiyunshan He Ji Gong Pharmaceutical Factory | 1,214,661.01 | 688,804.63 |
| 廣州采芝林藥業有限公司 Guangzhou Cai Zhi Lin Pharmaceutical Co., Ltd. | 1,130,004.31 | 1,351,417.11 |
| 廣州國盈醫藥有限公司 Guangzhou Guo Ying Pharmaceutical Co., Ltd. | 260,964.57 | 1,470,760.67 |
| 廣州欣特醫藥有限公司 Guangzhou Xin Te Pharmaceutical Co., Ltd. | 654,037.46 | 764,312.74 |
| 廣州醫藥股份有限公司 Guangzhou Pharmaceutical Co., Ltd. | 39,732,537.89 | 26,321,541.82 |
| 廣州白雲山中一藥業有限公司 Guangzhou Baiyunshan Zhong Yi Pharmaceutical Company Limited | 4,402,909.75 | - |
| 廣州白雲山光華製藥股份有限公司 Guangzhou Baiyunshan Guang Hua Pharmacy Co., Ltd. | 87,610.62 | - |
| 廣州白雲山奇星藥業有限公司 Guangzhou Baiyunshan Qi Xing Pharmaceutical Co., Ltd. | 48,054.16 | - |
| 廣州王老吉藥業股份有限公司 Guangzhou Wang Lao Ji Pharmaceutical Co., Ltd. | 71,525.94 | - |
| 江西江中醫藥商業運營有限責任公司 Jiangxi Jiangzhong Pharmaceutical Commercial Operation Co., Ltd. | 164,373.26 | |
| 應付票據 | | |
| Bills payables | | |
| 佛山市廣藥健擇醫藥有限公司 Foshan GPC Jianze Pharmaceutical Co., Ltd. | 427,284.00 | 516,870.00 |
| 廣西白雲山盈康藥業有限公司 Guangxi Baiyunshan Yingkang Pharmaceutical Co., Ltd | 16,272.00 | 167,600.00 |
| 廣州白雲山陳李濟藥廠有限公司 Guangzhou Baiyunshan Chen Li Ji Pharmaceutical Factory Co., Ltd. | 5,411,277.61 | 7,677,712.65 |
| 廣州白雲山光華製藥股份有限公司 Guangzhou Baiyunshan Guang Hua Pharmacy Co., Ltd. | 1,674,687.50 | 677,910.00 |
| 廣州白雲山和黃醫藥有限公司 Hutchison Whampoa Guangzhou Baiyunshan Pharmaceutical Co., Ltd. | 27,900.00 | 535,490.00 |
| 廣州白雲山和記黃埔中藥有限公司 Guangzhou Baiyunshan Hutchison Whampoa Chinese Medicine Co., Ltd. | 2,224,052.40 | 6,115,410.00 |
| 廣州白雲山潘高壽藥業股份有限公司 Guangzhou Baiyunshan Pan Gao Shou Pharmaceutical Co., Ltd. | 4,701,440.96 | 30,000,000.00 |
| 廣州白雲山奇星藥業有限公司 Guangzhou Baiyunshan Qi Xing Pharmaceutical Co., Ltd. | 2,103,876.40 | 2,681,659.70 |
| 廣州白雲山天心製藥股份有限公司 Guangzhou Baiyunshan Tian Xin Pharmaceutical Co., Ltd. | 6,725,416.30 | 8,233,930.10 |
| 廣州白雲山醫藥集團股份有限公司白雲山何濟公制藥廠 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Guangzhou Baiyunshan He Ji Gong Pharmaceutical Factory | 9,869,473.33 | 4,525,753.61 |

| 項目 Item | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|---|-------------------------|--|
| 廣州白雲山醫藥銷售有限公司 Guangzhou Baiyunshan Pharmaceutical Marketing Co., Ltd. | 19,501,174.50 | 22,592,716.21 |
| 廣州白雲山中一藥業有限公司 Guangzhou Baiyunshan Zhong Yi Pharmaceutical Company Limited | 38,634,056.28 | 35,036,343.47 |
| 廣州采芝林藥業有限公司 Guangzhou Cai Zhi Lin Pharmaceutical Co., Ltd. | 3,586,467.65 | 10,215,405.80 |
| 廣州國盈醫藥有限公司 Guangzhou Guo Ying Pharmaceutical Co., Ltd. | 1,496,937.05 | 2,312,429.84 |
| 廣州王老吉藥業股份有限公司 Guangzhou Wang Lao Ji Pharmaceutical Co., Ltd. | 20,967,720.00 | 14,551,940.00 |
| 廣州欣特醫藥有限公司 Guangzhou Xin Te Pharmaceutical Co., Ltd. | 1,724,964.00 | 3,250,950.00 |
| 廣州醫藥股份有限公司 Guangzhou Pharmaceutical Co., Ltd. | 16,810,064.57 | 15,391,181.18 |
| 合同負債 Contract liabilities | | |
| 一心堂藥業集團股份有限公司 Yixintang Pharmaceutical Group Co., Ltd. | 0.07 | - |
| 廣州國盈醫藥有限公司 Guangzhou Guo Ying Pharmaceutical Co., Ltd. | 0.16 | - |
| 江西江中醫藥商業運營有限責任公司 Jiangxi Jiangzhong Pharmaceutical Commercial Operation Co., Ltd. | 44,255,221.24 | - |
| 四川江中粵通醫藥有限公司 Sichuan Jiangzhong Yuetong Pharmaceutical Co., Ltd. | 21,245,309.73 | - |
| 廣州醫藥股份有限公司大眾藥品銷售分公司 Guangzhou Pharmaceuticals Co., Ltd. Da Zhong Drug Sales Branch | 5,523.88 | - |

(四) 關鍵管理人員薪酬

(IV). Compensation of key management

| 項目名稱 Name of Item | 本期金額 Current period | 上期金額 Prior period |
|----------------------------|------------------------|----------------------|
| 薪酬合計 Total remuneration | 1,444,454.60 | 1,381,308.14 |

十一、或有事項

XI. CONTINGENCIES

1. 本集團在報告期內對內擔保情況如下（單位：萬元）：

1. The Group's internal guarantees during the reporting period are as follows (Unit: RMB0'000):

| 擔保方名稱 Names of Guarantors | 被擔保方名稱 Names of Guarantees | 擔保金額 Guarantee Amount | 起始日 Commencement Date | 解除日期 Release Date | 擔保是否已經履行完畢 Whether the Guarantee has been fully performed | 說明 Explanation |
|---|--|--------------------------|---------------------------|---------------------------|--|------------------------------------|
| 創美藥業公司 Charmacy Pharmaceutical Company | 創美藥業公司、廣東創美公司 Charmacy Pharmaceutical Company, Guangdong Charmacy Company | 38,000.00 | 2019年8月2日 2019/8/2 | 2023年7月10日 2023/7/10 | 否 No | 動產抵押 Chattel mortgage |
| 創美藥業公司 Charmacy Pharmaceutical Company | 創美藥業公司、廣東創美公司 Charmacy Pharmaceutical Company, Guangdong Charmacy Company | 38,000.00 | 2019年8月2日 2019/8/2 | 2024年8月2日 2024/8/2 | 否 No | 房產抵押 Building property mortgage |
| 創美藥業公司 Charmacy Pharmaceutical Company | 廣東創美公司 Guangdong Charmacy Company | 18,000.00 | 2021年2月22日 2021/2/22 | 2022年2月21日 2022/2/21 | 是 Yes | |
| 創美藥業公司 Charmacy Pharmaceutical Company | 廣東創美公司 Guangdong Charmacy Company | 12,000.00 | 2020年10月28日 2020/10/28 | 2025年12月31日 2025/12/31 | 否 No | |
| 創美藥業公司 Charmacy Pharmaceutical Company | 廣東創美公司 Guangdong Charmacy Company | 6,000.00 | 2019年12月27日 2019/12/27 | 2023年3月15日 2023/3/15 | 是 Yes | |
| 創美藥業公司 Charmacy Pharmaceutical Company | 廣東創美公司 Guangdong Charmacy Company | 5,500.00 | 2019年9月18日 2019/9/18 | 注1 Note:1 | 是 Yes | |
| 創美藥業公司 Charmacy Pharmaceutical Company | 廣東創美公司 Guangdong Charmacy Company | 5,500.00 | 2021年9月8日 2021/9/8 | 2023年7月31日 2023/7/31 | 是 Yes | |
| 創美藥業公司 Charmacy Pharmaceutical Company | 廣東創美公司 Guangdong Charmacy Company | 4,000.00 | 2019年11月25日 2019/11/25 | 2022年12月31日 2022/12/31 | 是 Yes | |
| 創美藥業公司 Charmacy Pharmaceutical Company | 廣東創美公司 Guangdong Charmacy Company | 3,000.00 | 2020年6月23日 2020/6/23 | 2023年6月23日 2023/6/23 | 是 Yes | |
| 創美藥業公司 Charmacy Pharmaceutical Company | 廣東創美公司 Guangdong Charmacy Company | 3,000.00 | 2021年7月6日 2021/7/6 | 2022年6月24日 2022/6/24 | 否 No | |
| 廣東創美公司 Guangdong Charmacy Company | 創美藥業公司、廣東創美公司 Charmacy Pharmaceutical Company, Guangdong Charmacy Company | 26,000.00 | 2018年7月10日 2018/7/10 | 2023年7月10日 2023/7/10 | 否 No | 動產抵押 Chattel mortgage |
| 廣東創美公司 Guangdong Charmacy Company | 創美藥業公司 Charmacy Pharmaceutical Company | 20,000.00 | 2017年11月20日 2017/11/20 | 2022年11月19日 2022/11/19 | 否 No | |
| 廣東創美公司 Guangdong Charmacy Company | 創美藥業公司 Charmacy Pharmaceutical Company | 20,000.00 | 2021年2月22日 2021/2/22 | 2022年2月21日 2022/2/21 | 是 Yes | |



| 擔保方名稱 Names of Guarantors | 被擔保方名稱 Names of Guarantees | 擔保金額 Guarantee Amount | 起始日 Commencement Date | 解除日期 Release Date | 擔保是否已經履行完畢 Whether the Guarantee has been fully performed | 說明 Explanation |
|--------------------------------------|---|--------------------------|---------------------------|---------------------------|--|-------------------|
| 廣東創美公司 Guangdong Charmacy Company | 創美藥業公司 Charmacy Pharmaceutical Company | 18,000.00 | 2018年8月15日 2018/8/15 | 2025年8月15日 2025/8/15 | 否 No | |
| 廣東創美公司 Guangdong Charmacy Company | 創美藥業公司 Charmacy Pharmaceutical Company | 13,000.00 | 2019年12月27日 2019/12/27 | 2023年3月15日 2023/3/15 | 是 Yes | |
| 廣東創美公司 Guangdong Charmacy Company | 創美藥業公司 Charmacy Pharmaceutical Company | 9,600.00 | 2020年10月13日 2020/10/13 | 2025年10月12日 2025/10/12 | 否 No | |
| 廣東創美公司 Guangdong Charmacy Company | 創美藥業公司 Charmacy Pharmaceutical Company | 5,500.00 | 2019年9月18日 2019/9/18 | 注1 Note:1 | 是 Yes | |
| 廣東創美公司 Guangdong Charmacy Company | 創美藥業公司 Charmacy Pharmaceutical Company | 5,500.00 | 2021年9月8日 2021/9/8 | 2022年7月31日 2022/7/31 | 是 Yes | |
| 廣東創美公司 Guangdong Charmacy Company | 創美藥業公司 Charmacy Pharmaceutical Company | 3,000.00 | 2020年3月25日 2020/3/25 | 2023年3月24日 2023/3/24 | 是 Yes | |
| 廣東創美公司 Guangdong Charmacy Company | 創美藥業公司 Charmacy Pharmaceutical Company | 3,000.00 | 2021年3月19日 2021/3/19 | 2024年4月30日 2024/4/30 | 是 Yes | |
| 廣東創美公司 Guangdong Charmacy Company | 創美藥業公司 Charmacy Pharmaceutical Company | 3,000.00 | 2021年7月19日 2021/7/19 | 2023年7月19日 2023/7/19 | 否 No | |
| 廣東創美公司 Guangdong Charmacy Company | 創美藥業公司 Charmacy Pharmaceutical Company | 2,970.00 | 2021年5月12日 2021/5/12 | 2024年5月13日 2024/5/13 | 否 No | |
| 廣州創美公司 Guangzhou Charmacy Company | 創美藥業公司 Charmacy Pharmaceutical Company | 13,000.00 | 2019年12月27日 2019/12/27 | 2023年3月15日 2023/3/15 | 是 Yes | |
| 廣州創美公司 Guangzhou Charmacy Company | 創美藥業公司 Charmacy Pharmaceutical Company | 9,600.00 | 2020年10月13日 2020/10/13 | 2025年10月12日 2025/10/12 | 否 No | |
| 廣州創美公司 Guangzhou Charmacy Company | 創美藥業公司 Charmacy Pharmaceutical Company | 3,000.00 | 2020年3月25日 2020/3/25 | 2023年3月24日 2023/3/24 | 是 Yes | |
| 廣州創美公司 Guangzhou Charmacy Company | 創美藥業公司 Charmacy Pharmaceutical Company | 3,000.00 | 2021年7月19日 2021/7/19 | 2023年7月19日 2023/7/19 | 否 No | |
| 珠海創美公司 Zhuhai Charmacy Company | 創美藥業公司 Charmacy Pharmaceutical Company | 9,600.00 | 2020年10月13日 2020/10/13 | 2025年10月12日 2025/10/12 | 否 No | |
| 珠海創美公司 Zhuhai Charmacy Company | 創美藥業公司 Charmacy Pharmaceutical Company | 3,000.00 | 2020年3月25日 2020/3/25 | 2023年3月24日 2023/3/24 | 是 Yes | |

| 擔保方名稱 Names of Guarantors | 被擔保方名稱 Names of Guarantees | 擔保金額 Guarante e Amount | 起始日 Commencement Date | 解除日期 Release Date | 擔保是否已經 履行完畢 Whether the Guarantee has been fully performed | 說明 Explanation |
|---|---|---------------------------------|-----------------------------|---------------------------|---|-------------------|
| 創美藥業公司 Charmacy Pharmaceutical Company | 廣東創美公司 Guangdong Charmacy Company | 3,000.00 | 2022年5月10日 2022/5/10 | 2024年5月10日 2024/5/10 | 否 No | |
| 創美藥業公司 Charmacy Pharmaceutical Company | 廣東創美公司 Guangdong Charmacy Company | 5,500.00 | 2020年4月16日 2020/4/16 | 2025年4月16日 2025/4/16 | 否 No | |
| 創美藥業公司 Charmacy Pharmaceutical Company | 廣東創美公司 Guangdong Charmacy Company | 4,000.00 | 2021年1月1日 2021/1/1 | 2025年12月31日 2025/12/31 | 否 No | |
| 創美藥業公司 Charmacy Pharmaceutical Company | 廣東創美公司 Guangdong Charmacy Company | 6,000.00 | 2021年3月15日 2021/3/15 | 2031年6月30日 2031/6/30 | 否 No | |
| 創美藥業公司 Charmacy Pharmaceutical Company | 廣東創美公司 Guangdong Charmacy Company | 18,000.00 | 2022年2月28日 2022/2/28 | 2023年2月27日 2023/2/27 | 否 No | |
| 廣東創美公司 Guangdong Charmacy Company | 創美藥業公司 Charmacy Pharmaceutical Company | 13,000.00 | 2021年3月15日 2021/3/15 | 2031年6月30日 2031/6/30 | 否 No | |
| 廣州創美公司 Guangzhou Charmacy Company | 創美藥業公司 Charmacy Pharmaceutical Company | 13,000.00 | 2021年3月15日 2021/3/15 | 2031年6月30日 2031/6/30 | 否 No | |
| 廣東創美公司 Guangdong Charmacy Company | 創美藥業公司 Charmacy Pharmaceutical Company | 5,500.00 | 2020年4月16日 2020/4/16 | 2025年4月16日 2025/4/16 | 否 No | |
| 廣東創美公司 Guangdong Charmacy Company | 創美藥業公司 Charmacy Pharmaceutical Company | 3,000.00 | 2022年5月6日 2022/5/6 | 2023年5月6日 2023/5/6 | 否 No | |
| 廣東創美公司 Guangdong Charmacy Company | 創美藥業公司 Charmacy Pharmaceutical Company | 20,000.00 | 2022年2月28日 2022/2/28 | 2023年2月27日 2023/2/27 | 否 No | |
| 廣東創美公司 Guangdong Charmacy Company | 創美藥業公司 Charmacy Pharmaceutical Company | 6,000.00 | 2022年6月24日 2022/6/24 | 2023年6月23日 2023/6/23 | 否 No | |

註 1: 擔保義務自 2019 年 9 月 18 日起生效, 至自擔保義務履行期屆滿之日起 60 個月。

Note 1: The guarantee obligation became effective from 18 September 2019 for a term of 60 months from the expiration of the performance period of the guarantee obligation.

2. 除存在上述披露事項外, 本集團無其他需披露的或有事項。

2. Apart from the above disclosures, no other contingencies of the Group need to be disclosed.

十二、資本承諾

截至 2022 年 6 月 30 日，本集團不存在需對外披露的重要承諾事項。

XII.COMMITMENTS

By 30 June 2022, the Group had no important commitment which must be disclosed.

十三、資產負債表日後事項

截至本財務報告批准日，本集團無需要披露的資產負債表日後事項。

XIII.EVENTS SUBSEQUENT TO BALANCE SHEET DATE

As at the date of approval of this financial report, the Group has no subsequent events on the balance sheet date that are subject to disclosure.

十四、母公司財務報表主要項目註釋

XIV. NOTES TO MAJOR ITEMS OF FINANCIAL STATEMENTS OF PARENT COMPANY

1.應收賬款

1.Trade receivables

| 項目名稱 Name of item | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|---------------------------------------|-------------------------|--|
| 應收賬款 Trade receivables | 300,075,460.96 | 304,238,736.86 |
| 減：壞賬準備 Less:Provision for bad debt | 5,729,322.73 | 5,529,013.97 |
| 淨額 Net amount | 294,346,138.23 | 298,709,722.89 |

(1) 應收賬款按壞賬計提方法分類
列示

(1) Accounts receivable by the method of provisioning for bad
debt

| 類別 Classification | 期末餘額 Closing balance | | | | |
|--|-------------------------|--------------------------|--------------------------------|---------------------------------|-----------------------|
| | 賬面餘額 Book balance | | 壞賬準備 Provision for bad debt | | 賬面價值 Book value |
| | 金額 Amount | 比例 (%) Percentage (%) | 金額 Amount | 計提比例 (%) Provision ratio (%) | |
| 按單項計提壞賬準備 Bad debt provision made on individual basis | 2,872,700.08 | 0.96 | 2,872,700.08 | 100.00 | - |
| 按組合計提壞賬準備 Bad debt provision made on a collective basis | 297,202,760.88 | 99.04 | 2,856,622.65 | 0.96 | 294,346,138.23 |
| 其中：賬齡組合 InC: Aging portfolio | 297,202,760.88 | 99.04 | 2,856,622.65 | 0.96 | 294,346,138.23 |
| 低風險組合 Low risk portfolio | - | - | - | - | - |
| 合計 Total | 300,075,460.96 | 100.00 | 5,729,322.73 | — | 294,346,138.23 |

(續)

(continued)

| 類別 Classification | 上年年末餘額 Closing balance of last year | | | | |
|--|--|--------------------------|--------------------------------|---------------------------------|-----------------------|
| | 賬面餘額 Book balance | | 壞賬準備 Provision for bad debt | | 賬面價值 Book value |
| | 金額 Amount | 比例 (%) Percentage (%) | 金額 Amount | 計提比例 (%) Provision ratio (%) | |
| 按單項計提壞賬準備 Bad debt provision made on individual basis | 2,873,666.59 | 0.94 | 2,873,666.59 | 100.00 | - |
| 按組合計提壞賬準備 Bad debt provision made on a collective basis | 301,365,070.27 | 99.06 | 2,655,347.38 | 0.88 | 298,709,722.89 |
| 其中：賬齡組合 InC: Aging portfolio | 301,365,070.27 | 99.06 | 2,655,347.38 | 0.88 | 298,709,722.89 |
| 低風險組合 Low risk portfolio | - | - | - | - | - |
| 合計 Total | 304,238,736.86 | 100.00 | 5,529,013.97 | — | 298,709,722.89 |

2.其他應收款

2.Other receivables

| 項目 Items | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|------------------------------|-------------------------|--|
| 應收利息 Interests receivable | - | - |
| 應收股利 Dividend receivable | - | - |
| 其他應收款 Other receivables | 158,543,577.09 | 163,479,388.56 |
| 合計 Total | 158,543,577.09 | 163,479,388.56 |

2.1 其他應收款

2.1 Other receivables

| 項目名稱 Name of item | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|---------------------------------------|-------------------------|--|
| 其他應收款 Other receivables | 158,618,577.09 | 163,554,388.56 |
| 減：壞賬準備 Less:Provision for bad debt | 75,000.00 | 75,000.00 |
| 淨額 Net amount | 158,543,577.09 | 163,479,388.56 |

(1) 其他應收款按款項性質分類

(1) Classification of other receivables by fund nature

| 款項性質 Fund nature | 期末餘額 Closing balance | 上年年末餘額 Closing balance of last year |
|------------------------|-------------------------|--|
| 往來款 Money transfers | 150,766,741.22 | 155,596,124.01 |
| 保證金 Cash deposit | 7,519,516.00 | 7,594,516.00 |
| 備用金 Imprest fund | 332,319.87 | 358,748.55 |
| 其他 Others | - | 5,000.00 |
| 合計 Total | 158,618,577.09 | 163,554,388.56 |

(2) 其他應收款壞賬準備計提情況

(2) Provisions for bad debt of other receivables

| 壞賬準備 Provision for bad debt | 第一階段 First stage | 第二階段 Second stage | 第三階段 Third stage | 合計 Total |
|--|---|---|--|-------------|
| | 未來 12 個月 預期信用損失 12-month expected credit loss | 整個存續期預期信用 損失(未發生信用減 值) Lifetime expected credit loss (not credit-impaired) | 整個存續期預期信用 損失(已發生信用減 值) Lifetime expected credit loss (credit- impaired) | |
| 2022 年 1 月 1 日餘額 Balance on 1 January 2022 | - | 70,000.00 | 5,000.00 | 75,000.00 |
| 2022 年 1 月 1 日其他應收款賬面餘額在 本期 Book balance of other receivables on 1 January 2022 in the period | - | - | - | - |
| -轉入第二階段 -Transferred to the second stage | - | - | - | - |
| -轉入第三階段 -Transferred to the third stage | - | - | 70,000.00 | - |
| -轉回第二階段 -Reversed to the second stage | - | - | - | - |
| -轉回第一階段 -Reversed to the first stage | - | - | - | - |
| 本期計提 Accrued for the period | - | - | - | - |
| 本期轉回 Reversed in the period | - | - | - | - |
| 本期轉銷 Written off in the period | - | - | - | - |
| 本期核銷 Cancelled in the period | - | - | - | - |
| 其他變動 Other changes | - | - | - | - |
| 2022 年 6 月 30 日餘額 Balance on 30 June 2022 | - | - | 75,000.00 | 75,000.00 |

3. 長期股權投資

(1) 長期股權投資分類

3. Long-term equity investments

(1) Classification of long-term equity investments

| 項目 Item | 期末餘額 Closing balance | | | 上年年末餘額 Closing balance of last year | | |
|---|-------------------------|--------------------------------------|-----------------------|--|--------------------------------------|-----------------------|
| | 賬面餘額 Book balance | 減值準備 Provisions for impairment | 賬面價值 Book value | 賬面餘額 Book balance | 減值準備 Provisions for impairment | 賬面價值 Book value |
| 對子公司投資 Investment in the subsidiaries | 219,978,852.24 | - | 219,978,852.24 | 219,978,852.24 | - | 219,978,852.24 |
| 合計 Total | 219,978,852.24 | - | 219,978,852.24 | 219,978,852.24 | - | 219,978,852.24 |

(2) 對子公司投資

(2) Investment in the subsidiaries

| 被投資單位 Investees | 上年年末餘額 Closing balance of last year | 本期增加 Addition in the period | 本期減少 Reduction in the period | 期末餘額 Closing balance | 本期計提 減值準備 Provision for impairment for the period | 減值準備 期末餘額 Closing balance of provision for impairment |
|--|---|---|------------------------------------|----------------------------|---|---|
| 廣東創美公司 Guangdong Charmacy Company | 150,000,000.00 | - | - | 150,000,000.00 | - | - |
| 珠海創美公司 Zhuhai Charmacy Company | 25,710,000.00 | - | - | 25,710,000.00 | - | - |
| 廣州創美公司 Guangzhou Charmacy Company | 20,000,000.00 | - | - | 20,000,000.00 | - | - |
| 深圳創美公司 Shenzhen Charmacy Company | 20,800,000.00 | - | - | 20,800,000.00 | - | - |
| 惠州創美公司 Huizhou Charmacy Company | 3,468,852.24 | - | - | 3,468,852.24 | - | - |
| 合計 Total | 219,978,852.24 | - | - | 219,978,852.24 | - | - |

4.營業收入和營業成本

4.Operating revenue and operating cost

(1) 營業收入和營業成本情況

(1)Basic information on business revenue and business expenses

| 項目 Items | 本期金額 Current period | | 上期金額 Prior period | |
|------------------------------|------------------------|-----------------------|-----------------------|-----------------------|
| | 收入 Revenue | 成本 Cost | 收入 Revenue | 成本 Cost |
| 主營業務 Principal businesses | 715,834,817.49 | 682,107,339.93 | 780,033,701.19 | 735,760,813.67 |
| 其他業務 Other businesses | 38,759,194.44 | 3,486,963.96 | 31,191,150.26 | 5,705,627.49 |
| 合計 Total | 754,594,011.93 | 685,594,303.89 | 811,224,851.45 | 741,466,441.16 |

5.投資收益

5.Investment income

| 項目 Item | 本期金額 Current period | 上期金額 Prior period |
|---|------------------------|----------------------|
| 成本法核算的長期股權投資收益 Long-term equity investment income accounted for using the cost method | - | 18,000,000.00 |
| 合計 Total | - | 18,000,000.00 |

十五、財務報告批准

XV. APPROVAL FOR FINANCIAL REPORT

本財務報告於 2022 年 8 月 31 日由本公司董事會批准報出。

The financial report was approved and published by the Board of the Company on 31 August 2022.

創美藥業股份有限公司
二〇二二年八月三十一日

Charmacy Pharmaceutical Co., Ltd
31 August 2022

CH
MEI

創美藥業股份有限公司
CHARMACY PHARMACEUTICAL CO., LTD.

地址：中國廣東省汕頭市龍湖區高山北路235號

電話：86-754-88109272

郵箱：ir@charmacy.cn

Address: No. 235 Song Shan North Road, Longhu District,
Shantou City, Guangdong Province, the PRC

Tel: 86-754-88109272

Email: ir@charmacy.cn